

# Ezetimibe Added to Statin Therapy after Acute Coronar

New England Journal of Medicine

372, 2387-2397

DOI: [10.1056/nejmoa1410489](https://doi.org/10.1056/nejmoa1410489)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The evolution of domain arrangements in proteins and interaction networks. Cellular and Molecular Life Sciences, 2005, 62, 435-445.	2.4	120
2	Poly-ADP-ribosylation in health and disease. Cellular and Molecular Life Sciences, 2005, 62, 739-750.	2.4	115
3	Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase. Cellular and Molecular Life Sciences, 2005, 62, 599-605.	2.4	13
4	New Drug Review. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2014, 56, 118-118.	0.2	0
5	Lipid-modifying Therapy: The Clinician's Perspective. Clinical Therapeutics, 2015, 37, 2712-2715.	1.1	0
6	Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target. Medicina Clínica (English Edition), 2015, 145, 67-69.	0.1	0
7	Reply. Journal of the American College of Cardiology, 2015, 66, 2916-2917.	1.2	0
9	Lipids, blood pressure and kidney update 2015. Lipids in Health and Disease, 2015, 14, 167.	1.2	49
10	Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. Clinical Cardiology, 2015, 38, 763-769.	0.7	12
11	Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. Journal of Internal Medicine, 2015, 278, 433-446.	2.7	30
12	The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Global Cardiology Science & Practice, 2015, 2015, 59.	0.3	2
13	Current Focuses in Serum Lipid Abnormalities in Dialysis Patients. Blood Purification, 2015, 40, 326-331.	0.9	3
14	Treatment of dyslipidemia in diabetes. Should the lipid-management protocol which the ADA 2015 guideline recommends be used for Japanese as a reference?. Diabetology International, 2015, 6, 252-254.	0.7	0
16	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 1125.	0.4	57
18	PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?. Clinical Pharmacology and Therapeutics, 2015, 98, 590-601.	2.3	4
19	Statin effects on atherosclerotic plaques: regression or healing?. BMC Medicine, 2015, 13, 260.	2.3	43
20	PCSK9 inhibition: the way forward in the treatment of dyslipidemia. BMC Medicine, 2015, 13, 258.	2.3	32
23	Hyperlipidemia and cardiovascular disease. Current Opinion in Lipidology, 2015, 26, 468-469.	1.2	6

#	ARTICLE	IF	CITATIONS
24	Long-term follow-up of lipid-lowering trials. <i>Current Opinion in Lipidology</i> , 2015, 26, 572-579.	1.2	18
25	Statin intolerance. <i>Current Opinion in Lipidology</i> , 2015, 26, 492-501.	1.2	32
26	The hinterland of familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2015, 26, 475-483.	1.2	6
27	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2015, 26, 472-474.	1.2	0
28	Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies. <i>Pharmacotherapy</i> , 2015, 35, 1189-1203.	1.2	17
29	Biomarkers, Risk Factors, and Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 457-459.	0.9	10
30	Mendelian randomization studies. <i>Current Opinion in Lipidology</i> , 2015, 26, 566-571.	1.2	56
31	What does the future hold for cholesteryl ester transfer protein inhibition?. <i>Current Opinion in Lipidology</i> , 2015, 26, 526-535.	1.2	1
32	Has IMPROVE-IT improved cardiovascular outcome?. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2015, 45, 215-217.	0.2	0
33	Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel. <i>Current Vascular Pharmacology</i> , 2015, 13, 759-770.	0.8	25
34	Bioactive Plant Metabolites in the Management of Non-Communicable Metabolic Diseases: Looking at Opportunities beyond the Horizon. <i>Metabolites</i> , 2015, 5, 733-765.	1.3	22
35	Combination pharmacotherapy in lipid management. <i>Journal of the Korean Medical Association</i> , 2015, 58, 745.	0.1	0
36	The FADOI (Federation of Associations of Hospital Doctors on Internal Medicine) position paper on cardiovascular prevention in the higher risk complex patients. <i>Italian Journal of Medicine</i> , 2015, 9, 387.	0.2	1
37	ESTUDO IMPROVE-IT: REDUÇÃO DE EVENTOS CARDIOVASCULARES EM PORTADORES DE SÍNDROME CORONARIANA AGUDA (THE IMPROVED REDUCTION OF OUTCOMES: VYTORIN EFFICACY INTERNATIONAL) Tj ETQq1 0.784314 rgB		
38	Treating elevated LDL cholesterol in patients with low short-term risk: Decision making at the limits of EBM. <i>Evidence-Based Medicine</i> , 2015, 20, 151-153.	0.6	0
39	Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 353.	1.8	272
40	Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. <i>PLoS ONE</i> , 2015, 10, e0142430.	1.1	38
41	Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. <i>World Journal of Diabetes</i> , 2015, 6, 1246.	1.3	718

#	ARTICLE	IF	CITATIONS
42	Treatment Options for Statin-Associated Muscle Symptoms. Deutsches A&#x0308;rzteblatt International, 2015, 112, 748-55.	0.6	65
43	Proof That Lower Is Better â€” LDL Cholesterol and IMPROVE-IT. New England Journal of Medicine, 2015, 372, 2448-2450.	13.9	108
45	American College of Cardiology. Journal of the American College of Cardiology, 2015, 66, D1-D44.	1.2	6
46	Lipid Management in Diabetes with a Focus on Emerging Therapies. Canadian Journal of Diabetes, 2015, 39, S183-S190.	0.4	8
47	Intriguing Off-Target Effects of Ezetimibe. Journal of the American College of Cardiology, 2015, 66, 2808.	1.2	4
48	From the Editor: Is a goal a target?. Journal of Clinical Lipidology, 2015, 9, 727-730.	0.6	4
49	Statistical Controversies in Reporting of Clinical Trials. Journal of the American College of Cardiology, 2015, 66, 2648-2662.	1.2	72
50	Lipids and Cerebrovascular Disease. Stroke, 2015, 46, 3322-3328.	1.0	116
51	Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. Clinical Therapeutics, 2015, 37, 2732-2750.	1.1	7
52	Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes. Clinical Therapeutics, 2015, 37, 2751-2769.	1.1	27
53	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology, 2015, 9, S1-S122.e1.	0.6	430
54	The past, present and future of lipid-lowering therapy. Clinical Lipidology, 2015, 10, 481-498.	0.4	6
57	Evaluating Statin Versus Statin Plus Ezetimibe for Coronary Plaque Regression. Journal of the American College of Cardiology, 2015, 66, 2916.	1.2	1
59	Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. Journal of the American Heart Association, 2015, 4, e001675.	1.6	24
60	Management of patients with familial hypercholesterolaemia. Nature Reviews Cardiology, 2015, 12, 565-575.	6.1	101
61	The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. Journal of Clinical Lipidology, 2015, 9, 496-497.	0.6	1
63	New class PCSK9 blockers stride into cholesterol market. Nature Biotechnology, 2015, 33, 785-786.	9.4	8
64	Statins and Ezetimibe. , 2015, , 25-36.		1

#	ARTICLE	IF	CITATIONS
65	Ezetimibe and Plaque Regression—. Journal of the American College of Cardiology, 2015, 66, 508-510.	1.2	18
66	Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome. Journal of the American College of Cardiology, 2015, 66, 184-192.	1.2	91
67	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3140-3148.	1.8	198
68	A paradigm shift in the treatment of atherosclerosis. Archives of Cardiovascular Diseases, 2015, 108, 337-339.	0.7	1
69	Eggs and beyond: is dietary cholesterol no longer important?. American Journal of Clinical Nutrition, 2015, 102, 235-236.	2.2	14
70	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statins and Newer Drugs. Drugs, 2015, 75, 1201-1228.	4.9	18
71	Ezetimibe+Statin Combination to Reduce Cardiovascular Events: The Evidence Base. Metabolic Syndrome and Related Disorders, 2015, 13, 327-328.	0.5	0
72	Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events. Circulation: Cardiovascular Genetics, 2015, 8, 618-627.	5.1	61
73	No limit to the benefits of LDL-cholesterol lowering. Nature Reviews Cardiology, 2015, 12, 444-444.	6.1	0
74	Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels. Circulation Research, 2015, 117, 662-664.	2.0	11
75	Strategies for Improving Cardiovascular Health in Women With Diabetes Mellitus: a Review of the Evidence. Current Diabetes Reports, 2015, 15, 98.	1.7	2
76	Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Current Cardiology Reports, 2015, 17, 104.	1.3	24
77	Nonstatin Therapies for Management of Dyslipidemia: A Review. Clinical Therapeutics, 2015, 37, 2153-2179.	1.1	39
78	Nonstatin Low-Density Lipoprotein+Lowering Therapy and Cardiovascular Risk Reduction+Statement From the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2269-2280.	1.1	58
79	Protective alleles and modifier variants in human health and disease. Nature Reviews Genetics, 2015, 16, 689-701.	7.7	105
80	New Approaches in Detection and Treatment of Familial Hypercholesterolemia. Current Cardiology Reports, 2015, 17, 109.	1.3	28
81	Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis, 2015, 242, 357-366.	0.4	144
82	Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 66, 1864-1872.	1.2	24

#	ARTICLE	IF	CITATIONS
83	Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?. American Journal of Medicine, 2015, 128, 1160-1161.	0.6	1
84	Predicting the Overuse of PCSK-9 Inhibitors. JAMA - Journal of the American Medical Association, 2015, 314, 1909.	3.8	8
85	Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. Current Atherosclerosis Reports, 2015, 17, 72.	2.0	11
86	Effects of Evolocumab on Vitamin E and Steroid Hormone Levels. Circulation Research, 2015, 117, 731-741.	2.0	80
87	New Therapies in the Treatment of High Cholesterol. JAMA - Journal of the American Medical Association, 2015, 314, 1443.	3.8	40
88	Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. American Heart Journal, 2015, 170, 865-871.	1.2	20
89	Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 66, 1873-1875.	1.2	4
90	Statins and their increased risk of inducing diabetes. Expert Opinion on Drug Safety, 2015, 14, 1835-1844.	1.0	27
91	Ezetimibe plus a Statin after Acute Coronary Syndromes. New England Journal of Medicine, 2015, 373, 1473-1477.	13.9	28
92	Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab. Annals of Pharmacotherapy, 2015, 49, 1327-1335.	0.9	24
93	Reducing LDL with PCSK9 Inhibitors – The Clinical Benefit of Lipid Drugs. New England Journal of Medicine, 2015, 373, 1588-1591.	13.9	120
94	Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides. Postgraduate Medicine, 2015, 127, 869-873.	0.9	6
95	Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. International Journal of Cardiology, 2015, 201, 408-414.	0.8	55
96	Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines. Mayo Clinic Proceedings, 2015, 90, 1262-1271.	1.4	16
97	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate – statin combination therapy. Atherosclerosis Supplements, 2015, 19, 1-12.	1.2	66
98	Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1505-1515.	1.5	11
99	Safety and efficacy of ezetimibe: A meta-analysis. International Journal of Cardiology, 2015, 201, 247-252.	0.8	70
100	Cardiovascular and Renal Outcomes Trials – Is There a Difference?. American Journal of Cardiology, 2015, 116, 982-988.	0.7	3

#	ARTICLE	IF	CITATIONS
101	Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome. <i>Evidence-Based Medicine</i> , 2015, 20, 176-176.	0.6	1
102	Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2015, 243, 60-64.	0.4	36
103	New Pyripyropene A Derivatives, Highly SOAT2-Selective Inhibitors, Improve Hypercholesterolemia and Atherosclerosis in Atherogenic Mouse Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 355, 297-307.	1.3	17
104	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. <i>Circulation</i> , 2015, 132, 1224-1233.	1.6	267
105	Bringing Back Targets to "IMPROVE" Atherosclerotic Cardiovascular Disease Outcomes. <i>Circulation</i> , 2015, 132, 1218-1220.	1.6	6
106	Improve-it: Full disclosures?. <i>International Journal of Cardiology</i> , 2015, 201, 380-381.	0.8	1
107	Making Sense of Statistics in Clinical Trial Reports. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2536-2549.	1.2	57
108	How an Artery Heals. <i>Circulation Research</i> , 2015, 117, 909-913.	2.0	10
109	Genetic Variation in NPC1L1 and Risk of Gallstone Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1086.	1.2	2
110	An evaluation of alirocumab for the treatment of hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1307-1323.	0.6	21
111	LDL cholesterol levels and thin cap fibroatheromas: A dynamic and complex puzzle. <i>Atherosclerosis</i> , 2015, 243, 179-180.	0.4	0
112	Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease. , 0, , .		1
113	Ubiquinone, Ezetimibe/Simvastatin and Rosuvastatin Effects on Mitochondrial Function in Diabetic Polyneuropathy. , 0, , .		0
114	Drug treatment of dyslipidemia. <i>Journal of the Korean Medical Association</i> , 2016, 59, 366.	0.1	6
115	Bilateral upper extremity severe ecchymosis in a patient on alirocumab, rivaroxaban, and clopidogrel therapy. <i>Case Reports in Internal Medicine</i> , 2016, 3, .	0.0	0
117	Cardiology update: First scientific statement on acute MI in women, antidiabetic drugs with CV benefits. <i>Pharmacy Today</i> , 2016, 22, 26-27.	0.0	0
118	Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study. <i>Clinical Medicine Insights: Cardiology</i> , 2016, 10, CMC.S38123.	0.6	4
119	More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Hormones</i> , 2016, 15, 5-7.	0.9	6

#	ARTICLE	IF	CITATIONS
120	Reduction in total recurrent cardiovascular events in acute coronary syndrome patients with low-density lipoprotein cholesterol goal <70 mg/dL: a real-life cohort in a developing country. Therapeutics and Clinical Risk Management, 2016, 12, 353.	0.9	1
121	Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. Vascular Health and Risk Management, 2016, Volume 12, 421-433.	1.0	8
123	EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY. Rational Pharmacotherapy in Cardiology, 2016, 12, 351-358.	0.3	0
124	Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9, 109.	1.1	14
125	Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction. Vascular Health and Risk Management, 2016, 12, 163.	1.0	11
126	Cholesterol: until which age 'the lower the better'?. Monaldi Archives for Chest Disease, 2016, 84, 749.	0.3	0
127	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vascular Health and Risk Management, 2016, 12, 185.	1.0	16
128	Overview of guidelines for the management of dyslipidemia: EU perspectives. Vascular Health and Risk Management, 2016, Volume 12, 357-369.	1.0	16
129	Stabilization of high-risk plaques. Cardiovascular Diagnosis and Therapy, 2016, 6, 304-321.	0.7	19
130	Drugs That Affect Lipid Metabolism. Side Effects of Drugs Annual, 2016, 38, 469-477.	0.6	0
131	Ezetimibe-Statin Combination Therapy: Efficacy and Safety as Compared With Statin Monotherapy. Deutsches A&#x0308;rztblatt International, 2016, 113, 445-53.	0.6	17
132	Early Effects of Intensive Lipid-Lowering Treatment on Plaque Characteristics Assessed by Virtual Histology Intravascular Ultrasound. Yonsei Medical Journal, 2016, 57, 1087.	0.9	8
133	Progress in the care of familial hypercholesterolaemia: 2016. Medical Journal of Australia, 2016, 205, 232-236.	0.8	15
134	Lipids in Coronary Heart Disease. , 2016, , 67-80.		0
137	Management of Familial Hypercholesterolemia in Hong Kong. Journal of Atherosclerosis and Thrombosis, 2016, 23, 520-531.	0.9	10
138	Efficacy of Statin Therapy in Inducing Coronary Plaque Regression in Patients with Low Baseline Cholesterol Levels. Journal of Atherosclerosis and Thrombosis, 2016, 23, 1055-1066.	0.9	15
139	G = E: What GWAS Can Tell Us about the Environment. PLoS Genetics, 2016, 12, e1005765.	1.5	120
140	The NPC1L1 Polymorphism 1679C>G Is Associated with Gallstone Disease in Chinese Patients. PLoS ONE, 2016, 11, e0147562.	1.1	9



#	ARTICLE	IF	CITATIONS
141	Ezetimibe Promotes Brush Border Membrane-to-Lumen Cholesterol Efflux in the Small Intestine. PLoS ONE, 2016, 11, e0152207.	1.1	32
142	Reducing exposure to cardiovascular risk factors: the legacy of prevention. Journal of Thoracic Disease, 2016, 8, 2340-2343.	0.6	3
143	ACC/AHA Guidelines for Cardiovascular Disease Prevention and Cholesterol Management: Implications of New Therapeutic Agents. Cardiovascular Innovations and Applications, 2016, 1, .	0.1	1
144	What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 97-105.	1.2	9
145	What can we learn about lipoprotein metabolism and coronary heart disease from studying rare variants?. Current Opinion in Lipidology, 2016, 27, 99-104.	1.2	4
146	Statin myopathy. Current Opinion in Cardiology, 2016, 31, 417-425.	0.8	7
147	Statins in Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2016, 68, 252-260.	1.2	149
148	Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?. Journal of Clinical Lipidology, 2016, 10, 1067-1072.	0.6	5
149	Genetic insights into statin-associated diabetes risk. Current Opinion in Lipidology, 2016, 27, 125-130.	1.2	7
150	Is it time to reconsider combination lipid therapy in high-risk diabetic patients?. Current Opinion in Lipidology, 2016, 27, 310-311.	1.2	0
151	Using human genetics to predict the effects and side-effects of drugs. Current Opinion in Lipidology, 2016, 27, 105-111.	1.2	10
152	Regression of coronary atheroma with statin therapy. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 131-137.	1.2	12
153	Effect of Optimal Medical Therapy Before Procedures on Outcomes in Coronary Patients Treated With Drug-Eluting Stents. American Journal of Cardiology, 2016, 118, 790-796.	0.7	4
154	Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk. European Journal of Internal Medicine, 2016, 34, 54-57.	1.0	23
155	Do the mechanisms by which LDL-c levels are reduced influence the extent of clinical benefit which subsequently accrues?. Current Opinion in Lipidology, 2016, 27, 207-208.	1.2	0
156	Vascular Complications of Diabetes. Circulation Research, 2016, 118, 1771-1785.	2.0	262
157	Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm. Drugs, 2016, 76, 1081-1091.	4.9	17
158	Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease?. European Heart Journal, 2017, 38, ehw287.	1.0	17

#	ARTICLE	IF	CITATIONS
159	Highlights from the 65th American College of Cardiology Annual Scientific Session (ACC 2016). European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 142-144.	1.4	1
160	IMPROVE-IT. Current Opinion in Cardiology, 2016, 31, 426-433.	0.8	16
161	PCSK9 inhibitors. Journal of Cardiovascular Medicine, 2016, 17, 237-244.	0.6	5
162	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. American Journal of Cardiology, 2016, 118, 647-655.	0.7	21
163	Nutraceutical therapies for atherosclerosis. Nature Reviews Cardiology, 2016, 13, 513-532.	6.1	136
164	The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Current Opinion in Lipidology, 2016, 27, 473-483.	1.2	348
165	Multicenter Cohort Study of Acute Myocardial Infarction in Koreaâ€”Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry â€”. Circulation Journal, 2016, 80, 1427-1436.	0.7	166
166	Dawn of a New Eraâ€”The Far Lower, the Far Better Low-Density Lipoprotein Cholesterol Story in Japan â€”. Circulation Journal, 2016, 80, 1903-1904.	0.7	0
167	Cholesterol-lowering pattern affects the progression of atherosclerosis in apolipoprotein E deficient mice. Journal of Pharmacological Sciences, 2016, 132, 271-274.	1.1	4
168	Variation in <i>PCSK9</i> and <i>HMGCR</i> and Risk of Cardiovascular Disease and Diabetes. New England Journal of Medicine, 2016, 375, 2144-2153.	13.9	596
169	Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Communications, 2016, 7, 13457.	5.8	296
170	Secondary prevention after coronary artery bypass graft surgery. Current Opinion in Cardiology, 2016, 31, 635-643.	0.8	27
171	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm â€” 2016 EXECUTIVE SUMMARY. Endocrine Practice, 2016, 22, 84-113.	1.1	405
173	Looking Beyond Statins. Circulation, 2016, 134, 1944-1947.	1.6	1
175	Genetics: Implications for Prevention and Management of Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 2797-2818.	1.2	92
176	New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines. Annals of Internal Medicine, 2016, 164, 683.	2.0	8
179	Low-Density Lipoprotein Levels and Risk of Major Cardiovascular Events. JAMA Internal Medicine, 2016, 176, 1876.	2.6	1
180	Exchanging a few commercial, regularly consumed food items with improved fat quality reduces total cholesterol and LDL-cholesterol: a double-blind, randomised controlled trial. British Journal of Nutrition, 2016, 116, 1383-1393.	1.2	42

#	ARTICLE	IF	CITATIONS
181	Model-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1379-1388.	0.6	2
182	The future of lipid guidelines. <i>Current Opinion in Lipidology</i> , 2016, 27, 585-591.	1.2	4
183	Niacin is still beneficial. Implications from an updated meta-regression analysis. <i>Acta Cardiologica</i> , 2016, 71, 463-472.	0.3	5
184	New oral agents for treating dyslipidemia. <i>Current Opinion in Lipidology</i> , 2016, 27, 579-584.	1.2	8
185	The year in cardiology 2015: prevention. <i>Egyptian Heart Journal</i> , 2016, 68, 291-300.	0.4	0
187	Genetics of Lipid and Lipoprotein Disorders and Traits. <i>Current Genetic Medicine Reports</i> , 2016, 4, 130-141.	1.9	61
188	Trastornos del metabolismo lipídico. <i>Medicine</i> , 2016, 12, 1059-1071.	0.0	0
190	Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection. <i>European Heart Journal</i> , 2016, 37, 3545-3548.	1.0	3
191	Statin Therapy as Primary Prevention in Exercising Adults: Best Evidence for Avoiding Myalgia. <i>Journal of the American Board of Family Medicine</i> , 2016, 29, 727-740.	0.8	12
192	Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 251.	0.7	3
193	Efficacy and safety of Yirui capsule in patients with hyperlipidemia: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. <i>Trials</i> , 2016, 17, 291.	0.7	3
194	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016, 176, 83-92.	1.2	45
195	Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea. <i>European Heart Journal</i> , 2016, 37, 1357-1359.	1.0	8
196	Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". <i>Circulation</i> , 2016, 133, e463.	1.6	0
197	Quality of life in patients treated with lipoprotein apheresis. <i>Journal of Clinical Lipidology</i> , 2016, 10, 323-329.e6.	0.6	18
198	Diabetic dyslipidaemia. <i>Current Opinion in Lipidology</i> , 2016, 27, 313-322.	1.2	42
199	Management of stable angina: A commentary on the European Society of Cardiology guidelines. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1401-1412.	0.8	30
200	Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. <i>American Heart Journal</i> , 2016, 178, 135-144.	1.2	58

#	ARTICLE	IF	CITATIONS
201	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. Data in Brief, 2016, 7, 1541-1550.	0.5	1
202	Maximum Low-density Lipoprotein Cholesterol Lowering Capacity Achievable With Drug Combinations. When 50 Plus 20 Equals 60. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 342-343.	0.4	7
203	Low-carbohydrate diets increase LDL-cholesterol, and thereby indicate increased risk of CVD. British Journal of Nutrition, 2016, 115, 2264-2266.	1.2	5
204	Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. Current Medical Research and Opinion, 2016, 32, 1633-1638.	0.9	17
205	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016, 37, 2315-2381.	1.0	5,370
206	Managing dyslipidaemia in type 2 diabetes mellitus. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 431-444.	2.2	14
207	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. Journal of Clinical Lipidology, 2016, 10, 472-489.	0.6	219
208	Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. Journal of Clinical Lipidology, 2016, 10, 519-527.e4.	0.6	42
209	Cardiovascular Disease in Women. Obstetrics and Gynecology Clinics of North America, 2016, 43, 265-285.	0.7	6
210	Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR. Revista Espanola De Cardiologia, 2016, 69, 931-938.	0.6	72
211	Monoclonal Antibodies for Lipid Management. Current Atherosclerosis Reports, 2016, 18, 39.	2.0	6
212	Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. Current Cardiology Reports, 2016, 18, 65.	1.3	13
213	Response to the letter "No evidence to support high-intensity statin in Chinese patients with coronary heart disease". International Journal of Cardiology, 2016, 209, 192-193.	0.8	0
214	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European Heart Journal Supplements, 2016, 18, C2-C12.	0.0	71
215	Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). Journal of Clinical Lipidology, 2016, 10, 594-603.	0.6	88
216	Adiposity in Children and CVD Risk: ApoB48 Has a Stronger Association With Central Fat Than Classic Lipid Markers. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2915-2922.	1.8	10
217	Statin-centered treatment of dyslipidemia. New evidence-based paradigm, or only part of the evidence?. Endocrinología Y Nutrición (English Edition), 2016, 63, 1-3.	0.5	2
218	Viejos y nuevos hipolipemiantes. FMC Formacion Medica Continuada En Atencion Primaria, 2016, 23, 172-184.	0.0	0

#	ARTICLE	IF	CITATIONS
219	Silent myocardial ischemia in asymptomatic patients with type 2 diabetes mellitus without previous histories of cardiovascular disease. <i>International Journal of Cardiology</i> , 2016, 216, 151-155.	0.8	9
220	Reply. <i>Journal of the American College of Cardiology</i> , 2016, 67, 120-121.	1.2	0
221	Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1011-1021.	0.6	104
222	Long-term pharmacotherapy for elevated low density lipoprotein levels in children: A retrospective analysis. <i>Journal of Clinical Lipidology</i> , 2016, 10, 265-272.	0.6	4
223	Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2016, 69, 931-938.	0.4	14
224	Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2016, 118, 138-145.	0.7	134
225	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. <i>Atherosclerosis</i> , 2016, 244, 138-146.	0.4	163
227	Máxima reducción de colesterol unido a lipoproteínas de baja densidad alcanzable con combinaciones farmacológicas. Cuando 50 más 20 suma 60. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 342-343.	0.6	24
228	PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. <i>Future Cardiology</i> , 2016, 12, 139-148.	0.5	5
229	The metabolic vascular syndrome - guide to an individualized treatment. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 5-17.	2.6	29
230	CETP Inhibition in CVD Prevention: an Actual Appraisal. <i>Current Cardiology Reports</i> , 2016, 18, 43.	1.3	14
231	2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. <i>Journal of the American College of Cardiology</i> , 2016, 68, 92-125.	1.2	371
232	Comparison of Calipers for Matching on the Disease Risk Score. <i>American Journal of Epidemiology</i> , 2016, 183, 937-948.	1.6	11
233	Global cardiovascular protection in chronic kidney disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 603-608.	6.1	36
234	Ischemic Heart Disease and Acute Cardiac Care 2015: A Selection of Topical Issues. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2016, 69, 408-414.	0.4	2
235	PCSK9 Inhibitors for Statin Intolerance?. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1571.	3.8	16
236	EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. <i>Journal of Hepatology</i> , 2016, 65, 146-181.	1.8	399
237	Clinical Perspectives and Pearls from the 2015 ESC NSTEMI-ACS Guidelines. <i>Current Cardiology Reports</i> , 2016, 18, 48.	1.3	4

#	ARTICLE	IF	CITATIONS
238	Current and future trends in the lipid lowering therapy. <i>Pharmacological Reports</i> , 2016, 68, 737-747.	1.5	22
239	Statin combination therapy and cardiovascular risk reduction. <i>Future Cardiology</i> , 2016, 12, 289-315.	0.5	13
240	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016, 32, S15-S34.	0.8	9
242	Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements. <i>Future Cardiology</i> , 2016, 12, 261-268.	0.5	5
243	Plaque Rupture and Thrombosis: the Value of the Atherosclerotic Rabbit Model in Defining the Mechanism. <i>Current Atherosclerosis Reports</i> , 2016, 18, 29.	2.0	11
244	Lower might be better – It matters how you get there, and in whom. <i>European Heart Journal</i> , 2016, 37, 1380-1383.	1.0	10
245	Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. <i>Human Genetics</i> , 2016, 135, 453-467.	1.8	15
246	Phenome-Wide Association Studies as a Tool to Advance Precision Medicine. <i>Annual Review of Genomics and Human Genetics</i> , 2016, 17, 353-373.	2.5	193
247	Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 117-127.	2.6	5
248	Recent Update to the US Cholesterol Treatment Guidelines. <i>Circulation</i> , 2016, 133, 1795-1806.	1.6	89
249	Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 229-239.	1.0	46
251	Lipids and cardiovascular disease: where does dietary intervention sit alongside statin therapy?. <i>Food and Function</i> , 2016, 7, 2603-2614.	2.1	22
253	Pleiotropic effects of statins: new therapeutic targets in drug design. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 695-712.	1.4	129
254	Non-alcoholic fatty liver disease and dyslipidemia: An update. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1109-1123.	1.5	363
255	The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016, 110, 76-88.	3.1	94
256	Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or <sc>TIA</sc>: Insights From the <sc>REACH</sc> Registry. <i>Clinical Cardiology</i> , 2016, 39, 670-677.	0.7	45
257	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>Atherosclerosis</i> , 2016, 253, 281-344.	0.4	1,189
258	Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. <i>International Journal of Cardiology</i> , 2016, 223, 750-757.	0.8	54

#	ARTICLE	IF	CITATIONS
259	The Primary Outcome Is Positive – Is That Good Enough?. <i>New England Journal of Medicine</i> , 2016, 375, 971-979.	13.9	112
260	Challenges in secondary prevention after acute myocardial infarction: A call for action. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1994-2006.	0.8	117
261	Cholesterol Biosynthesis: A Mechanistic Overview. <i>Biochemistry</i> , 2016, 55, 5483-5506.	1.2	203
262	Integrating Biomarkers and Imaging for Cardiovascular Disease Risk Assessment in Diabetes. <i>Current Cardiology Reports</i> , 2016, 18, 105.	1.3	6
263	Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies. <i>American Journal of Cardiology</i> , 2016, 118, 13A-18A.	0.7	3
264	Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. <i>American Journal of Cardiology</i> , 2016, 118, 19A-32A.	0.7	8
265	Ézetimibe : plus de preuves pour un effet sur la réduction du risque cardiovasculaire. <i>Medicine Des Maladies Metaboliques</i> , 2016, 10, 430-433.	0.1	0
266	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2016, 118, 1812-1820.	0.7	7
268	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. <i>Atherosclerosis</i> , 2016, 253, 81-87.	0.4	39
271	Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes. <i>Heart Lung and Circulation</i> , 2016, 25, 1051-1054.	0.2	0
273	Intestinal CREBH overexpression prevents high-cholesterol diet-induced hypercholesterolemia by reducing Npc1l1 expression. <i>Molecular Metabolism</i> , 2016, 5, 1092-1102.	3.0	32
274	Ezetimibe and cholesterol: how low should you go?. <i>British Journal of Cardiac Nursing</i> , 2016, 11, 288-289.	0.0	0
275	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1289.	3.8	974
276	U-shaped relation between cholesterol and prior ischemic stroke. <i>Brain and Behavior</i> , 2016, 6, e00574.	1.0	2
277	On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). <i>American Heart Journal</i> , 2016, 182, 89-96.	1.2	15
278	Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1212-1222.	0.6	45
279	New directions for pharmacotherapy in the treatment of acute coronary syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2291-2306.	0.9	15
280	Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care. <i>Advances in Therapy</i> , 2016, 33, 2049-2058.	1.3	4

#	ARTICLE	IF	CITATIONS
281	Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis. <i>International Journal of Cardiology</i> , 2016, 225, 50-59.	0.8	16
282	Association Between Low-Density Lipoprotein Cholesterolâ€“Lowering Genetic Variants and Risk of Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1383.	3.8	310
283	Imaging to Assess the Effect of Anti-Inflammatory Therapy in Aortic and Carotid Atherosclerosis âˆ—. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1781-1784.	1.2	1
284	Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients. <i>Postgraduate Medicine</i> , 2016, 128, 859-864.	0.9	7
287	Effect of evolocumab on cholesterol synthesis and absorption. <i>Journal of Lipid Research</i> , 2016, 57, 2217-2224.	2.0	12
288	High-density lipoprotein subclass profile and mortality in patients with coronary artery disease: Results from the GENES study. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 607-617.	0.7	7
289	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. <i>International Journal of Cardiology</i> , 2016, 225, 184-196.	0.8	155
290	Data Monitoring Committees â€” Expect the Unexpected. <i>New England Journal of Medicine</i> , 2016, 375, 1365-1371.	13.9	46
294	Consensus statement on the management of dyslipidaemias in adults. <i>Diabetes and Metabolism</i> , 2016, 42, 398-408.	1.4	18
295	Familial Hypercholesterolemia: Advances in Recognition and Therapy. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 125-134.	1.6	13
296	Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. <i>JAMA Cardiology</i> , 2016, 1, 692.	3.0	233
297	Unmet Needs in LDL-C Lowering: When Statins Wonâ€™t Do!. <i>Drugs</i> , 2016, 76, 1175-1190.	4.9	57
298	Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 222, 119-129.	0.8	23
299	Advances in Lipid Therapy: The Role of Lipid Treatment in Women in Primary Prevention. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 178-189.	1.6	6
300	Ezetimibe increases intestinal expression of the <scp>LDL</scp> receptor gene in dyslipidaemic men with insulin resistance. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1226-1235.	2.2	8
301	Drugs for hypercholesterolaemia â€“ from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. <i>Clinical Medicine</i> , 2016, 16, 353-357.	0.8	8
302	The re-emergence of lipoprotein(a) in a broader clinical arena. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 135-144.	1.6	24
303	Statin Intolerance: A Literature Review and Management Strategies. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 153-164.	1.6	60



#	ARTICLE	IF	CITATIONS
304	Cholesterol Guidelines: More Similar Than Different. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 190-199.	1.6	2
305	Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZetimibe). <i>Cardiovascular Therapeutics</i> , 2016, 34, 371-382.	1.1	45
306	Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 165-171.	1.6	11
307	The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction. <i>American Heart Journal</i> , 2016, 181, 35-42.	1.2	35
308	Cost-Effectiveness of LDL Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. <i>Clinical Cardiology</i> , 2016, 39, 313-320.	0.7	74
309	Discussion around statin discontinuation in older adults and patients with wasting diseases. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 396-399.	2.9	39
310	Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2004-2010.	1.1	130
311	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	1.0	2,393
312	Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 217-230.	1.0	31
313	The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. <i>European Heart Journal</i> , 2016, 37, 3576-3584.	1.0	71
314	Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21-years follow-up on the Steno-2 randomised trial. <i>Diabetologia</i> , 2016, 59, 2298-2307.	2.9	378
315	The efficacy of ezetimibe does not seem a credible real effect. <i>International Journal of Cardiology</i> , 2016, 222, 795-796.	0.8	2
316	Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. <i>International Journal of Cardiology</i> , 2016, 223, 488-493.	0.8	18
317	National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. <i>Heart Lung and Circulation</i> , 2016, 25, 895-951.	0.2	222
318	Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2016, 252, 21-27.	0.4	27
319	Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 743.	3.8	286
320	Hypolipidemic drugs in elderly subjects: Indications and limits. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 1064-1070.	1.1	6
322	Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins – ODYSSEY JAPAN Randomized Controlled Trial. <i>Circulation Journal</i> , 2016, 80, 1980-1987.	0.7	92

#	ARTICLE	IF	CITATIONS
323	Introduction: What Have We Learned Since the 2013 ACC/AHA Guidelines?. American Journal of Cardiology, 2016, 118, 1A-3A.	0.7	2
324	Determining When to Add Nonstatin Therapy. Journal of the American College of Cardiology, 2016, 68, 2412-2421.	1.2	125
325	Bringing Structure to the Art of Lipid-Lowering Therapy. Journal of the American College of Cardiology, 2016, 68, 2422-2424.	1.2	1
327	Future of the Prevention and Treatment of Coronary Artery Disease. Circulation Journal, 2016, 80, 1067-1072.	0.7	37
328	Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes. Endocrine Journal, 2016, 63, 431-440.	0.7	14
329	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160mg/dl or Higher. Cardiovascular Drugs and Therapy, 2016, 30, 473-483.	1.3	160
330	Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis, 2016, 255, 200-209.	0.4	88
331	Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. Journal of Clinical Lipidology, 2016, 10, 1406-1413.	0.6	7
332	Oxidized Low-density Lipoprotein (OxLDL)-Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let-7c Is Integral to the Effect. Journal of the American Heart Association, 2016, 5, .	1.6	61
333	Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment. Pharmacogenomics, 2016, 17, 1621-1628.	0.6	11
334	Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet, The, 2016, 388, 2239-2253.	6.3	584
335	Personalizing Treatment: Between Primary and Secondary Prevention. American Journal of Cardiology, 2016, 118, 4A-12A.	0.7	15
336	2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2016, 252, 207-274.	0.4	415
337	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	0.8	775
338	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. Atherosclerosis, 2016, 252, 1-8.	0.4	26
339	Updates on Acute Coronary Syndrome. JAMA Cardiology, 2016, 1, 718.	3.0	127
340	LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. American Journal of Cardiovascular Drugs, 2016, 16, 323-336.	1.0	18
342	Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis, 2016, 251, 248-254.	0.4	61

#	ARTICLE	IF	CITATIONS
343	Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Studyâ€”Observational Study. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1091-1097.	0.6	8
344	Carboxylic Acids and Lactones as HMG-CoA Reductase Inhibitors. , 2016, , 71-85.		1
346	Amendment of the lowâ€”density lipoprotein cholesterol target in the â€”Chinese Guidelines for the Prevention and Treatment of Adult Dyslipidemiaâ€™: Opinion. <i>Chronic Diseases and Translational Medicine</i> , 2016, 2, 7-9.	0.9	7
347	Intensive statin therapy in India: Demonstrating efficacy and safety. <i>Indian Heart Journal</i> , 2016, 68, 756-757.	0.2	1
348	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. <i>International Journal of Cardiology</i> , 2016, 225, 268-283.	0.8	17
349	Complicaciones macrovasculares de la diabetes. EvaluaciÃ³n del riesgo cardiovascular y objetivos terapÃ©uticos. Estrategias de prevenciÃ³n y tratamiento. <i>Medicine</i> , 2016, 12, 947-957.	0.0	1
350	Very low LDLâ€” levels may safely provide additional clinical cardiovascular benefit: the evidence to date. <i>International Journal of Clinical Practice</i> , 2016, 70, 886-897.	0.8	20
351	Impact of diet and exercise on proprotein convertase subtilisin/kexin 9: A mini-review. <i>Vascular Pharmacology</i> , 2016, 87, 10-13.	1.0	5
352	Glycaemic Effects of Non-statin Lipid-Lowering Therapies. <i>Current Cardiology Reports</i> , 2016, 18, 133.	1.3	4
353	LDL cholesterol in early pregnancy and offspring cardiovascular disease risk factors. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1369-1378.e7.	0.6	36
354	Effect of selected clinical trial publication on adjunctive nonstatin medication prescribing in the Veterans Health Administration system. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, S141-S147.	0.5	0
355	Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1967.	3.8	14
356	Reductions in Atherogenic Lipids and Major Cardiovascular Events. <i>Circulation</i> , 2016, 134, 1931-1943.	1.6	110
357	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , 2017, 38, ehw480.	1.0	137
359	Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes. <i>Current Cardiology Reports</i> , 2016, 18, 114.	1.3	3
360	Microvesicles in Autoimmune Diseases. <i>Advances in Clinical Chemistry</i> , 2016, 77, 125-175.	1.8	46
361	Improving cardiovascular outcomes by intensifying low density lipoprotein lowering therapy in high-risk patients. <i>European Heart Journal</i> , 2016, 37, 3585-3587.	1.0	3
362	Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis. <i>Scientific Reports</i> , 2016, 6, 31337.	1.6	38

#	ARTICLE	IF	CITATIONS
364	Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future: Table 1.. International Journal of Epidemiology, 2016, 45, 1351-1371.	0.9	22
365	Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Annals of Internal Medicine, 2016, 164, 542.	2.0	487
366	The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids in Health and Disease, 2016, 15, 95.	1.2	47
367	Title is missing!. Kagaku To Seibutsu, 2016, 54, 379-381.	0.0	0
369	Low-density lipoprotein cholesterol goals: still not in patients' best interest: Table 1. Evidence-Based Medicine, 2016, 21, 128-133.	0.6	1
372	Impact of metabolic syndrome on lipid target achievements in the Arabian Gulf: findings from the CEPHEUS study. Diabetology and Metabolic Syndrome, 2016, 8, 49.	1.2	2
374	A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol. Mediterranean Journal of Nutrition and Metabolism, 2016, 9, 125-135.	0.2	19
377	Lactobacillus plantarum CUL66 can impact cholesterol homeostasis in Caco-2 enterocytes. Beneficial Microbes, 2016, 7, 443-451.	1.0	34
379	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. Wiener Klinische Wochenschrift, 2016, 128, 216-228.	1.0	8
382	Lipoprotein (a), an independent cardiovascular risk marker. Clinical Diabetes and Endocrinology, 2016, 2, 7.	1.3	26
383	Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment. JAMA Internal Medicine, 2016, 176, 1105.	2.6	66
386	Cholesterol-absorbed in thought. Current Opinion in Lipidology, 2016, 27, 202-203.	1.2	0
387	Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial. Atherosclerosis, 2016, 251, 367-372.	0.4	22
388	Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. Expert Opinion on Biological Therapy, 2016, 16, 1125-1134.	1.4	23
389	Where to now in cardiovascular disease prevention. Atherosclerosis, 2016, 251, 483-489.	0.4	2
390	What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond. Journal of the American Pharmacists Association: JAPhA, 2016, 56, 284-292.	0.7	6
391	Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology, 2016, 67, 3025.	1.2	1
392	Reply. Journal of the American College of Cardiology, 2016, 67, 3025-3026.	1.2	1

#	ARTICLE	IF	CITATIONS
394	Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1524-1528.	0.8	12
395	Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2994-3001.	1.8	17
396	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. <i>Diabetes</i> , 2016, 65, 1767-1778.	0.3	155
397	Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. <i>American Journal of Cardiology</i> , 2016, 117, 1928-1933.	0.7	92
399	PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions. <i>Hellenic Journal of Cardiology</i> , 2016, 57, 86-91.	0.4	19
400	Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. <i>Journal of Clinical Lipidology</i> , 2016, 10, 833-841.	0.6	92
402	Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: A Critique. <i>American Journal of Medicine</i> , 2016, 129, 906-912.	0.6	6
403	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. <i>Journal of Clinical Lipidology</i> , 2016, 10, 635-645.e1.	0.6	35
404	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. <i>Endocrine</i> , 2016, 54, 32-37.	1.1	1
405	Implementation of a new guideline in cardiovascular secondary preventive care: subanalysis of a randomized controlled trial. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 77.	0.7	6
406	Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. <i>BMC Medicine</i> , 2016, 14, 4.	2.3	68
407	Expert opinion: the therapeutic challenges faced by statin intolerance. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1497-1507.	0.9	43
408	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. <i>Circulation</i> , 2016, 133, 2459-2502.	1.6	766
409	Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 65-74.	1.3	11
410	A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. <i>Journal of Medical Economics</i> , 2016, 19, 1003-1010.	1.0	6
411	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	0.8	683
412	Cholesterol trials and mortality. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 168-177.	1.1	17
413	Mendelian Randomization for the Identification of Causal Pathways in Atherosclerotic Vascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 41-49.	1.3	10

#	ARTICLE	IF	CITATIONS
414	Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome. Journal of the American College of Cardiology, 2016, 67, 353-361.	1.2	173
415	PROVE-IT to IMPROVE-IT. Journal of the American College of Cardiology, 2016, 67, 362-364.	1.2	3
416	Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease. Journal of Vascular Surgery, 2016, 63, 756-763.	0.6	12
417	The year in cardiology 2015: acute coronary syndromes. European Heart Journal, 2016, 37, 221-228.	1.0	13
418	Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey. Atherosclerosis, 2016, 246, 243-250.	0.4	173
419	Update on PCSK9 therapies for the treatment of dyslipidemia. Expert Review of Endocrinology and Metabolism, 2016, 11, 87-95.	1.2	2
420	Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications. Future Cardiology, 2016, 12, 115-128.	0.5	19
421	Might ezetimibe be considered an expensive placebo?. International Journal of Cardiology, 2016, 207, 48-49.	0.8	1
422	Definition of Best Medical Treatment in Asymptomatic and Symptomatic Carotid Artery Stenosis. Angiology, 2016, 67, 411-419.	0.8	59
423	Immunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys Infused with a Lipidated Tetranectin-ApoA-I Fusion Protein. Toxicological Sciences, 2016, 150, 378-389.	1.4	8
424	Overcoming Challenges With Statin Therapy. Journal of the American Heart Association, 2016, 5, .	1.6	49
425	Advances in treatment of dyslipidaemia. Nature Reviews Cardiology, 2016, 13, 74-75.	6.1	10
426	Catch and Release. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 7-8.	1.1	4
427	Comparative impact of implementing the 2013 or 2014 cholesterol guideline on vascular events in a quality improvement network. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 56-66.	1.0	0
428	Niacin: old habits die hard. Heart, 2016, 102, 170-171.	1.2	1
429	The Role of Ezetimibe in the Treatment of Cardiovascular Disease. Current Atherosclerosis Reports, 2016, 18, 8.	2.0	3
430	The 2013 ACC/AHA Cholesterol Treatment Guidelines: Applicability to Patients with Diabetes. Current Diabetes Reports, 2016, 16, 13.	1.7	10
431	Does IMPROVE-IT prove it?. Preventive Medicine, 2016, 85, 32-35.	1.6	2

#	ARTICLE	IF	CITATIONS
432	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Canadian Journal of Cardiology, 2016, 32, S35-S65.	0.8	194
433	Vascular Risk and Cardiac Rehabilitation 2015: A Selection of Topical Issues. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 294-299.	0.4	1
434	History and future of omega-3 fatty acids in cardiovascular disease. Current Medical Research and Opinion, 2016, 32, 301-311.	0.9	29
435	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. Expert Opinion on Pharmacotherapy, 2016, 17, 275-281.	0.9	9
436	Statin therapy across the lifespan: evidence in major age groups. Expert Review of Cardiovascular Therapy, 2016, 14, 341-366.	0.6	12
437	Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?. American Heart Journal, 2016, 172, 42-44.	1.2	1
438	Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. American Journal of Cardiovascular Drugs, 2016, 16, 83-92.	1.0	10
439	New Strategies to Treat High Cholesterol. JAMA - Journal of the American Medical Association, 2016, 315, 1169.	3.8	0
440	Mendelian randomization to assess causal effects of blood lipids on coronary heart disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 124-130.	1.2	58
441	Heart Failure Prevention: Special Considerations for Women. Current Cardiovascular Risk Reports, 2016, 10, 1.	0.8	0
442	Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circulation Research, 2016, 118, 579-585.	2.0	131
443	Translational atherosclerosis research: From experimental models to coronary artery disease in humans. Atherosclerosis, 2016, 248, 110-116.	0.4	16
444	Recent advances in the pharmacological management of hypercholesterolaemia. Lancet Diabetes and Endocrinology, the, 2016, 4, 436-446.	5.5	28
445	Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT. Atherosclerosis, 2016, 248, 216-218.	0.4	18
447	New Era of Lipid-Lowering Drugs. Pharmacological Reviews, 2016, 68, 458-475.	7.1	45
448	Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 586-590.	1.1	15
449	Pharmacological approaches of refractory angina. , 2016, 163, 118-131.		9
450	Comparison of <sc>PCSK9</sc> Inhibitor Evolocumab vs Ezetimibe in Statinâ€ntolerant Patients: Design of the Goal Achievement After Utilizing an Antiâ€sc>PCSK9</sc> Antibody in Statinâ€ntolerant Subjects 3 (<sc>GAUSS</sc>â€3) Trial. Clinical Cardiology, 2016, 39, 137-144.	0.7	32

#	ARTICLE	IF	CITATIONS
451	Selección de temas de actualidad en cardiopatía isquémica y cuidados agudos cardiológicos 2015. Revista Española De Cardiología, 2016, 69, 408-414.	0.6	4
452	From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 44-53.	1.4	30
453	Are plant sterols and plant stanols a viable future treatment for dyslipidemia?. Expert Review of Cardiovascular Therapy, 2016, 14, 549-551.	0.6	6
454	Rationale and design of the Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. American Heart Journal, 2016, 173, 94-101.	1.2	158
455	Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens. Current Atherosclerosis Reports, 2016, 18, 11.	2.0	11
456	Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia. Atherosclerosis, 2016, 247, 40-47.	0.4	19
457	The year in cardiology 2015: prevention. European Heart Journal, 2016, 37, 510-519.	1.0	13
458	The Success Story of LDL Cholesterol Lowering. Circulation Research, 2016, 118, 721-731.	2.0	48
459	From Lipids to Inflammation. Circulation Research, 2016, 118, 732-749.	2.0	180
460	A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. Journal of Clinical Lipidology, 2016, 10, 240-264.	0.6	3
461	Association between statin treatment and LDL-cholesterol levels on the rate of ST-elevation myocardial infarction among patients with acute coronary syndromes: ACS Israeli Survey (ACSIS) 2002-2010. International Journal of Cardiology, 2016, 210, 133-138.	0.8	6
462	Reply to: Ezetimibe: A real effect?. International Journal of Cardiology, 2016, 209, 337-338.	0.8	1
463	A Test in Context. Journal of the American College of Cardiology, 2016, 67, 712-723.	1.2	258
464	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes and Endocrinology, 2016, 4, 403-410.	5.5	133
465	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	2.1	19
466	Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. Current Neurology and Neuroscience Reports, 2016, 16, 24.	2.0	12
467	HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation. Expert Opinion on Therapeutic Targets, 2016, 20, 907-921.	1.5	11
468	Getting What the Guidelines Stated Matters. Journal of the American College of Cardiology, 2016, 67, 119-120.	1.2	0



#	ARTICLE	IF	CITATIONS
469	ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. <i>Nutrition</i> , 2016, 32, 767-776.	1.1	15
470	Changing characteristics of statin-related cIMT trials from 1988 to 2006. <i>Atherosclerosis</i> , 2016, 246, 121-129.	0.4	3
471	Randomized trials of closure of persistent foramen ovale (PFO) vs medical therapy for patients with cryptogenic stroke – Effect of lost-to-follow-up and withdrawal of consent. <i>International Journal of Cardiology</i> , 2016, 207, 308-309.	0.8	8
472	New Therapeutic Approaches to the Treatment of Dyslipidemia. <i>Cell Metabolism</i> , 2016, 23, 405-412.	7.2	67
473	Almanac 2015: coronary artery disease. <i>Heart</i> , 2016, 102, 492-499.	1.2	7
474	Effects of phytosterols on markers of inflammation: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2016, 248, 76-83.	0.4	74
475	Why do patients participate in long-term cardiovascular trials? – a questionnaire-based study. <i>Scandinavian Cardiovascular Journal</i> , 2016, 50, 83-87.	0.4	2
476	Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 804-814.	1.8	36
477	Approach to Statin Use in 2016: an Update. <i>Current Atherosclerosis Reports</i> , 2016, 18, 20.	2.0	26
478	Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature. <i>Atherosclerosis</i> , 2016, 247, 189-192.	0.4	16
479	Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1278-1285.	1.2	221
480	Genetics of Coronary Artery Disease. <i>Circulation Research</i> , 2016, 118, 564-578.	2.0	288
481	Efficacy of ezetimibe: A real effect?. <i>International Journal of Cardiology</i> , 2016, 209, 335-336.	0.8	1
482	Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. <i>European Heart Journal</i> , 2016, 37, 1373-1379.	1.0	180
483	A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2016, 117, 40-47.	0.7	93
484	Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2016, 133, 1574-1581.	1.6	66
485	Cardiovascular risk reduction: the future of cholesterol lowering drugs. <i>Current Opinion in Pharmacology</i> , 2016, 27, 62-69.	1.7	7
486	National Lipid Association Annual Summary of Clinical Lipidology 2016. <i>Journal of Clinical Lipidology</i> , 2016, 10, S1-S43.	0.6	99

#	ARTICLE	IF	CITATIONS
487	Genetic mutations you want. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2554-2557.	3.3	6
488	Celecoxib for the treatment of atherosclerosis. Expert Opinion on Investigational Drugs, 2016, 25, 619-633.	1.9	16
489	Perspectives on Treatment for Nonalcoholic Steatohepatitis. Gastroenterology, 2016, 150, 1835-1848.	0.6	71
490	PCSK9 Inhibitors: A Technology Worth Paying For?. Pharmacoeconomics, 2016, 34, 217-220.	1.7	21
491	Statin therapy with or without ezetimibe and the progression to diabetes. Journal of Clinical Lipidology, 2016, 10, 306-313.	0.6	37
492	Management of residual risk after statin therapy. Atherosclerosis, 2016, 245, 161-170.	0.4	71
493	Current Controversies With Recent Cholesterol Treatment Guidelines. Journal of Pharmacy Practice, 2016, 29, 15-25.	0.5	6
494	8. Cardiovascular Disease and Risk Management. Diabetes Care, 2016, 39, S60-S71.	4.3	237
495	Postprandial hyperlipidemia as a potential residual risk factor. Journal of Cardiology, 2016, 67, 335-339.	0.8	84
496	Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease. Heart Lung and Circulation, 2016, 25, 459-465.	0.2	38
497	Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque. European Heart Journal, 2016, 37, 1959-1967.	1.0	181
498	Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution. European Heart Journal, 2016, 37, 520-523.	1.0	5
499	Reply to comment on: Effects of ezetimibe/simvastatin combination on metabolic parameters by Prof. Moses S Elisaf. International Journal of Cardiology, 2016, 202, 154-155.	0.8	0
500	Tratamiento estatino-céntrico de la dislipemia. ¿Nuevo paradigma basado en la evidencia o solo parte de la evidencia?. Endocrinología Y Nutricion: Organó De La Sociedad Espanola De Endocrinología Y Nutricion, 2016, 63, 1-3.	0.8	1
501	Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opinion on Pharmacotherapy, 2016, 17, 369-380.	0.9	43
502	The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. European Heart Journal, 2016, 37, 536-545.	1.0	211
503	Metabolic syndrome update. Trends in Cardiovascular Medicine, 2016, 26, 364-373.	2.3	576
504	The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?. European Journal of Preventive Cardiology, 2016, 23, 1062-1064.	0.8	5

#	ARTICLE	IF	CITATIONS
505	Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 944-952.	0.4	23
506	Califf for the FDA. <i>New England Journal of Medicine</i> , 2016, 374, 176-177.	13.9	2
507	Evidence, Guidelines, and Gut Checks: Musings on Entering the Post-Statins Era of Lipid Management. <i>Canadian Journal of Cardiology</i> , 2016, 32, 271-274.	0.8	1
509	Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 205-215.	0.9	2
510	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
511	Statin tolerability: In defence of placebo-controlled trials. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 891-896.	0.8	32
512	Statin-Ezetimibe Combination Therapy In Diabetic Individuals. <i>Angiology</i> , 2016, 67, 507-509.	0.8	6
513	Individualized lipid-lowering therapy to further reduce residual cardiovascular risk. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 169, 198-201.	1.2	8
514	Ezetimibe enhances and stabilizes anticoagulant effect of warfarin. <i>Heart and Vessels</i> , 2017, 32, 47-54.	0.5	10
515	Treatment of Hypercholesterolemia in 2015. <i>American Journal of Therapeutics</i> , 2017, 24, e121-e129.	0.5	2
516	Evaluating bempedoic acid for the treatment of hyperlipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 251-259.	1.9	40
517	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. <i>Journal of Medical Economics</i> , 2017, 20, 555-564.	1.0	49
518	A Randomized Open-Label Trial to Assess the Effect of Plant Sterols Associated with Ezetimibe in Low-Density Lipoprotein Levels in Patients with Coronary Artery Disease on Statin Therapy. <i>Journal of Medicinal Food</i> , 2017, 20, 30-36.	0.8	12
519	Clinical Study on efficacy of allopurinol in patients with acute coronary syndrome and its functional mechanism. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 360-365.	0.4	22
520	Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 440.	3.8	0
521	Absence of intestinal microbiota increases cyclodextrin stimulated reverse cholesterol transport. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1600674.	1.5	5
522	Statin-associated muscle symptoms—Managing the highly intolerant. <i>Journal of Clinical Lipidology</i> , 2017, 11, 24-33.	0.6	44
523	Lipid and other management to improve arterial disease and survival in end stage renal disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 343-349.	0.9	3

#	ARTICLE	IF	CITATIONS
524	Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series. <i>Journal of Clinical Lipidology</i> , 2017, 11, 289-293.	0.6	3
526	Pleiotropic Effects of Statins on the Cardiovascular System. <i>Circulation Research</i> , 2017, 120, 229-243.	2.0	808
527	Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients. <i>American Journal of Cardiology</i> , 2017, 119, 742-748.	0.7	17
530	Genetics for the Identification of Lipid Targets Beyond PCSK9. <i>Canadian Journal of Cardiology</i> , 2017, 33, 334-342.	0.8	8
531	Standards of Care and Treatment in Diabetes. <i>Physician Assistant Clinics</i> , 2017, 2, 13-23.	0.1	11
532	Psychometric Evaluation of a Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection. <i>Value in Health</i> , 2017, 20, 430-440.	0.1	6
533	Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 12.	0.7	16
534	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2017, 19, 7.	1.3	42
535	Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab. <i>Journal of the American College of Cardiology</i> , 2017, 69, 471-482.	1.2	166
537	Consensus statement on the management of dyslipidaemias in adults. <i>Annales D'Endocrinologie</i> , 2017, 78, 43-53.	0.6	3
538	Comprehensive efforts to increase adherence to statin therapy. <i>European Heart Journal</i> , 2017, 38, ehw628.	1.0	40
539	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 391-402.	5.5	56
541	Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 72-77.	0.4	5
542	Evidence-based goals in LDL-C reduction. <i>Clinical Research in Cardiology</i> , 2017, 106, 237-248.	1.5	69
543	Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 981-989.	0.8	33
544	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. <i>Diabetes Care</i> , 2017, 40, 419-430.	4.3	256
545	Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. <i>Circulation</i> , 2017, 135, 2091-2101.	1.6	403
546	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 911-921.	1.2	157

#	ARTICLE	IF	CITATIONS
548	Design and rationale of the <sc>EBBINGHAUS</sc> trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy. A cognitive study of patients enrolled in the <sc>FOURIER</sc> trial. <i>Clinical Cardiology</i> , 2017, 40, 59-65.	0.7	54
549	Adaptación española de las guías europeas de 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017, 29, 69-85.	0.4	7
550	Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study. <i>International Journal of Cardiology</i> , 2017, 233, 43-51.	0.8	10
552	Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. <i>BMJ Open</i> , 2017, 7, e013255.	0.8	32
553	Ezetimibe: an update on its clinical usefulness in specific patient groups. <i>Therapeutic Advances in Chronic Disease</i> , 2017, 8, 4-11.	1.1	44
554	Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. <i>Journal of Clinical Lipidology</i> , 2017, 11, 674-681.	0.6	28
555	Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2017, 33, 869-876.	0.9	5
556	Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) – A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. <i>American Heart Journal</i> , 2017, 187, 182-190.	1.2	66
557	Genetics of coronary artery disease: discovery, biology and clinical translation. <i>Nature Reviews Genetics</i> , 2017, 18, 331-344.	7.7	448
558	Alirocumab for the treatment of hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 633-643.	1.4	23
559	Challenges with Evidence-Based Management of Stable Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2017, 19, 11.	1.3	6
560	From the Editor: New guidelines are coming. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1-2.	0.6	3
561	2017 Taiwan lipid guidelines for high risk patients. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 217-248.	0.8	123
562	Who Should Receive Ezetimibe? –. <i>Journal of the American College of Cardiology</i> , 2017, 69, 922-923.	1.2	1
563	A Test in Context: Lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2017, 69, 692-711.	1.2	668
564	Plant sterol enriched functional food and atherosclerosis. <i>British Journal of Pharmacology</i> , 2017, 174, 1281-1289.	2.7	45
565	Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 167-178.	0.7	18
566	Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells. <i>Stem Cell Reports</i> , 2017, 8, 605-618.	2.3	27

#	ARTICLE	IF	CITATIONS
567	Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. <i>Current Heart Failure Reports</i> , 2017, 14, 59-70.	1.3	72
568	Lipoprotein(a) in nephrological patients. <i>Clinical Research in Cardiology Supplements</i> , 2017, 12, 27-30.	2.0	5
569	Pathophysiology and treatment of atherosclerosis. <i>Netherlands Heart Journal</i> , 2017, 25, 231-242.	0.3	186
570	Cost Effectiveness of Nonstatin-to-Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1995.	1.2	1
571	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1994-1995.	1.2	0
572	PCSK9 as a therapeutic target for cardiovascular disease. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 810-814.	0.8	15
573	Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. <i>Journal of Medical Economics</i> , 2017, 20, 723-731.	1.0	12
574	Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk. <i>Current Cardiology Reports</i> , 2017, 19, 52.	1.3	13
575	Should a statin be given to all hypertensive patients?. <i>Artery Research</i> , 2017, 18, 66.	0.3	0
576	Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HJ-PROPER study, a prospective, open-label, randomized trial. <i>European Heart Journal</i> , 2017, 38, 2264-2276.	1.0	94
577	Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome. <i>JAMA Internal Medicine</i> , 2017, 177, 887.	2.6	8
578	Incident Myocardial Infarction and Very Late Stent Thrombosis in Outpatients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2149-2156.	1.2	35
579	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	1.0	2,292
580	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , 2017, 261, 12-18.	0.4	32
581	Non-ST Elevation Acute Coronary Syndromes: A Comprehensive Review. <i>Current Problems in Cardiology</i> , 2017, 42, 266-305.	1.1	14
582	Dyslipidaemia in type 2 diabetes mellitus. <i>Current Opinion in Cardiology</i> , 2017, 32, 422-429.	0.8	26
583	Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. <i>Current Atherosclerosis Reports</i> , 2017, 19, 29.	2.0	11
584	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. <i>Circulation Research</i> , 2017, 121, 81-88.	2.0	68

#	ARTICLE	IF	CITATIONS
585	Advances in the management of dyslipidemia. <i>Current Opinion in Cardiology</i> , 2017, 32, 348-355.	0.8	1
586	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	8
587	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. <i>Endocrine Practice</i> , 2017, 23, 1-87.	1.1	766
588	PCSK9 inhibitors: smooth sailing or a little turbulence ahead?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 490-492.	5.5	1
589	Deep thoughts on lipids and cognition. <i>Current Opinion in Lipidology</i> , 2017, 28, 288-289.	1.2	0
590	Early Detection and Treatment of the Vulnerable Coronary Plaque. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	60
591	Challenges in secondary prevention after acute myocardial infarction: A call for action. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 299-310.	0.4	25
592	Do triglyceride-lowering drugs decrease risk of cardiovascular disease?. <i>Current Opinion in Lipidology</i> , 2017, 28, 374-379.	1.2	12
593	Mendelian Randomization Implicates High-Density Lipoprotein Cholesterol-Associated Mechanisms in Etiology of Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2017, 124, 1165-1174.	2.5	109
594	Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition) <a href="#">Tj ETQq1 1 0.784314 egBT /Over</a>	1.7	14
595	Cardiovascular risk assessment in patients with diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 25.	1.2	154
596	PCSK9 inhibitors- A new age in lipid management?. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 171-171.	0.9	0
597	The PCSK9 adventure â€” humanizing extreme LDL lowering. <i>Nature Reviews Cardiology</i> , 2017, 14, 319-320.	6.1	2
598	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. <i>Atherosclerosis Supplements</i> , 2017, 26, 16-24.	1.2	24
599	Practical aspects in the management of statin-associated muscle symptoms (SAMS). <i>Atherosclerosis Supplements</i> , 2017, 26, 45-55.	1.2	21
600	On the Stability of Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2157-2159.	1.2	4
601	Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 447-452.	1.0	2
602	Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol $\geq 50$ mg/dl. <i>American Journal of Cardiology</i> , 2017, 120, 174-180.	0.7	6

#	ARTICLE	IF	CITATIONS
603	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. <i>Metabolism: Clinical and Experimental</i> , 2017, 74, 43-46.	1.5	19
604	Effect of alirocumab dose increase on LDL-lowering and lipid goal attainment. <i>Coronary Artery Disease</i> , 2017, 28, 186-187.	0.3	0
605	A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels. <i>Postgraduate Medical Journal</i> , 2017, 93, 205-208.	0.9	1
606	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2017, 4, CD011748.	1.5	93
607	Human genetic insights into lipoproteins and risk of cardiometabolic disease. <i>Current Opinion in Lipidology</i> , 2017, 28, 113-119.	1.2	12
608	Role of Nonstatin Therapies for Low-Density Lipoprotein Cholesterol Lowering in Management of Atherosclerotic Cardiovascular Disease Risk. <i>JAMA Cardiology</i> , 2017, 2, 218.	3.0	1
609	Ezetimibe: Use, costs, and adverse events in Australia. <i>Cardiovascular Therapeutics</i> , 2017, 35, 40-46.	1.1	12
610	Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 110-117.	0.3	30
611	The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2017, 70, 754-762.	0.4	6
612	Reduction of LDL-C-related residual cardiovascular risk with ezetimibe: are mechanistic considerations warranted in practice?. <i>European Heart Journal</i> , 2017, 38, 2276-2278.	1.0	1
613	Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. <i>Circulation</i> , 2017, 136, e1-e23.	1.6	884
614	Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. <i>Journal of Clinical Lipidology</i> , 2017, 11, 929-937.	0.6	9
615	Emerging biologic therapies for hypercholesterolaemia. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1077-1087.	1.4	10
616	Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 88-100.	0.8	45
617	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1933-1942.	13.9	593
618	Evidence for more intensive cholesterol lowering. <i>Current Opinion in Lipidology</i> , 2017, 28, 291-299.	1.2	13
619	Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3034-3043.	3.0	30
620	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 313-329.	1.0	9



#	ARTICLE	IF	CITATIONS
621	Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 919-926.	1.0	4
622	Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. <i>Current Cardiology Reports</i> , 2017, 19, 62.	1.3	3
624	Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. <i>Atherosclerosis</i> , 2017, 263, 36-41.	0.4	59
625	Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 71-76.	0.8	15
626	Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. <i>Annals of Pharmacotherapy</i> , 2017, 51, 914-920.	0.9	3
627	Planning secondary prevention: Room for improvement. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 22-28.	0.8	25
628	Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL). <i>Journal of Clinical Lipidology</i> , 2017, 11, 872-879.	0.6	9
629	Challenges in secondary prevention after acute myocardial infarction: A call for action. <i>European Journal of Cardiovascular Nursing</i> , 2017, 16, 369-380.	0.4	18
630	PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?. <i>Heart</i> , 2017, 103, 1670-1679.	1.2	21
631	Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. <i>Scientific Reports</i> , 2017, 7, 2169.	1.6	29
632	Cardiovascular and Metabolic Effects of <i>ANGPTL3</i> Antisense Oligonucleotides. <i>New England Journal of Medicine</i> , 2017, 377, 222-232.	13.9	482
633	JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2). <i>Journal of Clinical Lipidology</i> , 2017, 11, 846-854.	0.6	1
634	Statins in Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2707-2709.	1.2	7
635	Coronary Artery Disease and Myocardial Infarction. , 2017, , 127-163.		0
636	Interventions in type 2 diabetes mellitus and cardiovascular mortality—An overview of clinical trials. <i>European Journal of Internal Medicine</i> , 2017, 42, 1-15.	1.0	11
637	Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. <i>Nature Reviews Cardiology</i> , 2017, 14, 577-590.	6.1	443
639	A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies. <i>Journal of Medical Economics</i> , 2017, 20, 767-775.	1.0	2
640	Prognostic impact of subclinical or manifest extracoronary artery diseases after acute myocardial infarction. <i>Atherosclerosis</i> , 2017, 263, 53-59.	0.4	7

#	ARTICLE	IF	CITATIONS
641	Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. <i>Nature Medicine</i> , 2017, 23, 839-849.	15.2	225
642	Cost-effectiveness of Maintaining Daily Intake of Oat $\beta$ -Glucan for Coronary Heart Disease Primary Prevention. <i>Clinical Therapeutics</i> , 2017, 39, 804-818.e3.	1.1	12
643	Progress toward newer guidelines of lipid management. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 119-121.	1.2	0
644	Lipid control in patients with coronary artery disease in a healthcare area in Caceres (Spain): LIPICERES study. <i>Clnica E Investigacin En Arteriosclerosis (English Edition)</i> , 2017, 29, 13-19.	0.1	0
646	Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. <i>Clinical Therapeutics</i> , 2017, 39, 771-786.e3.	1.1	45
647	Extensive carotid atherosclerosis and the diagnostic accuracy of coronary risk calculators. <i>Preventive Medicine Reports</i> , 2017, 6, 182-186.	0.8	20
648	Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe. <i>Biochemical Pharmacology</i> , 2017, 135, 116-125.	2.0	8
649	Current status of lipid management in acute coronary syndrome. <i>Journal of Cardiology</i> , 2017, 70, 101-106.	0.8	16
650	Association Between the Presence of Carotid Artery Plaque and Cardiovascular Events in Patients With Genetic Hypercholesterolemia. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2017, 70, 551-558.	0.4	5
651	Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DMINSULIN trial. <i>Diabetes and Metabolism</i> , 2017, 43, 453-459.	1.4	15
652	Chronic kidney disease and dyslipidaemia. <i>Clnica E Investigacin En Arteriosclerosis (English Edition)</i> , 2017, 29, 22-35.	0.1	6
653	Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. <i>Scientific Reports</i> , 2017, 7, 238.	1.6	29
654	ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia. <i>Current Opinion in Lipidology</i> , 2017, 28, 193-200.	1.2	74
655	Seeking meta guidelines™ for lipids. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 72-75.	0.8	1
657	Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids. <i>Endocrine Practice</i> , 2017, 23, 100-112.	1.1	39
658	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm  2017 Executive Summary. <i>Endocrine Practice</i> , 2017, 23, 207-238.	1.1	362
659	Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. <i>Clinical Therapeutics</i> , 2017, 39, 819-827.e1.	1.1	38
660	Evaluation of Antiatherogenic Properties of Ezetimibe Using <sup>3</sup> H-Labeled Low-Density-Lipoprotein Cholesterol and <sup>99m</sup> Tc-AbVCAM15 SPECT in ApoE <sup>/</sup> Mice Fed the Paigen Diet. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1088-1093.	2.8	19

#	ARTICLE	IF	CITATIONS
661	Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol. <i>JAMA Cardiology</i> , 2017, 2, 547.	3.0	144
663	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. <i>The Cochrane Library</i> , 2017, , .	1.5	2
664	Effects of dyslipidaemia on monocyte production and function in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 387-400.	6.1	66
665	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	13.9	307
666	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722.	13.9	4,179
667	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 321-419.	0.8	84
668	Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient With Diabetes. <i>Diabetes Care</i> , 2017, 40, 476-484.	4.3	9
669	The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation. <i>Journal of Biological Chemistry</i> , 2017, 292, 1573-1590.	1.6	30
670	Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. <i>Clinical Therapeutics</i> , 2017, 39, 107-117.	1.1	37
671	Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. <i>International Journal of Cardiology</i> , 2017, 228, 173-179.	0.8	66
672	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 343-349.	0.8	16
673	Low-density lipoprotein cholesterol lowering by adding ezetimibe to statin is associated with improvement of postprandial hyperlipidemia in diabetic patients with coronary artery disease. <i>IJC Metabolic &amp; Endocrine</i> , 2017, 14, 9-15.	0.5	1
674	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 1-26.	1.0	45
675	Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 350-358.	1.1	36
676	Secondary cvd preventionâ€”Lipid modification strategies: A critical analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, S187-S193.	1.8	0
677	Investigating cholesterol metabolism and ageing using a systems biology approach. <i>Proceedings of the Nutrition Society</i> , 2017, 76, 378-391.	0.4	16
678	Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.7	4
679	9. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , 2017, 40, S75-S87.	4.3	203

#	ARTICLE	IF	CITATIONS
680	Statins, Ezetimibe, and Proprotein Convertase Subtilisinâ€“Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2017, 119, 565-571.	0.7	14
681	Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 169-181.	1.0	19
682	Optimal Low-Density Lipoprotein Cholesterol for Cardiovascular Prevention: How Low Should We Go?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 405-408.	0.8	3
683	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017, 66, 241-255.	0.3	454
684	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. <i>Advances in Therapy</i> , 2017, 34, 300-323.	1.3	37
685	The challenges of proprotein convertase subtilisinâ€“kexin-9 inhibitors for lipid guidelines and models of care. <i>Current Opinion in Lipidology</i> , 2017, 28, 470-476.	1.2	1
686	Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2017, 3, 281-288.	1.8	2
687	Response to Letter to the Editor: â€œAssociation of TSH With Cardiovascular Disease Risk in Overweight and Obese Children During Lifestyle Interventionâ€œ. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4660-4661.	1.8	0
688	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq0 0 0 rgt /Overlock 10 Tf		
689	Systematic Review and Network Metaâ€“Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	61
690	Moderate to high intensity statin in dialysis patients after acute myocardial infarction: A national cohort study in Asia. <i>Atherosclerosis</i> , 2017, 267, 158-166.	0.4	23
692	Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?. <i>Postgraduate Medicine</i> , 2017, 129, 822-827.	0.9	22
693	Diabetes Mellitus and Control of Cardiovascular Disease Risk Factors. <i>Circulation</i> , 2017, 136, 1204-1206.	1.6	1
694	CETP Inhibitors â€” A New Inning?. <i>New England Journal of Medicine</i> , 2017, 377, 1284-1285.	13.9	23
695	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. <i>Current Diabetes Reports</i> , 2017, 17, 112.	1.7	22
696	Statin Discontinuation, Reinitiation, and Persistence Patterns Among Medicare Beneficiaries After Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	38
697	Coronary Artery Calcium Scoring in Current Clinical Practice: How to Define Its Value?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 85.	0.4	10
698	Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders. <i>Trends in Molecular Medicine</i> , 2017, 23, 1047-1063.	3.5	71

#	ARTICLE	IF	CITATIONS
699	Do Oxidized Lipoproteins Cause Atherosclerotic Cardiovascular Diseases?. Canadian Journal of Cardiology, 2017, 33, 1513-1516.	0.8	2
700	How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. Journal of the American College of Cardiology, 2017, 70, 2171-2185.	1.2	59
701	Critical Appraisal of Biomedical Literature With a Succinct Journal Club Template: The ROOTs Format. Hospital Pharmacy, 2017, 52, 488-495.	0.4	2
702	Review of the top 5 cardiology studies of 2015-16. Canadian Pharmacists Journal, 2017, 150, 380-386.	0.4	2
703	Statins. Vascular Medicine, 2017, 22, 442-445.	0.8	8
704	10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open, 2017, 7, e014150.	0.8	34
705	Interleukin-1 Beta as a Target for Atherosclerosis Therapy. Journal of the American College of Cardiology, 2017, 70, 2278-2289.	1.2	477
706	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1069.	3.0	119
707	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy—Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. JAMA Cardiology, 2017, 2, 1066.	3.0	7
708	Endothelial Functions. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, e108-e114.	1.1	328
709	Ezetimibe, Risk Stratification, and Secondary Prevention. Journal of the American College of Cardiology, 2017, 70, 1199.	1.2	1
710	Evolocumab in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 785-788.	13.9	31
711	Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis, 2017, 266, 158-166.	0.4	96
712	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine, 2017, 377, 1217-1227.	13.9	780
713	Statin Therapy in Patients With Low Serum Levels of Low-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2017, 120, 1947-1954.	0.7	3
714	Strategies for the use of nonstatin therapies. Current Opinion in Lipidology, 2017, 28, 458-464.	1.2	2
715	Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1099-1104.	1.5	16
716	Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Postgraduate Medicine, 2017, 129, 801-810.	0.9	2

#	ARTICLE	IF	CITATIONS
717	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. Progress in Lipid Research, 2017, 68, 57-82.	5.3	63
718	PCSK9 inhibition and type 2 diabetes. Lancet Diabetes and Endocrinology, 2017, 5, 926-927.	5.5	1
719	Dyslipidemia. Physician Assistant Clinics, 2017, 2, 633-650.	0.1	3
720	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY 4</scp> randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1781-1792.	2.2	105
721	Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	1.6	14
722	Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. Scientific Reports, 2017, 7, 9179.	1.6	37
723	Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naïve Individuals. Scientific Reports, 2017, 7, 8422.	1.6	15
724	High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy. Atherosclerosis, 2017, 265, 110-116.	0.4	15
725	Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate. Atherosclerosis, 2017, 266, 229-233.	0.4	4
726	Cholesterol Management After Stroke. , 2017, , 285-294.		0
727	2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2017, 70, 1785-1822.	1.2	313
728	Time for new low density lipoprotein cholesterol (LDL-C) targets?. Expert Opinion on Pharmacotherapy, 2017, 18, 1539-1541.	0.9	2
729	Clinoptilolite for Treatment of Dyslipidemia: Preliminary Efficacy Study. Journal of Alternative and Complementary Medicine, 2017, 23, 738-744.	2.1	8
731	Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. Advances in Therapy, 2017, 34, 1876-1896.	1.3	11
732	Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism. Journal of Cellular and Molecular Medicine, 2017, 21, 3150-3161.	1.6	19
733	CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1770-1775.	1.1	71
734	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. Clínica E Investigación En Arteriosclerosis (English) Tj ETQq0 0 0 rgBT. Overlook 10 Tf 50		
735	The evolving model of care for familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2017, 24, 1729-1732.	0.8	4

#	ARTICLE	IF	CITATIONS
736	Prognostic value of electrocardiogram exercise testing for risk stratification in asymptomatic coronary artery disease. <i>Coronary Artery Disease</i> , 2017, 28, 664-669.	0.3	4
737	Recomendaciones prácticas para el manejo del riesgo cardiovascular asociado a la dislipemia aterogénica, con especial atención al riesgo residual. Adaptación española de un Consenso Europeo de Expertos. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017, 29, 168-177.	0.4	8
738	Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients. <i>Atherosclerosis</i> , 2017, 263, 278-286.	0.4	13
739	Treatment of Cholesterol in 2017. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 417.	3.8	29
741	Electronic clinical decision support system and multifactorial risk factor control in patients with type 2 diabetes in primary health care. <i>European Journal of Internal Medicine</i> , 2017, 44, e35-e37.	1.0	3
742	2016 Guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. <i>Canadian Pharmacists Journal</i> , 2017, 150, 243-250.	0.4	11
743	Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). <i>American Journal of Cardiology</i> , 2017, 120, 931-939.	0.7	25
744	Diabetes-Related Dyslipidemia and Cardiovascular Events. <i>American Journal of the Medical Sciences</i> , 2017, 354, 103-104.	0.4	3
745	History of lipidology and lipoprotein apheresis. <i>Atherosclerosis Supplements</i> , 2017, 30, 1-8.	1.2	20
746	The FOURIER study: The profound study of Nature is the most fertile source of discovery. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 146-147.	0.4	3
747	Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1223-1233.	0.6	61
748	Tratamiento de la angina estable. <i>Medicine</i> , 2017, 12, 2163-2173.	0.0	0
751	Comment on "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease". <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2017, 36, 485-486.	0.2	0
753	Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care. <i>International Journal of Clinical Practice</i> , 2017, 71, e12979.	0.8	11
754	Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further). <i>American Journal of Cardiology</i> , 2017, 120, 1220-1222.	0.7	3
755	Statin Intolerance and the Obsession With Aggressive Cholesterol Lowering to Prevent Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 684.	1.2	0
756	Treating Dyslipidemia for the Primary and Secondary Prevention of Stroke. <i>Seminars in Neurology</i> , 2017, 37, 286-293.	0.5	1
757	Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017, 2, 959.	3.0	124

#	ARTICLE	IF	CITATIONS
758	Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. <i>Clínica e Investigación en Arteriosclerosis (English Edition)</i> , 2017, 29, 168-177.	0.1	1
759	Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk. <i>JAMA Cardiology</i> , 2017, 2, 937.	3.0	0
760	Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era. <i>JAMA Cardiology</i> , 2017, 2, 935.	3.0	17
761	Plaque burden, microstructures and compositions underachieving very low LDL-C levels. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 122-132.	1.2	7
762	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 813-826.	1.2	95
765	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017, 377, 633-643.	13.9	366
766	Evolocumab for the treatment of hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-15.	1.4	5
767	Cholesterol Management in the Era of PCSK9 Inhibitors. <i>Current Cardiology Reports</i> , 2017, 19, 83.	1.3	4
769	Primary Prevention of Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2992-2994.	1.2	26
770	Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	147
772	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2017, 70, 1082.	0.4	189
773	Familial hypercholesterolaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17093.	18.1	315
774	CANTOS. <i>Circulation Research</i> , 2017, 121, 1320-1322.	2.0	30
775	Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	43
776	On P values and effect modification. <i>International Journal of Evidence-Based Healthcare</i> , 2017, 15, 144-151.	0.1	3
777	Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia. <i>Complementary Therapies in Medicine</i> , 2017, 35, 140-144.	1.3	12
778	LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China. <i>Medicine (United States)</i> , 2017, 96, e8555.	0.4	13
780	Adjuvant Therapy for Incremental Low-Density Lipoprotein Cholesterol Reduction With Ezetimibe. <i>Clinical Medicine Insights Therapeutics</i> , 2017, 9, 1179559X1769555.	0.4	0



#	ARTICLE	IF	CITATIONS
781	PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2677-2687.	1.2	96
782	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	29
783	<i>Monascus purpureus</i> for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study. <i>Atherosclerosis Supplements</i> , 2017, 30, 86-91.	1.2	10
784	Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. <i>Clinical Therapeutics</i> , 2017, 39, 2311-2320.e2.	1.1	10
785	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin. <i>JAMA Cardiology</i> , 2017, 2, 1385.	3.0	89
787	Tratamiento de las dislipidemias en situaciones especiales: diabetes mellitus, cardiopatía isquémica e insuficiencia renal. <i>Medicine</i> , 2017, 12, 2526-2533.	0.0	0
788	Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1383-1401.	0.8	43
789	Statistical vs clinical significance: A matter of debate for orlistat treatment. <i>Pharmacological Research</i> , 2017, 124, 158-159.	3.1	0
790	Statin Therapy and Risk of Intracranial Hemorrhage in Patients with Ischemic Stroke. <i>Drug Safety</i> , 2017, 40, 851-853.	1.4	2
791	Sex and gender differences in therapy of type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2017, 131, 230-241.	1.1	76
792	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1243-1260.	0.9	35
795	Systematic Review and Meta-Analysis of the Association Between C-Reactive Protein and Major Cardiovascular Events in Patients with Peripheral Artery Disease. <i>European Journal of Vascular and Endovascular Surgery</i> , 2017, 54, 220-233.	0.8	70
796	Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. <i>Current Cardiology Reports</i> , 2017, 19, 61.	1.3	12
797	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 58.	0.4	16
798	Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. <i>BMC Nephrology</i> , 2017, 18, 147.	0.8	12
799	Are potentially clinically meaningful benefits misinterpreted in cardiovascular randomized trials? A systematic examination of statistical significance, clinical significance, and authors' conclusions. <i>BMC Medicine</i> , 2017, 15, 58.	2.3	5
800	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. <i>BMC Medicine</i> , 2017, 15, 83.	2.3	38
801	Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. <i>Lipids in Health and Disease</i> , 2017, 16, 49.	1.2	7

#	ARTICLE	IF	CITATIONS
802	Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. <i>Lipids in Health and Disease</i> , 2017, 16, 122.	1.2	16
803	Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 22.	1.2	46
805	Hypercholesterolaemia and vascular dementia. <i>Clinical Science</i> , 2017, 131, 1561-1578.	1.8	94
806	Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer. <i>International Journal of Epidemiology</i> , 2017, 46, 1777-1785.	0.9	10
807	The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention. <i>Current Opinion in Cardiology</i> , 2017, 32, 633-641.	0.8	2
809	Statin myopathy: navigating the maze. <i>Current Medical Research and Opinion</i> , 2017, 33, 327-329.	0.9	4
810	Perioperative Cardiovascular Evaluation for Orthotopic Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 26-34.	1.1	15
811	Perspective on Trends in Statin Use. <i>JAMA Cardiology</i> , 2017, 2, 11.	3.0	14
813	Plaque imaging to refine indications for emerging lipid-lowering drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 58-67.	1.4	26
814	Abnormal Coronary Artery Calcium Scans in Asymptomatic Patients. <i>American Journal of Medicine</i> , 2017, 130, 394-397.	0.6	8
815	Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 83-95.	1.0	11
816	Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PROper level of lipid lowering with Pitavastatin and Ezetimibe in acute coronary syndrome (HIJ-PROPER). <i>Journal of Cardiology</i> , 2017, 69, 536-541.	0.8	9
817	PCSK9: Regulation and Target for Drug Development for Dyslipidemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 223-244.	4.2	58
818	Does tablet formulation alone improve adherence and persistence: a comparison of ezetimibe fixed dose combination versus ezetimibe separate pill combination?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 202-210.	1.1	16
819	PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 7-32.	1.0	41
820	Acute myocardial infarction. <i>Lancet, The</i> , 2017, 389, 197-210.	6.3	869
821	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. <i>Annals of Medicine</i> , 2017, 49, 51-62.	1.5	17
822	Pleiotropic effects of statins on acute kidney injury: involvement of KrÄ¼ppel-like factor 4. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 175-181.	0.7	9

#	ARTICLE	IF	CITATIONS
823	Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German <scp>DIVE</scp> and <scp>DPV</scp> registries. Diabetes, Obesity and Metabolism, 2017, 19, 61-69.	2.2	9
824	Leveraging human genetics to guide drug target discovery. Trends in Cardiovascular Medicine, 2017, 27, 352-359.	2.3	26
825	Enfermedad del hĂgado graso no alcohĂlico, asociaciĂn con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hĂgado graso no alcohĂlico. ClĂnica E InvestigaciĂn En Arteriosclerosis, 2017, 29, 185-200.	0.4	6
826	PCSK9 inhibitors: A new era in stroke prevention?. European Journal of Internal Medicine, 2017, 37, e44.	1.0	7
827	Ezetimibe inhibits platelet activation and uPAR expression on endothelial cells. International Journal of Cardiology, 2017, 227, 858-862.	0.8	16
828	Statins and the cholesterol mortality paradox. Scottish Medical Journal, 2017, 62, 19-23.	0.7	10
829	Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. Journal of Clinical Lipidology, 2017, 11, 70-79.e1.	0.6	38
830	Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 2-17.	1.1	81
831	Evaluation of the efficacy, safety and glycaemic effects of evolocumab (<scp>AMG</scp> 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes, Obesity and Metabolism, 2017, 19, 98-107.	2.2	60
832	Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat. European Journal of Preventive Cardiology, 2017, 24, 76-83.	0.8	26
833	Statin intolerance " a question of definition. Expert Opinion on Drug Safety, 2017, 16, 55-63.	1.0	14
834	The need for a new classification of cholesterol lowering therapies. Current Medical Research and Opinion, 2017, 33, 67-69.	0.9	0
835	Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1258-1264.	1.8	40
836	Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same. Journal of the American Association of Nurse Practitioners, 2017, 29, 791-801.	0.5	11
838	Managing hypertriglyceridemia. Nurse Practitioner, 2017, 42, 3-9.	0.2	1
839	Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Experimental and Therapeutic Medicine, 2017, 14, 4942-4950.	0.8	15
840	Effect of Plant Protein on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2017, 6, .	1.6	77
842	ANMCO Scientific Statement: clinical management of hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal Supplements, 2017, 19, D64-D69.	0.0	2

#	ARTICLE	IF	CITATIONS
843	Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*. Journal of Market Access & Health Policy, 2017, 5, 1412753.	0.8	7
844	Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque—The ZIPANGU Study. Circulation Journal, 2017, 81, 1611-1619.	0.7	29
845	Genetic Studies Help Clarify the Complexities of Lipid Biology and Treatment. JAMA - Journal of the American Medical Association, 2017, 318, 915.	3.8	5
846	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology, 2017, 70, 1290-1301.	1.2	162
847	Chronic kidney disease and diabetes associated with long-term outcomes in patients receiving percutaneous coronary intervention. BMC Cardiovascular Disorders, 2017, 17, 242.	0.7	15
848	Prevalence and predictors of elevated high-sensitivity C-reactive protein in post-myocardial infarction patients: Insights from the VIRGO and TRIUMPH registries. Clinical Cardiology, 2017, 40, 1205-1211.	0.7	7
849	Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, The, 2017, 390, 1962-1971.	6.3	487
850	Lipid lowering in renal disease. Australian Prescriber, 2017, 40, 141-146.	0.5	6
851	Thyroid hormones: a potential ally to LDL-cholesterol-lowering agents. Hormones, 2017, 15, 500-510.	0.9	16
853	Una historia resumida. Impacto de los avances en el control lipídico. Revista Espanola De Cardiologia Suplementos, 2017, 17, 7-9.	0.2	0
854	Postprandial Hyperlipidemia and Remnant Lipoproteins. Journal of Atherosclerosis and Thrombosis, 2017, 24, 95-109.	0.9	110
855	Flipped classroom model for learning evidence-based medicine. Advances in Medical Education and Practice, 2017, Volume 8, 619-625.	0.7	10
856	Evolocumab and clinical outcomes in patients with cardiovascular disease. Journal of the Royal College of Physicians of Edinburgh, The, 2017, 47, 153-155.	0.2	12
857	Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug Design, Development and Therapy, 2017, Volume 11, 2121-2129.	2.0	10
858	Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases. Molecules, 2017, 22, 1795.	1.7	21
859	Anti-inflammatory Nanomedicine for Cardiovascular Disease. Frontiers in Cardiovascular Medicine, 2017, 4, 87.	1.1	70
860	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 2017, 1, 1-45.	0.4	70
861	The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis. International Journal of Molecular Sciences, 2017, 18, 1260.	1.8	28

#	ARTICLE	IF	CITATIONS
862	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes. <i>Current Cardiology Reviews</i> , 2017, 13, 168-182.	0.6	9
863	The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery diseaseâ€”The REMEDY-EPC early substudy. <i>PLoS ONE</i> , 2017, 12, e0172800.	1.1	10
864	Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry. <i>PLoS ONE</i> , 2017, 12, e0182687.	1.1	11
865	Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? â€™ Data from a multicenter registry cohort study in Taiwan. <i>PLoS ONE</i> , 2017, 12, e0186861.	1.1	20
866	Transporters for the Intestinal Absorption of Cholesterol, Vitamin E, and Vitamin K. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 347-359.	0.9	44
867	Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0171682.	1.1	10
868	Enhanced Impact of Cholesterol Absorption Marker on New Atherosclerotic Lesion Progression After Coronary Intervention During Statin Therapy. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 123-132.	0.9	10
869	Impact of CD14++CD16+ monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2017, 16, 96.	2.7	30
870	Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. <i>Cardiovascular Diabetology</i> , 2017, 16, 124.	2.7	107
871	Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology. <i>Cardiovascular Diabetology</i> , 2017, 16, 156.	2.7	18
872	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 53.	1.2	34
873	Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 71.	1.2	7
874	One-Year Efficacy and Safety of Evolocumab in Japanese Patientsâ€™â€™â€• A Pooled Analysis From the Open-Label Extension OSLER Studies â€™â€™. <i>Circulation Journal</i> , 2017, 81, 1029-1035.	0.7	10
875	Lipid Lowering Therapy to Modify Plaque Microstructures:. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 360-372.	0.9	7
877	Now is good, earlier is better. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2017, 3, 256-257.	1.8	1
878	Role of Cholesterol Crystals During Acute Myocardial Infarction and Cerebrovascular Accident. <i>Cardiovascular Innovations and Applications</i> , 2017, 2, .	0.1	0
879	The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. <i>Global Cardiology Science &amp; Practice</i> , 2017, 2017, e201702.	0.3	31
881	Diabetes mellitus and stroke: A clinical update. <i>World Journal of Diabetes</i> , 2017, 8, 235.	1.3	105

#	ARTICLE	IF	CITATIONS
882	Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 1270-1276.	0.5	15
883	Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. <i>Oncotarget</i> , 2017, 8, 41582-41589.	0.8	16
884	Atherosclerosis revisited from a clinical perspective: still an inflammatory disease?. <i>Thrombosis and Haemostasis</i> , 2017, 117, 231-237.	1.8	13
885	High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3425-3434.	2.0	14
886	Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 77-94.	0.9	20
887	Statin Intolerance: Diagnosis and Management. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 2017, 02, 014-020.	0.1	0
888	Implementation of a New Clinic-Based, Pharmacist-Managed PCSK9 Inhibitor Consultation Service. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 918-925.	0.5	8
889	New European Society of Cardiology/European Atherosclerosis Society Guideline for the Management of Dyslipidemia. <i>Journal of Lipid and Atherosclerosis</i> , 2017, 6, 8.	1.1	0
891	Advances in Hypercholesterolemia. , 2017, , 663-693.		1
892	Primary and secondary prevention in diabetic patients. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e83-e90.	0.6	0
893	Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. <i>Journal of Thoracic Disease</i> , 2017, 9, 1345-1352.	0.6	6
894	Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease. <i>Journal of Thoracic Disease</i> , 2017, 9, 1822-1825.	0.6	1
896	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 45-51.	0.7	49
897	Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 67, S11-S20.	0.7	15
898	Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors. <i>European Cardiology Review</i> , 2017, 12, 30.	0.7	0
900	Treating Dyslipidemia in Type 2 Diabetes. <i>Cardiology Clinics</i> , 2018, 36, 233-239.	0.9	11
901	Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2018, 34, 1885-1892.	0.9	7
902	Lipid-Lowering Therapy With Ezetimibe Decreases Spontaneous Atherothrombotic Occlusions in a Rabbit Model of Plaque Erosion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 757-771.	1.1	21

#	ARTICLE	IF	CITATIONS
903	RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. International Journal of Diabetes in Developing Countries, 2018, 38, 1-115.	0.3	85
904	Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence. Stroke, 2018, 49, 865-871.	1.0	18
905	PCSK9 inhibitor valuation: A science-based review of the two recent models. Clinical Cardiology, 2018, 41, 544-550.	0.7	7
906	Evolocumab: Considerations for the Management of Hyperlipidemia. Current Atherosclerosis Reports, 2018, 20, 17.	2.0	9
907	Statin Intolerance. Cardiology Clinics, 2018, 36, 225-231.	0.9	36
909	A Clinical Guide to Combination Lipid-Lowering Therapy. Current Atherosclerosis Reports, 2018, 20, 19.	2.0	21
910	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis, 2018, 271, 120-127.	0.4	31
911	Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in Lipid and Vascular Risk Units. EROMOT study. Clínica E Investigación En Arteriosclerosis (English Edition), 2018, 30, 1-9.	0.1	4
912	Bempedoic Acid (ETC-1002). Cardiology Clinics, 2018, 36, 257-264.	0.9	39
913	Predictors of a successful statin reattempt after an adverse reaction. Journal of Clinical Lipidology, 2018, 12, 643-651.	0.6	7
914	Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines. Circulation, 2018, 138, 244-254.	1.6	34
915	The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia. Annals of Pharmacotherapy, 2018, 52, 1000-1018.	0.9	21
916	Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins. Journal of Clinical Lipidology, 2018, 12, 849-856.	0.6	34
917	Diabetes and lipid metabolism. Hormones, 2018, 17, 61-67.	0.9	192
918	Real-life achievement of lipid-lowering treatment targets in the DIABetes and LiFEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors. Nutrition and Diabetes, 2018, 8, 24.	1.5	15
920	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. JAMA - Journal of the American Medical Association, 2018, 319, 1566.	3.8	339
921	Challenges in Interpreting the Lipid-Lowering Trials. JAMA - Journal of the American Medical Association, 2018, 319, 1549.	3.8	10
922	What is new in recent STEMI guidelines?. Journal of Indian College of Cardiology, 2018, 8, 87-94.	0.1	0

#	ARTICLE	IF	CITATIONS
923	Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design. <i>Journal of Cardiology</i> , 2018, 71, 583-589.	0.8	9
924	Intravascular Ultrasound Studies of Plaque Progression and Regression. <i>Cardiology Clinics</i> , 2018, 36, 329-334.	0.9	0
925	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. <i>Circulation</i> , 2018, 138, 770-781.	1.6	126
926	<i>Preventive Cardiology</i> . , 2018, , 269-289.		0
927	Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. <i>Diabetes Care</i> , 2018, 41, 1275-1284.	4.3	43
928	<i>Cardiovascular Risk Factors and Peripheral Arterial Disease</i> . , 2018, , 189-200.		0
929	Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. <i>Heart</i> , 2018, 104, 1699-1705.	1.2	12
930	Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018, 1863, 762-771.	1.2	12
931	Advances in Cardiovascular Care. <i>JACC Basic To Translational Science</i> , 2018, 3, 114-118.	1.9	0
932	Dyslipidemia. <i>Canadian Journal of Diabetes</i> , 2018, 42, S178-S185.	0.4	50
933	Ezetimibe. <i>Circulation</i> , 2018, 137, 1583-1584.	1.6	2
934	Major unmet needs in the cardiovascular area. <i>European Heart Journal Supplements</i> , 2018, 20, C4-C7.	0.0	0
935	Prevention and management of statin adverse effects: A practical approach for pharmacists. <i>Canadian Pharmacists Journal</i> , 2018, 151, 179-188.	0.4	19
936	Cardiovascular Protection in People With Diabetes. <i>Canadian Journal of Diabetes</i> , 2018, 42, S162-S169.	0.4	44
937	Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease—Real-world experience within a large integrated health care system: The IMPRES study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1008-1018.e1.	0.6	8
938	The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 301-308.	1.0	6
939	Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor Deficient (LDLR <sup>+/Δ</sup> and LDLR <sup>-/-</sup> ) Mice. <i>Journal of Lipid Research</i> , 2018, 59, 1178-1190.	1.1	35
940	Documented coronary atherothrombosis as the cause of death in post-discharge patients after coronary revascularization. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 597-606.	0.3	0



#	ARTICLE	IF	CITATIONS
941	Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk. <i>Cardiology Clinics</i> , 2018, 36, 299-310.	0.9	11
942	Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. <i>Canadian Journal of Cardiology</i> , 2018, 34, 532-535.	0.8	1
943	Insights from population-based analyses of plasma lipids across the allele frequency spectrum. <i>Current Opinion in Genetics and Development</i> , 2018, 50, 1-6.	1.5	9
944	Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. <i>Current Opinion in Lipidology</i> , 2018, 29, 95-103.	1.2	23
945	Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. <i>European Heart Journal</i> , 2018, 39, 354-359.	1.0	43
946	Disconnect Between Genes Associated With Ischemic Heart Disease and Targets of Ischemic Heart Disease Treatments. <i>EBioMedicine</i> , 2018, 28, 311-315.	2.7	15
947	Inclisiran for the treatment of dyslipidemia. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 287-294.	1.9	40
948	Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. <i>Atherosclerosis</i> , 2018, 269, 219-228.	0.4	67
949	Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study. <i>International Journal of Cardiology</i> , 2018, 254, 36-42.	0.8	25
950	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levelsâ€”The zero-LDL hypothesis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 292-299.e3.	0.6	51
951	Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2018, 12, 277-291.e3.	0.6	19
952	The pharmacodynamic and clinical trial evidence for statin dose. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1128-1135.	1.1	17
953	Cardiovascular Risk Beyond Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2018, 71, 633-635.	1.2	7
954	Prevention of Cardiovascular Disease. <i>Primary Care - Clinics in Office Practice</i> , 2018, 45, 25-44.	0.7	45
955	Alirocumab vs usual lipidâ€”lowering care as addâ€”on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DMâ€”DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1479-1489.	2.2	76
956	Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 118-129.	1.2	30
957	Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. <i>Annals of Internal Medicine</i> , 2018, 168, 85.	2.0	60
958	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	22

#	ARTICLE	IF	CITATIONS
959	Modeling Survival Distribution as a Function of Time to Treatment Discontinuation: A Dynamic Treatment Regime Approach. <i>Biometrics</i> , 2018, 74, 900-909.	0.8	11
960	The systematic review of randomized controlled trials of PCSK9 antibodies challenges their "efficacy breakthrough" and the "lower, the better" theory. <i>Current Medical Research and Opinion</i> , 2018, 34, 1725-1730.	0.9	4
961	Advances in lipid-lowering therapy through gene-silencing technologies. <i>Nature Reviews Cardiology</i> , 2018, 15, 261-272.	6.1	101
962	PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option. <i>Postgraduate Medicine</i> , 2018, 130, 287-298.	0.9	8
963	Hypolipidemic Drugs and Diabetes Mellitus—Mechanisms and Data From Genetic Trials. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 187-191.	1.0	5
964	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY) Tj ETQq1 1 0.784314 rgBT9 Overlock	1.0	5
965	The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 1-32.	1.2	16
966	Lipid-lowering treatment in peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018, 39, 19-26.	1.7	19
967	The pharmacological management of metabolic syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 397-410.	1.3	80
968	Hypertension with diabetes mellitus complications. <i>Hypertension Research</i> , 2018, 41, 147-156.	1.5	86
969	Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. <i>Clinical Pharmacokinetics</i> , 2018, 57, 769-779.	1.6	81
970	Evolving Role of Non-Statins for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. <i>Pharmacotherapy</i> , 2018, 38, 164-171.	1.2	7
971	Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. <i>Clinical Research in Cardiology</i> , 2018, 107, 380-388.	1.5	59
972	Dyslipidemia. , 2018, , 303-309.		0
973	PCSK9 inhibitors in clinical practice: Delivering on the promise?. <i>Atherosclerosis</i> , 2018, 270, 205-210.	0.4	45
974	Managing Dyslipidemia in Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 153-173.	1.2	24
975	Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 237-257.	1.2	28
977	Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome. <i>Heart and Vessels</i> , 2018, 33, 695-705.	0.5	16

#	ARTICLE	IF	CITATIONS
978	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. <i>Canadian Journal of Cardiology</i> , 2018, 34, 595-604.	0.8	56
979	Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. <i>Circulation</i> , 2018, 137, 1571-1582.	1.6	304
980	New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. <i>Acta Diabetologica</i> , 2018, 55, 209-218.	1.2	32
981	Cholesterol Transport Revisited: A New Turbo Mechanism to Drive Cholesterol Excretion. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 123-133.	3.1	46
982	Nutraceuticals in endocrine disorders. <i>Nature Reviews Endocrinology</i> , 2018, 14, 68-70.	4.3	7
983	Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 338-347.	0.6	18
984	Dyslipidaemia in the elderly: to treat or not to treat?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 259-278.	1.3	7
985	Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 5-7.	1.0	0
986	Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. <i>International Journal of Cardiology</i> , 2018, 253, 148-154.	0.8	23
987	From the editor: A run of success in treating atherosclerotic vascular disease. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1-2.	0.6	3
988	LDL cholesterol: How low to go?. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 348-354.	2.3	12
989	“Highest risk” “highest benefit”™ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. <i>European Heart Journal</i> , 2018, 39, 2546-2550.	1.0	69
990	The year in cardiology 2017: prevention. <i>European Heart Journal</i> , 2018, 39, 345-353.	1.0	3
991	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. <i>Drugs</i> , 2018, 78, 203-214.	4.9	5
992	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 119-127.	1.4	17
993	Prevention of cardiovascular disease: Much more is needed. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1083-1086.	0.8	11
994	Pharmacogenomics of blood lipid regulation. <i>Pharmacogenomics</i> , 2018, 19, 651-665.	0.6	3
995	Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2018, 200, 118-124.	1.2	14

#	ARTICLE	IF	CITATIONS
996	Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways. <i>Biotechnology Advances</i> , 2018, 36, 1586-1607.	6.0	78
997	Variations in time to benefit among clinical trials of cholesterol-lowering drugs. <i>Journal of Clinical Lipidology</i> , 2018, 12, 857-862.	0.6	21
999	How does the TRS 2Â°P score relate to real-world patients?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 72-74.	1.4	5
1000	The prevalence and correlates of subclinical atherosclerosis among adults with low-density lipoprotein cholesterol <70â€ mg/dL: The Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Atherosclerosis</i> , 2018, 274, 61-66.	0.4	8
1001	Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits. <i>Circulation Journal</i> , 2018, 82, 937-943.	0.7	15
1002	Causal Effect of Lipids and Lipoproteins on Atherosclerosis. <i>Cardiology Clinics</i> , 2018, 36, 203-211.	0.9	26
1003	Impact of statin therapy on coronary plaque burden and composition assessed by coronary computed tomographic angiography: a systematic review and meta-analysis. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 850-858.	0.5	51
1004	A decade of genome-wide association studies for coronary artery disease: the challenges ahead. <i>Cardiovascular Research</i> , 2018, 114, 1241-1257.	1.8	217
1005	Inflammatory and Cholesterol Risk in the FOURIER Trial. <i>Circulation</i> , 2018, 138, 131-140.	1.6	194
1006	Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes. <i>Stroke</i> , 2018, 49, 820-827.	1.0	132
1007	Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM). <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 45-54.	1.1	15
1008	Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes. <i>Annals of Medicine</i> , 2018, 50, 303-311.	1.5	15
1009	An update on trials of novel lipid-lowering drugs. <i>Current Opinion in Cardiology</i> , 2018, 33, 416-422.	0.8	5
1011	Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia. <i>Journal of Cardiology Cases</i> , 2018, 17, 204-207.	0.2	2
1012	The Emerging Role of Inflammation in Cardiovascular Disease. <i>Annals of Pharmacotherapy</i> , 2018, 52, 801-809.	0.9	35
1013	Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice. <i>Current Atherosclerosis Reports</i> , 2018, 20, 23.	2.0	5
1014	Poststatin era in atherosclerosis management. <i>Current Opinion in Lipidology</i> , 2018, 29, 246-258.	1.2	7
1016	A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 844-853.	0.8	43

#	ARTICLE	IF	CITATIONS
1017	A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe) Tj ETQq0 00 rgt /Overlock 10	1.1	37
1018	Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00390.	1.1	4
1019	Lipid Lowering in Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1325.	3.8	6
1020	Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 958-971.	5.4	27
1021	A consensus statement on lipid management after acute coronary syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 532-543.	0.4	27
1023	Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 15-22.	1.4	48
1024	Re: Fei Y, Guyatt GH, Alexander PE, et al. Addition of ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patientâ€™important outcomes. <i>J Eval Clin Pract</i>. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 264-265.	0.9	0
1025	Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus. <i>Current Problems in Cardiology</i> , 2018, 43, 68-110.	1.1	22
1026	Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patientâ€™important outcomes. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 222-231.	0.9	7
1028	The Zero-LDL Hypothesis. Towards Extremely Low LDL Concentrations. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 591-592.	0.4	1
1029	MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 224-233.	2.9	27
1030	PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 270-282.	2.2	22
1032	Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. <i>Heart Lung and Circulation</i> , 2018, 27, 656-665.	0.2	10
1033	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	1.0	7,100
1034	Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2018, 39, 1172-1180.	1.0	150
1035	Causas de no consecuci3n del objetivo terap3utico del colesterol de las lipoprote3nas de baja densidad en pacientes de alto y muy alto riesgo vascular controlados en Unidades de L3pidos y Riesgo Vascular. <i>Estudio EROMOT. Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2018, 30, 1-9.	0.4	8
1036	Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. <i>Journal of Clinical Lipidology</i> , 2018, 12, 78-88.	0.6	22
1037	Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2018, 4, 132-141.	1.8	18

#	ARTICLE	IF	CITATIONS
1038	Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction. <i>Journal of Diabetes</i> , 2018, 10, 200-212.	0.8	3
1039	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1435-1447.	1.4	4
1040	Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 34-41.	1.0	7
1041	Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia. <i>Journal of Pharmaceutical Investigation</i> , 2018, 48, 233-241.	2.7	3
1042	Authorâ€™s Reply to: Comment: Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. <i>Annals of Pharmacotherapy</i> , 2018, 52, 92-93.	0.9	0
1044	Should an LDL-Cholesterol Targetâ€™Based Approach Be Readopted?. <i>Annals of Pharmacotherapy</i> , 2018, 52, 175-184.	0.9	6
1045	PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. <i>Annual Review of Medicine</i> , 2018, 69, 133-145.	5.0	55
1046	The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 409-418.	2.3	42
1047	Suppression of Hepatic FLOT1 (Flotillin-1) by Type 2 Diabetes Mellitus Impairs the Disposal of Remnant Lipoproteins via Syndecan-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 102-113.	1.1	20
1048	Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease. <i>Pharmacoeconomics</i> , 2018, 36, 115-126.	1.7	8
1050	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. <i>Diabetes Care</i> , 2018, 41, 577-585.	4.3	25
1051	SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018, 136, 23-31.	1.1	14
1052	Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 634-643.	0.7	8
1053	9. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€™2018</i>. <i>Diabetes Care</i> , 2018, 41, S86-S104.	4.3	461
1054	Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. <i>Journal of Clinical Lipidology</i> , 2018, 12, 62-69.e1.	0.6	17
1055	Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe. <i>Pharmacoeconomics</i> , 2018, 36, 205-213.	1.7	15
1056	Statin use and risk for type 2 diabetes: what clinicians should know. <i>Postgraduate Medicine</i> , 2018, 130, 166-172.	0.9	23
1057	Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 51-69.	0.7	8

#	ARTICLE	IF	CITATIONS
1058	Effect of Evolocumab on Lipoprotein Particles. American Journal of Cardiology, 2018, 121, 308-314.	0.7	29
1059	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet, The, 2018, 391, 319-328.	6.3	628
1060	How to use Mendelian randomization to anticipate the results of randomized trials. European Heart Journal, 2018, 39, 360-362.	1.0	64
1061	American Association of Clinical Endocrinologists/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines. Diabetes Spectrum, 2018, 31, 234-245.	0.4	34
1063	A pilot study of the effect of ezetimibe for postprandial hyperlipidemia. Medicine (United States), 2018, 97, e12960.	0.4	2
1064	Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-based Review. Cureus, 2018, 10, e2114.	0.2	15
1065	Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?. Journal of Thoracic Disease, 2018, 10, S2149-S2152.	0.6	2
1067	New and Future Parenteral Therapies for the Management of Lipid Disorders. Archives of Medical Research, 2018, 49, 538-547.	1.5	8
1068	Lipid Measurements. , 2018, , 88-97.		0
1069	Primary Prevention of Atherosclerotic Cardiovascular Disease. , 2018, , 433-458.		0
1070	Therapy and clinical trials. Current Opinion in Lipidology, 2018, 29, 357-358.	1.2	0
1071	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. Open Cardiovascular Medicine Journal, 2018, 12, 29-40.	0.6	19
1072	Cardiovascular Disease as a Result of the Interactions Between Obesity, Climate Change, and Inflammation: The COCCI Syndemic. Journal of Osteopathic Medicine, 2018, 118, 719-729.	0.4	3
1073	Available oral lipid-lowering agents could bring most high-risk patients to target. Journal of Cardiovascular Medicine, 2018, 19, 485-490.	0.6	6
1074	Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. Annals of Internal Medicine, 2018, 168, 640-650.	2.0	66
1075	Lipid Management for Prevention of Atherosclerotic Cardiovascular Diseases. Health Evaluation and Promotion, 2018, 45, 755-769.	0.0	0
1076	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane Library, 2018, 2018, CD012502.	1.5	53
1077	Atherothrombosis as a Leading Cause of Acute Coronary Syndromes and Stroke: The Main Killers in Developed Countries. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1078	Lipid-Lowering Therapies: Risks in Women and Evidence-Based Options. <i>Texas Heart Institute Journal</i> , 2018, 45, 238-239.	0.1	1
1079	Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2018, 39, 697-704.	0.5	3
1080	Hypolipidemic effect of SIPI-7623, a derivative of an extract from oriental wormwood, through farnesoid X receptor antagonism. <i>Chinese Journal of Natural Medicines</i> , 2018, 16, 572-579.	0.7	6
1081	OBSOLETE: Lipids and Cardiovascular Diseases: Epidemiologic Perspectives. , 2018, , .		0
1082	OBSOLETE: STEMI: Management. , 2018, , .		0
1083	OBSOLETE: Pharmacology of Medications Used in the Treatment of Atherosclerotic Cardiovascular Disease. , 2018, , .		0
1085	Association Between Obesity and Cardiovascular Outcomes. <i>JAMA Network Open</i> , 2018, 1, e183788.	2.8	208
1086	Is lower low-density lipoprotein cholesterol associated with lower androgen and erectile dysfunction in men?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 1304-1310.	1.1	8
1087	Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies. <i>Nutrients</i> , 2018, 10, 1789.	1.7	32
1088	Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. <i>Lipids in Health and Disease</i> , 2018, 17, 265.	1.2	18
1089	Design of the randomized, placebo-controlled evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. <i>Clinical Cardiology</i> , 2018, 41, 1513-1520.	0.7	20
1090	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
1091	Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs. <i>IJC Heart and Vasculature</i> , 2018, 21, 80-86.	0.6	4
1092	Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3320-3331.	1.2	120
1093	Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects. <i>Translational and Clinical Pharmacology</i> , 2018, 26, 16.	0.3	5
1094	Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2018, 30, 1-19.	0.4	5
1095	Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2018, 8, 17887.	1.6	48
1096	Effects of Ramelteon and Other Sleep-Promoting Drugs on Serum Low-Density Lipoprotein and Non-high-density Lipoprotein Cholesterol: A Retrospective Comparative Pilot Study. <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 1778-1790.	0.6	3



#	ARTICLE	IF	CITATIONS
1097	Hypertension and chronic kidney disease affect long-term outcomes in patients with stable coronary artery disease receiving percutaneous coronary intervention. <i>Scientific Reports</i> , 2018, 8, 17673.	1.6	10
1098	Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. <i>JAMA Network Open</i> , 2018, 1, e185554.	2.8	67
1099	Intestinal cholesterol absorption. <i>Current Opinion in Lipidology</i> , 2018, 29, 484-485.	1.2	3
1100	Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. <i>Journal of the American Heart Association</i> , 2018, 7, e009876.	1.6	24
1101	Current concepts in atherosclerosis. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 34, 198-205.	0.2	4
1103	Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2886-2903.	1.2	68
1104	Hitting Hard and Early: A Novel Paradigm for Lipid Lowering in Primary Prevention. <i>Cardiology</i> , 2018, 140, 68-70.	0.6	0
1105	Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus. <i>Drugs in Context</i> , 2018, 7, 1-7.	1.0	14
1106	Reply to: "Call for an ezetimibe effectiveness test". <i>Atherosclerosis</i> , 2018, 278, 335.	0.4	0
1107	Lipids and Cardiovascular Diseases: Epidemiologic Perspectives. , 2018, , 221-229.		0
1108	Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. <i>Atherosclerosis</i> , 2018, 277, 355-361.	0.4	21
1109	Time to Make a Change: Assessing LDL-C Accurately in the Era of Modern Pharmacotherapeutics and Precision Medicine. <i>Current Cardiovascular Risk Reports</i> , 2018, 12, 1.	0.8	2
1110	Familial hypercholesterolemia treatments: Guidelines and new therapies. <i>Atherosclerosis</i> , 2018, 277, 483-492.	0.4	128
1111	Development and Population Results of a Fully Automated Homogeneous Assay for LDL Triglyceride. <i>Journal of Applied Laboratory Medicine</i> , The, 2018, 2, 746-756.	0.6	24
1112	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 327-341.	1.0	18
1113	T2 mapping MRI technique quantifies carotid plaque lipid, and its depletion after statin initiation, following acute myocardial infarction. <i>Atherosclerosis</i> , 2018, 279, 100-106.	0.4	25
1114	Sterol Metabolism and Transport in Atherosclerosis and Cancer. <i>Frontiers in Endocrinology</i> , 2018, 9, 509.	1.5	39
1117	Managing Chronic Coronary Artery Disease in Patients with Diabetes. , 2018, , 355-373.		0

#	ARTICLE	IF	CITATIONS
1118	Dyslipidemias in clinical practice. <i>Clinica Chimica Acta</i> , 2018, 487, 117-125.	0.5	26
1119	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. <i>Cmaj</i> , 2018, 190, E1192-E1206.	0.9	39
1121	LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. <i>Atherosclerosis</i> , 2018, 277, 327-333.	0.4	12
1122	Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 10.	0.6	59
1123	Genetics of Coronary Atherosclerosis. , 2018, , 33-44.		0
1124	Effect of statins on oxidative DNA damage in diabetic polyneuropathy. <i>Journal of Circulating Biomarkers</i> , 2018, 7, 184945441880409.	0.8	4
1125	Letter by Donzelli et al Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)" <i>Circulation</i> , 2018, 138, 1912-1913.	1.6	1
1126	High-Intensity Versus Non-High-Intensity Statins in Patients Achieving Low-Density Lipoprotein Cholesterol Goal After Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2018, 7, e009517.	1.6	13
1127	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 934-943.	5.5	96
1128	CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 997-1005.	1.9	18
1129	Managing Clinical Heterogeneity: An Argument for Benefit-Based Action Limits. <i>Journal of Engineering and Science in Medical Diagnostics and Therapy</i> , 2018, 1, .	0.3	4
1130	Lipid management in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 727-749.	4.1	153
1131	Evidence-Based Management of Diabetes in Older Adults. <i>Drugs and Aging</i> , 2018, 35, 1065-1078.	1.3	19
1132	Beyond Statins: Who and When to Prescribe?. <i>Current Diabetes Reports</i> , 2018, 18, 126.	1.7	4
1133	Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. <i>Current Diabetes Reports</i> , 2018, 18, 138.	1.7	4
1134	The best in coronary artery disease management is yet to come. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 621-624.	0.7	1
1135	Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors. <i>European Cardiology Review</i> , 2018, 13, 9.	0.7	1
1136	Safety and efficacy of statin therapy. <i>Nature Reviews Cardiology</i> , 2018, 15, 757-769.	6.1	239

#	ARTICLE	IF	CITATIONS
1137	Lower Onâ€Treatment Lowâ€Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. <i>Journal of the American Heart Association</i> , 2018, 7, e009221.	1.6	14
1138	Guidelineâ€Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, e009885.	1.6	21
1139	Measurement of Lowâ€Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009251.	1.6	9
1141	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 846-984.	0.9	541
1142	Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1966-1976.	0.8	50
1143	Relationship between cholesterol synthesis/absorption marker and vascular function in healthy subjects. <i>Vascular Failure</i> , 2018, 2, 20-24.	0.2	1
1144	A comment to: Predictors of low-density lipoprotein cholesterol target value attainment in the DYSIS II Europe Study. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1964-1965.	0.8	0
1145	Associations of device-measured physical activity across adolescence with metabolic traits: Prospective cohort study. <i>PLoS Medicine</i> , 2018, 15, e1002649.	3.9	35
1146	Primary and Secondary Prevention of Cardiovascular Disease. , 2018, , 63-76.		0
1147	Lipids: a personal view of the past decade. <i>Hormones</i> , 2018, 17, 461-478.	0.9	5
1148	Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis. <i>BMC Pharmacology &amp; Toxicology</i> , 2018, 19, 58.	1.0	15
1149	Association of Genetically Enhanced Lipoprotein Lipaseâ€Mediated Lipolysis and Low-Density Lipoprotein Cholesterolâ€Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. <i>JAMA Cardiology</i> , 2018, 3, 957.	3.0	55
1150	LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 959-970.	1.3	88
1151	Biologic bases of residual risk of cardiovascular events: A flawed concept. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1831-1835.	0.8	8
1152	Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1950-1963.	0.8	28
1153	Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. <i>Atherosclerosis</i> , 2018, 278, 135-142.	0.4	20
1154	Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome. <i>Egyptian Heart Journal</i> , 2018, 70, 129-134.	0.4	4
1156	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>European Heart Journal</i> , 2018, 39, 3641-3653.	1.0	69

#	ARTICLE	IF	CITATIONS
1157	Impact of Combination Therapy with Ezetimibe/Simvastatin Treatment on the Neointimal Response to Biodegradable Polymer Biolimus-Eluting Stent Implantation in Patients with Acute Myocardial Infarction: Serial Assessment with Optical Coherence Tomography. <i>Applied Sciences (Switzerland)</i> , 2018, 8, 1968.	1.3	1
1158	Pharmacogenetics in Cardiovascular Medicine. <i>Advances in Pharmacology</i> , 2018, 83, 333-360.	1.2	5
1159	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. <i>International Journal of Cardiology</i> , 2018, 270, 245-252.	0.8	51
1160	A Deeper Dive Into the CANTOS "Responders" Substudy. <i>Mayo Clinic Proceedings</i> , 2018, 93, 830-833.	1.4	5
1161	Further options for treating lipids in people with diabetes: targeting <sc>LDL</sc> cholesterol and beyond. <i>Diabetic Medicine</i> , 2018, 35, 1173-1180.	1.2	3
1162	Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International Cholesterol management Practice Study (ICLPS). <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1087-1094.	0.8	86
1163	Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 138, e1-e34.	1.6	316
1164	Early and Chronic Dipeptidylâ€Peptidaseâ€IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	9
1165	Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2018, 20, 56.	1.3	2
1166	Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials. <i>Progress in Cardiovascular Diseases</i> , 2018, 61, 43-53.	1.6	130
1167	Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. <i>Current Cardiology Reports</i> , 2018, 20, 55.	1.3	6
1168	Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines " Full report. <i>Atherosclerosis Supplements</i> , 2018, 31, e1-e12.	1.2	20
1169	Mendelian randomization: Its impact on cardiovascular disease. <i>Journal of Cardiology</i> , 2018, 72, 307-313.	0.8	23
1170	Lower Level of Low Density Lipoprotein Cholesterol is Associated with a Higher Increase in the Fractional Flow Reserve in Patients with Fixed-dose Rosuvastatin. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 233-243.	0.9	5
1171	Prognosis and lipid profile improvement by a specialized outpatient clinic for acute coronary syndrome patients. <i>Atherosclerosis</i> , 2018, 275, 28-34.	0.4	9
1172	Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 273-280.	1.3	10
1173	Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	11
1174	Cholesterol-Lowering Nutraceuticals Affecting Vascular Function and Cardiovascular Disease Risk. <i>Current Cardiology Reports</i> , 2018, 20, 53.	1.3	31

#	ARTICLE	IF	CITATIONS
1175	Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?. Indian Heart Journal, 2018, 70, 331-334.	0.2	0
1176	Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome. Circulation Journal, 2018, 82, 757-766.	0.7	31
1177	Non-ST-Elevation Myocardial Infarction: Management. , 2018, , 522-530.		0
1178	Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 995-1010.	1.1	109
1179	Study of the effect of the herbal composition SR2004 on hemoglobin A1c, fasting blood glucose, and lipids in patients with type 2 diabetes mellitus. Integrative Medicine Research, 2018, 7, 248-256.	0.7	16
1181	Lipid management in ACS: Should we go lower faster?. Atherosclerosis, 2018, 275, 368-375.	0.4	27
1182	Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease " Sub-analysis of PRECISE-IVUS trial. International Journal of Cardiology, 2018, 268, 23-26.	0.8	5
1183	Postprandial Hyperchylomicronemia and Thin-Cap Fibroatheroma in Nonculprit Lesions. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1940-1947.	1.1	9
1184	PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. Journal of the American Heart Association, 2018, 7, .	1.6	54
1185	Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial. Clinical Cardiology, 2018, 41, 1117-1122.	0.7	11
1186	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. International Journal of Cardiology, 2018, 272, 20-25.	0.8	24
1187	Treating Lipid Disorders in Athletes. , 2018, , 25-48.		0
1188	STEMI: Management. , 2018, , 474-488.		0
1189	Pharmacology of Medications Used in the Treatment of Atherosclerotic Cardiovascular Disease. , 2018, , 68-88.		2
1190	TÎ²4 Increases Neovascularization and Cardiac Function in Chronic Myocardial Ischemia of Normo- and Hypercholesterolemic Pigs. Molecular Therapy, 2018, 26, 1706-1714.	3.7	11
1191	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. European Heart Journal, 2018, 39, 2589-2596.	1.0	100
1192	Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 237-242.	1.4	6
1193	Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels. JAMA Cardiology, 2018, 3, 823.	3.0	158

#	ARTICLE	IF	CITATIONS
1194	Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 369-382.	0.6	4
1195	Cholesterol-Lowering Effects of Plant Sterols in One Serve of Wholegrain Wheat Breakfast Cereal Biscuitsâ€”A Randomised Crossover Clinical Trial. <i>Foods</i> , 2018, 7, 39.	1.9	9
1196	Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. <i>Circulation Journal</i> , 2018, 82, 183-191.	0.7	0
1197	Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. <i>Journal of Stroke</i> , 2018, 20, 145-166.	1.4	39
1198	Diabetes and Dislipidemia. <i>Endocrinology</i> , 2018, , 1-20.	0.1	0
1199	Dyslipidemia. , 2018, , 353-360.		2
1200	Hypercholesterolaemia â€” practical information for non-specialists. <i>Archives of Medical Science</i> , 2018, 1, 1-21.	0.4	39
1201	Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. <i>Frontiers in Pharmacology</i> , 2018, 9, 707.	1.6	31
1202	Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients â€” A consensus document. <i>Indian Heart Journal</i> , 2018, 70, 736-744.	0.2	4
1203	Impact of statin-ezetimibe combination in chronic kidney disease. <i>International Journal of Cardiology</i> , 2018, 268, 36-37.	0.8	1
1204	Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis. <i>Endocrinology and Metabolism</i> , 2018, 33, 219.	1.3	18
1205	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018, 122, 1451-1458.	0.7	2
1206	Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 365-372.	1.3	19
1207	Secondary Prevention of Coronary Artery Disease. , 2018, , 479-487.		1
1208	Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 44.	1.0	3
1209	Overexpression of transforming growth factor $\beta^2$ induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. <i>Atherosclerosis</i> , 2018, 275, 246-255.	0.4	4
1210	Editorial commentary: Confessions of a drug dealer. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 532-533.	2.3	0
1211	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. <i>Annals of Medicine</i> , 2018, 50, 461-484.	1.5	28

#	ARTICLE	IF	CITATIONS
1212	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2522-2533.	1.8	7
1213	PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 567-578.	0.6	11
1214	Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 1067-1075.	1.0	29
1215	Comparison of the 2017 Taiwan lipid guidelines and the Western lipid guidelines for high risk patients. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 853-859.	0.6	7
1216	The Evolving Future of PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 72, 314-329.	1.2	162
1217	The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1680.	1.8	41
1218	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	1.1	388
1219	2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 766-790.	0.8	44
1220	Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 810-815.	1.1	13
1221	Long-term atorvastatin treatment decreases heart maximal oxygen consumption and its vulnerability to in vitro oxidative stress in Watanabe heritable hyperlipidemic rabbit. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 1112-1118.	0.7	4
1222	Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia. <i>Current Cardiology Reports</i> , 2018, 20, 71.	1.3	0
1223	Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 269-281.	2.3	5
1224	Extending the “Lower is Better” Principle to Japanese and Possibly Other Asian Populations. <i>Circulation</i> , 2018, 137, 2010-2012.	1.6	4
1225	High- Versus Low-Dose Statin. <i>Circulation</i> , 2018, 137, 2013-2015.	1.6	6
1226	Short-Term Efficacy and Safety of Adding Ezetimibe to Current Regimen of Lipid-Lowering Drugs in Human Immunodeficiency Virus-Infected Thai Patients Treated with Protease Inhibitors. <i>Japanese Journal of Infectious Diseases</i> , 2018, 71, 220-224.	0.5	4
1227	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 257-268.	2.3	12
1228	Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study. <i>Lipids in Health and Disease</i> , 2018, 17, 8.	1.2	8
1229	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <i>American Heart Journal</i> , 2018, 201, 25-32.	1.2	9

#	ARTICLE	IF	CITATIONS
1230	PCSK9. <i>Circulation Research</i> , 2018, 122, 1420-1438.	2.0	198
1231	Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER. <i>Atherosclerosis</i> , 2018, 274, 139-145.	0.4	28
1232	Prescription of statins at discharge and 1-year risk of major clinical outcomes among acute coronary syndromes patients with extremely low LDL cholesterol in clinical pathways for acute coronary syndromes studies. <i>Clinical Cardiology</i> , 2018, 41, 1192-1200.	0.7	6
1233	Angina in Patients with Evidence of Myocardial Ischemia and No Obstructive Coronary Artery Disease. , 2018, , 374-390.		0
1235	Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study. <i>Scientific Reports</i> , 2018, 8, 11925.	1.6	8
1236	Goals of Therapy. , 2018, , 227-233.		1
1237	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 22.	1.0	10
1238	Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients. <i>Journal of Cardiovascular Development and Disease</i> , 2018, 5, 27.	0.8	27
1239	Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy. <i>JAMA Cardiology</i> , 2018, 3, 849.	3.0	75
1240	Progress and perspectives in plant sterol and plant stanol research. <i>Nutrition Reviews</i> , 2018, 76, 725-746.	2.6	54
1241	Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients. <i>Current Medical Research and Opinion</i> , 2018, 34, 1713-1715.	0.9	0
1242	National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	21
1243	The ODYSSEY Outcomes trial: Clinical implications and exploration of the limits of what can be achieved through lipid lowering. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1102-1105.	0.6	8
1244	Lipid-lowering therapy with PCSK9 inhibitors in the real-world setting: Two-year experience of a regional lipid clinic. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12439.	1.1	27
1246	If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis. <i>Journal of General Internal Medicine</i> , 2018, 33, 1213-1214.	1.3	1
1247	Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved) Tj ETQq1 1 0.784314 rgBTd/Overlo		
1248	HDL-cholesterol, genetics, and coronary artery disease: the myth of the "good cholesterol"? <i>European Heart Journal</i> , 2018, 39, 2179-2182.	1.0	15
1249	Human Genetics of Obesity and Type 2 Diabetes Mellitus. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002090.	1.6	58



#	ARTICLE	IF	CITATIONS
1250	NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. <i>Circulation Research</i> , 2018, 122, 1722-1740.	2.0	564
1251	Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. <i>Cardiovascular Research</i> , 2018, 114, 1073-1081.	1.8	49
1252	Lowering <sc>LDL</sc>â€Cholesterol and <sc>CV</sc> Benefits: Is There a Limit to How Low <sc>LDL</sc>â€C Needs to be for Optimal Health Benefits?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 290-296.	2.3	6
1253	Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the Dyslipidemia International Study II. <i>International Journal of Cardiology</i> , 2018, 265, 1-5.	0.8	10
1254	Measuring Low-Density Lipoprotein Cholesterol. <i>JAMA Cardiology</i> , 2018, 3, 754.	3.0	0
1255	Familial hypercholesterolemia in very young myocardial infarction. <i>Scientific Reports</i> , 2018, 8, 8861.	1.6	14
1256	Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 747-754.	0.5	2
1257	ESC 2017 STEMI Guidelines: a step forward for a better cure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 133-135.	1.4	4
1258	Pharmacological treatment for dyslipidemia. <i>Journal of the Japanese Coronary Association</i> , 2018, 24, 32-37.	0.0	0
1259	Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now. <i>Canadian Journal of Cardiology</i> , 2019, 35, 590-597.	0.8	4
1260	Adverse Events Associated With <sc>PCSK</sc>9 Inhibitors: A Realâ€World Experience. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 496-504.	2.3	51
1261	Short- and long-term clinical impact of tissue protrusion after newer-generation drug-eluting stent implantation for acute coronary syndrome. <i>Cardiovascular Intervention and Therapeutics</i> , 2019, 34, 155-163.	1.2	1
1262	Dyslipidemia. , 2019, , 150-155.		0
1263	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 568-581.	2.3	6
1264	A New Perspective for Chinese Medicine Intervention for Coronary Artery Disease: Targeting Inflammation. <i>Chinese Journal of Integrative Medicine</i> , 2019, 25, 3-8.	0.7	12
1265	Increased triglyceride/high-density lipoprotein cholesterol ratio may be associated with reduction in the low-density lipoprotein particle size: assessment of atherosclerotic cardiovascular disease risk. <i>Heart and Vessels</i> , 2019, 34, 227-236.	0.5	19
1266	Assessing Treatment Effects That Capture Disease Burden in Serious Chronic Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 387-397.	0.8	5
1267	Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 151-161.e1.	0.4	24

#	ARTICLE	IF	CITATIONS
1268	The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 54-61.	1.0	5
1269	Strategies to Overcome Residual Risk During Statins Era. <i>Circulation Journal</i> , 2019, 83, 1973-1979.	0.7	27
1271	Use of Inflammatory Biomarkers to Predict the Clinical Benefit of Ezetimibe. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1069-1070.	1.2	0
1272	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1057-1068.	1.2	32
1273	Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e012428.	1.6	10
1274	Atherosclerosis. <i>Nature Reviews Disease Primers</i> , 2019, 5, 56.	18.1	1,601
1275	More- Versus Less-Intensive Lipid-Lowering Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005460.	0.9	8
1276	Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia. <i>Hypertension Research</i> , 2019, 42, 1923-1931.	1.5	7
1278	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <i>Lancet, The</i> , 2019, 394, 697-708.	6.3	67
1279	The Bioequivalence and Effect of Food on the Pharmacokinetics of a Fixed-Dose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects. <i>Clinical and Translational Science</i> , 2019, 12, 704-712.	1.5	4
1280	Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome. <i>Diabetic Medicine</i> , 2019, 36, 1643-1651.	1.2	16
1281	Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2007-2017.	0.9	21
1282	Myocardial Infarction—From Atherosclerosis to Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e176-e185.	1.1	90
1283	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. <i>Current Cardiology Reports</i> , 2019, 21, 110.	1.3	24
1284	Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2019, 216, 30-41.	1.2	11
1286	Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 201.	0.7	8
1287	Intensive Lipid Lowering in Elderly Patients. <i>JAMA Cardiology</i> , 2019, 4, 855.	3.0	7
1288	Medication Adherence/Persistence and Demographics of Japanese Dyslipidemia Patients on Statin-Ezetimibe as a Separate Pill Combination Lipid-Lowering Therapy—An Observational Pharmacy Claims Database Study. <i>Circulation Journal</i> , 2019, 83, 1689-1697.	0.7	5

#	ARTICLE	IF	CITATIONS
1289	Diabetes and Atherogenic Dyslipidemia. , 2019, , 587-596.		3
1290	Treating dyslipidemia: something more than giving statins. Clínica E Investigación En Arteriosclerosis (English Edition), 2019, 31, 119-120.	0.1	0
1291	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. JAMA Cardiology, 2019, 4, 846.	3.0	81
1292	Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 263-272.	1.0	7
1293	Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta. Canadian Journal of Cardiology, 2019, 35, 884-891.	0.8	20
1294	Improving Statin Noncompliance: If You Build It, Will They Come?. Canadian Journal of Cardiology, 2019, 35, 813-815.	0.8	3
1295	Efficient reabsorption of transintestinally excreted cholesterol is a strong determinant for cholesterol disposal in mice. Journal of Lipid Research, 2019, 60, 1562-1572.	2.0	19
1296	Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. Current Diabetes Reports, 2019, 19, 61.	1.7	44
1297	Guia prático para a utilização dos inibidores da PCSK9 em Portugal. Revista Portuguesa De Cardiologia, 2019, 38, 391-405.	0.2	0
1298	Non-ST Elevation Myocardial Infarction: Diagnosis and Management. , 0, , .		3
1299	Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits. BMC Medical Genomics, 2019, 12, 108.	0.7	8
1300	Inflammation as a Therapeutic Target in Atherosclerosis. Journal of Clinical Medicine, 2019, 8, 1109.	1.0	118
1301	Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. Journal of the American College of Cardiology, 2019, 74, 712-714.	1.2	21
1302	Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. Drugs and Therapy Perspectives, 2019, 35, 431-441.	0.3	3
1303	Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?. Current Cardiology Reports, 2019, 21, 77.	1.3	6
1304	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 38.	0.4	1
1305	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. Clínica E Investigación En Arteriosclerosis (English Edition), 2019, 31, 128-139.	0.1	6
1306	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology, 2019, 7, 618-628.	5.5	207

#	ARTICLE	IF	CITATIONS
1307	A new rational approach to reach LDL-cholesterol concentration objectives after an acute coronary syndrome. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 93-100.	0.1	1
1308	The cost-effectiveness of lipid lowering for primary cardiovascular prevention in chronic kidney disease: moving beyond statins. <i>Kidney International</i> , 2019, 96, 22-25.	2.6	1
1309	Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1557-1567.	13.9	216
1310	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2132-2146.	1.2	101
1311	Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 989-996.	0.6	29
1312	Targeting dyslipidaemia to prevent cardiovascular disease. <i>The Prescriber</i> , 2019, 30, 23-26.	0.1	0
1313	Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5253-5262.	1.8	4
1314	The Effect of Polyphenols on Hypercholesterolemia through Inhibiting the Transport and Expression of Niemann-Pick C1-Like 1. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4939.	1.8	26
1315	Practical guide for the use of PCSK9 inhibitors in Portugal. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2019, 38, 391-405.	0.2	1
1316	A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	1
1317	Risk Factors Management in Diabetic Patients. <i>Journal of Korean Diabetes</i> , 2019, 20, 157.	0.1	1
1318	Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 414-422.	1.6	34
1319	Suggested clinical approach for the diagnosis and management of "statin intolerance" with an emphasis on muscle-related side effects. <i>Internal Medicine Journal</i> , 2019, 49, 1081-1091.	0.5	15
1320	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2019, 218, 46-56.	1.2	72
1321	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 240.	0.7	22
1322	Factors associated with longitudinal changes in serum concentrations of Mac-2 binding protein: A prospective 3-year observational study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1337-1344.	1.1	6
1323	Angiotensin-Like 3. <i>JACC Basic To Translational Science</i> , 2019, 4, 755-762.	1.9	31
1324	Implications for REDUCE IT in clinical practice. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 395-400.	1.6	12

#	ARTICLE	IF	CITATIONS
1325	New insights into managing symptoms during statin therapy. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 390-394.	1.6	14
1326	Bempedoic Acid for Lowering LDL Cholesterol. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1769.	3.8	12
1327	Ischemic Event Rates in Very-High-Risk Adults. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2496-2507.	1.2	35
1328	Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: A population-based cohort study. <i>Thrombosis Research</i> , 2019, 183, 124-130.	0.8	10
1329	Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale. <i>Journal of Drug Assessment</i> , 2019, 8, 167-174.	1.1	1
1330	Update of therapeutic planning tables oriented towards obtaining therapeutic objectives. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 271-277.	0.1	3
1331	&lt;p&gt;Therapeutic targets of hypercholesterolemia: HMGCR and LDLR&lt;p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1543-1553.	1.1	35
1332	Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes. <i>American Journal of Cardiology</i> , 2019, 124, 1869-1875.	0.7	15
1333	Sea Change for Marine Omega-3s. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2524-2533.	1.4	24
1335	IL-1 $\beta$ and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1764.	1.0	21
1336	2018 Guidelines for the Management of Dyslipidemia in Korea. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 78.	1.1	100
1337	Impact of improved low-density lipoprotein cholesterol assessment on guideline classification in the modern treatment era – Results from a racially diverse Brazilian cross-sectional study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 804-811.e2.	0.6	10
1338	An update on pharmacotherapies in diabetic dyslipidemia. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 334-341.	1.6	24
1339	Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75). <i>Circulation</i> , 2019, 140, 992-1003.	1.6	132
1340	2018 George Lyman Duff Memorial Lecture. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1925-1937.	1.1	6
1341	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.4	1,753
1342	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	1.2	49
1343	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34

#	ARTICLE	IF	CITATIONS
1344	Cyanidin-3-rutinoside acts as a natural inhibitor of intestinal lipid digestion and absorption. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 242.	3.7	32
1345	PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads. <i>Journal of Clinical Lipidology</i> , 2019, 13, 714-720.	0.6	9
1346	How the Cow Ate the CABG. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1187-1189.	1.2	0
1347	From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1618-1636.	1.2	33
1348	Lipid management for coronary heart disease patients: an appraisal of updated international guidelines applying Appraisal of Guidelines for Research and Evaluation clinical practice guideline appraisal for lipid management in coronary heart disease. <i>Journal of Thoracic Disease</i> , 2019, 11, 3534-3546.	0.6	8
1349	Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. <i>BMJ: British Medical Journal</i> , 2019, 366, l5125.	2.4	58
1350	Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects. <i>European Journal of Medicinal Chemistry</i> , 2019, 184, 111749.	2.6	13
1351	Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels. <i>JAMA Cardiology</i> , 2019, 4, 1067.	3.0	104
1352	Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 455-458.	0.7	2
1353	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019, 217, 72-83.	1.2	45
1354	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019, 218, 110-122.	1.2	7
1355	Statins in Females. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 2019, 04, 099-106.	0.1	0
1356	Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). <i>American Journal of Cardiology</i> , 2019, 123, 1193-1201.	0.7	7
1357	Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 477-487.	1.2	102
1358	A Review of the 2018 Cholesterol Guidelines: Focus on Nonstatin Lipid-lowering Drugs. <i>Journal for Nurse Practitioners</i> , 2019, 15, 205-206.e1.	0.4	0
1359	Lipid-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 386-404.	2.0	124
1360	Cholesterol-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 364-385.	2.0	45
1361	A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography. <i>Journal of Cardiovascular Computed Tomography</i> , 2019, 13, 99-104.	0.7	2

#	ARTICLE	IF	CITATIONS
1362	PCSK9 inhibition 2018: riding a new wave of coronary prevention. <i>Clinical Science</i> , 2019, 133, 205-224.	1.8	8
1363	Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 343-348.	1.0	7
1364	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2. <i>American Journal of Medicine</i> , 2019, 132, e599-e609.	0.6	10
1365	Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 237-247.	1.0	10
1366	Polyphenol Health Effects on Cardiovascular and Neurodegenerative Disorders: A Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 351.	1.8	177
1367	Identification of hepatic NPC1L1 as an NAFLD risk factor evidenced by ezetimibe-mediated steatosis prevention and recovery. <i>FASEB BioAdvances</i> , 2019, 1, 283-295.	1.3	17
1368	Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2019, 31, 128-139.	0.4	28
1369	The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 592-600.	0.9	30
1370	Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 611-621.	1.0	36
1371	Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 547.	1.6	14
1372	LDL-C Targets in Secondary Prevention: How Low Should We Go?. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	4
1373	Advances in cardiovascular imaging. <i>Current Opinion in Biomedical Engineering</i> , 2019, 9, A3.	1.8	0
1374	TIMI risk score for secondary prevention of recurrent cardiovascular events in a real-world cohort of post-non-ST-elevation myocardial infarction patients. <i>Postgraduate Medical Journal</i> , 2019, 95, 372-377.	0.9	2
1375	New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2019, 21, 69.	1.3	13
1376	Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1719-1729.	0.9	10
1377	Cost-Effectiveness Analysis of Non-Statins Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. <i>Pharmacoeconomics</i> , 2019, 37, 1277-1286.	1.7	10
1378	Hellenic Postprandial Lipemia Study (HPLS): Rationale and design of a prospective, open-label trial to determinate the prevalence of abnormal postprandial lipemia as well as its interaction with statins in patients at high- and very high-risk for cardiovascular disease. <i>Contemporary Clinical Trials</i> , 2019, 82, 101-105.	0.8	2
1379	Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial. <i>Journal of Clinical Lipidology</i> , 2019, 13, 568-579.	0.6	51

#	ARTICLE	IF	CITATIONS
1380	Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem. <i>Journal of the American Heart Association</i> , 2019, 8, e012924.	1.6	53
1381	Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. <i>Atherosclerosis</i> , 2019, 288, 194-202.	0.4	56
1382	Atherogenic markers in predicting cardiovascular risk and targeting residual cardiovascular risk. <i>Atherosclerosis: X</i> , 2019, 1, 100001.	0.0	3
1383	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2019, 214, 113-124.	1.2	17
1384	Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus. <i>Endocrinology &amp; Diabetes &amp; Nutrition (English Ed)</i> , 2019, 66, 223-231.	0.1	2
1385	Effects of Icosapent Ethyl on TotalÂschemic Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2791-2802.	1.2	208
1386	Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 140, e98-e124.	1.6	376
1387	Management of diabetic dyslipidemia: An update. <i>World Journal of Diabetes</i> , 2019, 10, 280-290.	1.3	58
1388	Alirocumab after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2019, 380, 2074-2077.	13.9	2
1389	Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 583-591.	0.9	34
1390	Hepatic Expression of Niemann-Pick C1-Like 1, a Cholesterol Reabsorber from Bile, Exacerbates Western Dietâ€“Induced Atherosclerosis in LDL Receptor Mutant Mice. <i>Molecular Pharmacology</i> , 2019, 96, 47-55.	1.0	16
1391	Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study. <i>BMJ Open</i> , 2019, 9, e022702.	0.8	4
1392	Effects of dietary intervention and n-3 PUFA supplementation on markers of gut-related inflammation and their association with cardiovascular events in a high-risk population. <i>Atherosclerosis</i> , 2019, 286, 53-59.	0.4	16
1393	Diabetic outcomes: Cardiovascular outcomes with lipid modification H2D. <i>Journal of Diabetes</i> , 2019, 11, 617-618.	0.8	2
1394	Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations. <i>Science China Life Sciences</i> , 2019, 62, 758-770.	2.3	15
1395	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019, 13, 374-392.	0.6	315
1396	Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. <i>Atherosclerosis: X</i> , 2019, 39, 100002.	0.0	9
1397	The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 415-424.	0.6	33



#	ARTICLE	IF	CITATIONS
1399	Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opinion on Pharmacotherapy, 2019, 20, 1277-1288.	0.9	18
1400	Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia. Medicine (United States), 2019, 98, e14400.	0.4	29
1401	Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. Clínica E Investigaci3n En Arteriosclerosis (English Edition), 2019, 31, 75-88.	0.1	6
1402	Benefit of Early Statin Initiation within 48 Hours after Admission in Statin-Na3ve Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Korean Circulation Journal, 2019, 49, 419.	0.7	9
1403	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. Journal of the American College of Cardiology, 2019, 73, 2439-2450.	1.2	69
1404	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2019, 13, 525-537.	0.6	45
1405	Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke. International Journal of Stroke, 2019, 14, 476-482.	2.9	11
1406	Status of PCSK9 Monoclonal Antibodies in Australia. Heart Lung and Circulation, 2019, 28, 1571-1579.	0.2	9
1407	Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statins Low-Density Lipoprotein Cholesterol Levels <70 mg/dL. Circulation Journal, 2019, 83, 1302-1308.	0.7	34
1408	An updated review of lipid-modifying therapy. Medical Journal of Australia, 2019, 211, 87-92.	0.8	9
1410	Emerging Lipid-Lowering Therapies in Secondary Prevention. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	0
1411	Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention—A Meta-Analysis of 12 Randomized Trials. Circulation Journal, 2019, 83, 1356-1367.	0.7	6
1412	Nonglucuronidated Ezetimibe Disrupts CD13and CD64Coassembly in Membrane Microdomains and Decreases Cellular Cholesterol Content in Human Monocytes/Macrophages. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 869-884.	1.1	2
1413	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis, 2019, 285, 40-48.	0.4	39
1414	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	1.6	17
1415	2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol—Secondary Prevention. JAMA Cardiology, 2019, 4, 589.	3.0	38
1416	Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia. Diabetes, Obesity and Metabolism, 2019, 21, 39-51.	2.2	8
1417	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 6-16.	2.2	13

#	ARTICLE	IF	CITATIONS
1418	Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1221-1225.	0.9	7
1419	Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 544-554.	0.5	11
1420	Is There a Need to Revise Goals in the Management of Dyslipidemias?. <i>Current Cardiology Reports</i> , 2019, 21, 51.	1.3	6
1421	Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 465-467.	1.2	6
1422	PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. <i>Journal of the American Heart Association</i> , 2019, 8, e011246.	1.6	44
1423	PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. <i>Journal of Clinical Lipidology</i> , 2019, 13, 443-454.	0.6	2
1424	Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 14.	1.1	26
1425	Management of high cholesterol levels in older people. <i>Geriatrics and Gerontology International</i> , 2019, 19, 375-383.	0.7	6
1426	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179.	2.6	13
1427	Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project. <i>American Heart Journal</i> , 2019, 212, 120-128.	1.2	15
1428	The emerging concept of "individualized cholesterol-lowering therapy": A change in paradigm. , 2019, 199, 111-116.		34
1429	Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication. <i>Journal of Endovascular Therapy</i> , 2019, 26, 402-410.	0.8	2
1430	Don't stop at statins: complementary PCSK9 use in patients at high risk for recurrent cardiac events. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 5, 193-194.	1.8	0
1431	The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. <i>Current Cardiology Reports</i> , 2019, 21, 18.	1.3	6
1432	Statins: Rationale, Mode of Action, and Side Effects. , 2019, , 171-200.		6
1433	Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention of Recurrent Cardiovascular Events in a Real-World Cohort of Post-Acute Myocardial Infarction Patients. <i>Circulation Journal</i> , 2019, 83, 809-817.	0.7	7
1434	Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. <i>Heart</i> , 2019, 105, heartjnl-2019-314763.	1.2	20
1435	Lipoprotein(a) and mortality—a high risk relationship. <i>Clinical Research in Cardiology Supplements</i> , 2019, 14, 13-19.	2.0	8

#	ARTICLE	IF	CITATIONS
1436	Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2019, 123, 1739-1744.	0.7	12
1437	Role of Lipoprotein Apheresis in Cardiovascular Disease Risk Reduction. <i>Blood Purification</i> , 2019, 47, 301-316.	0.9	6
1438	Cholesterol and Inflammation in Stroke Recurrence. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 406-407.	0.9	2
1439	Management of dyslipidaemias in the elderly populationâ€”A narrative review. <i>Maturitas</i> , 2019, 124, 93-99.	1.0	3
1440	Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 917-928.	0.9	17
1441	Trials in â€œTrueâ€”Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 960-967.	2.3	2
1442	Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 315-322.	1.0	14
1443	Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. <i>European Journal of Cancer</i> , 2019, 112, 118-126.	1.3	36
1444	Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. <i>Nature Medicine</i> , 2019, 25, 569-574.	15.2	200
1445	Most Promising Therapies in Interventional Cardiology. <i>Current Cardiology Reports</i> , 2019, 21, 26.	1.3	6
1446	Metformin was associated with lower all-cause mortality in type 2 diabetes with acute coronary syndrome: A Nationwide registry with propensity score-matched analysis. <i>International Journal of Cardiology</i> , 2019, 291, 152-157.	0.8	17
1447	Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage â€” A Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 1703-1709.	0.7	31
1448	The benefit of secondary prevention with oat fiber in reducing future cardiovascular event among CAD patients after coronary intervention. <i>Scientific Reports</i> , 2019, 9, 3091.	1.6	11
1449	Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 934-944.	1.1	25
1451	Emerging drugs for the treatment of hypercholesterolemia. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 63-69.	1.0	16
1452	Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 16.	1.1	109
1453	Drugs for Treatment of Dyslipidemia Available in theÂUSA. , 2019, , 171-195.		0
1454	Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Neurology</i> , 2019, 21, 22.	0.7	16

#	ARTICLE	IF	CITATIONS
1455	Guidelines impact cholesterol management. Journal of Clinical Lipidology, 2019, 13, 432-442.	0.6	6
1456	Translating the dose response into risk and benefit. British Journal of Clinical Pharmacology, 2019, 85, 2187-2193.	1.1	8
1457	Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, Nonalcoholic Steatohepatitis (NASH) and Other Cardiometabolic Disorders. , 2019, , 487-515.		0
1458	Transitioning from Preclinical to Clinical Drug Development. , 2019, , 467-486.		1
1459	Diabetes and Dyslipidemia. Endocrinology, 2019, , 1-20.	0.1	0
1460	Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiology, 2019, 4, 473.	3.0	1
1461	2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiology, 2019, 4, 488.	3.0	33
1462	ACC/AHA lipids & ASCVD guidelines: 2018 update. Metabolism: Clinical and Experimental, 2019, 99, 116-118.	1.5	4
1463	The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial. Rational Pharmacotherapy in Cardiology, 2019, 14, 922-934.	0.3	5
1464	A practical approach for a comprehensive evaluation and management of diabetes mellitus. Italian Journal of Medicine, 2019, 13, 68-72.	0.2	0
1466	Baseline LDL-C levels and risk of cardiovascular events: is there any room for questions?. International Journal of Cardiology, 2019, 286, 166-167.	0.8	0
1467	Lipid Disorders and Familial Hypercholesterolaemia. , 2019, , 1101-1120.		1
1468	Synthesis of <i>N</i> -aryl $\beta$ -amino acid derivatives via Cu(II)-catalyzed asymmetric 1,4-reduction in air. RSC Advances, 2019, 9, 9187-9192.	1.7	10
1469	CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins?. Journal of the American Heart Association, 2019, 8, e012352.	1.6	11
1470	The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Current Atherosclerosis Reports, 2019, 21, 20.	2.0	13
1471	High intensity lipid-lowering therapy after acute coronary syndromes: room for improvement. Medical Journal of Australia, 2019, 210, 73-74.	0.8	0
1472	Evidence-Based Cardiovascular Risk Management in Diabetes. American Journal of Cardiovascular Drugs, 2019, 19, 439-448.	1.0	10
1473	Relative effects of LDL-C on ischemic stroke and coronary disease. Neurology, 2019, 92, e1176-e1187.	1.5	40

#	ARTICLE	IF	CITATIONS
1474	Current pharmacotherapies for atherosclerotic cardiovascular diseases. Archives of Pharmacal Research, 2019, 42, 206-223.	2.7	10
1475	PDM-ProValue meets cardiovascular outcome trials in diabetes. Cardiovascular Diabetology, 2019, 18, 10.	2.7	2
1476	Prevalence, treatment, and control of dyslipidemia in diabetic participants of two brazilian cohorts: a place far from heaven. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2019, 65, 3-8.	0.3	2
1477	Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. Medical Journal of Australia, 2019, 210, 80-85.	0.8	18
1478	Management of dyslipidemia in adult solid organ transplant recipients. Journal of Clinical Lipidology, 2019, 13, 231-245.	0.6	36
1479	Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. American Journal of Cardiology, 2019, 123, 1202-1207.	0.7	11
1480	Una nueva estrategia para alcanzar los niveles objetivos de colesterol LDL tras un sÃndrome coronario agudo. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 93-100.	0.4	6
1481	How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. Mayo Clinic Proceedings, 2019, 94, 660-669.	1.4	6
1482	ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opinion on Pharmacotherapy, 2019, 20, 791-803.	0.9	37
1483	Real-world study: Escalating targeted lipid-lowering treatment with PCSK9 inhibitors and lipoprotein apheresis. Journal of Clinical Apheresis, 2019, 34, 423-433.	0.7	11
1484	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€” 2019 Executive Summary. Endocrine Practice, 2019, 25, 69-101.	1.1	245
1485	Cholesterol and stroke: role of PCSK9 inhibitors. NeurologÃa (English Edition), 2019, 34, 198-203.	0.2	0
1486	DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses. Nutrients, 2019, 11, 338.	1.7	300
1487	Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines. Current Pharmacology Reports, 2019, 5, 87-97.	1.5	0
1488	Non-statin lipid lowering and coronary plaque composition. Journal of Cardiovascular Computed Tomography, 2019, 13, 301-302.	0.7	0
1489	Type 2 Diabetes. Annals of Internal Medicine, 2019, 171, ITC65-ITC80.	2.0	46
1490	2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline*. Annals of Internal Medicine, 2019, 170, 779.	2.0	38
1491	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ”2019</i>. Diabetes Care, 2019, 42, S103-S123.	4.3	676

#	ARTICLE	IF	CITATIONS
1492	Correction of Hypertriglyceridemia as the Way to Reduce Residual Risk in Diseases Caused by Atherosclerosis. Conclusion of the Advisory Board of the Russian Society of Cardiology, the Russian Scientific Medical Society of Therapists, the Eurasian Association of Therapists, the Russian National Atherosclerosis Society, the Russian Association of Endocrinologists, and the National League of Cardiologic Genetics. Rational Pharmacotherapy in Cardiology, 2019, 15, 282-288.	0.3	5
1493	2018 Guidelines for the management of dyslipidemia. Korean Journal of Internal Medicine, 2019, 34, 723-771.	0.7	144
1494	Correction of Hypercholesterolemia in Primary and Secondary Prevention of Cardiovascular Diseases: Features and Controversial Issues. Rational Pharmacotherapy in Cardiology, 2019, 14, 917-921.	0.3	3
1495	Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease and ESRD, and Minority Groups. , 0, , .		6
1497	Evidence, Guidelines and Treatment Algorithms for Patients with Arterial Hypertension and Dyslipidemia: the Need for Compromise and Optimization of Tactics in Practical Healthcare. Rational Pharmacotherapy in Cardiology, 2019, 15, 578-585.	0.3	0
1498	Medical therapeutics: mortality effects, uncertainty, and informed consent. Porto Biomedical Journal, 2019, 4, e35.	0.4	1
1499	A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice. Drugs - Real World Outcomes, 2019, 6, 205-213.	0.7	6
1500	The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. Journal of Clinical Lipidology, 2019, 13, 797-803.e1.	0.6	25
1501	Ezetimibe and Rosuvastatin Combination Treatment Can Reduce the Dose of Rosuvastatin Without Compromising Its Lipid-lowering Efficacy. Clinical Therapeutics, 2019, 41, 2571-2592.	1.1	7
1502	Initiating PCSK9 Inhibition in Hospital for ACS. Journal of the American College of Cardiology, 2019, 74, 2463-2465.	1.2	2
1503	The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. Progress in Cardiovascular Diseases, 2019, 62, 375-383.	1.6	32
1504	Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition. PLoS Biology, 2019, 17, e3000572.	2.6	29
1505	Primary and Novel Lipid-Lowering Therapies to Reduce Risk in Patients With Peripheral Arterial Disease. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 94.	0.4	1
1506	Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial. Future Cardiology, 2019, 15, 391-394.	0.5	10
1507	Statins and myocardial infarction. Journal of Cardiovascular Medicine, 2019, 20, 220-222.	0.6	4
1508	Modulation of cholesterol efflux capacity in patients with myocardial infarction. Current Opinion in Cardiology, 2019, 34, 714-720.	0.8	4
1509	Risk factor reduction in type 2 diabetes demands a multifactorial approach. European Journal of Preventive Cardiology, 2019, 26, 81-91.	0.8	13
1510	Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk. Current Diabetes Reports, 2019, 19, 146.	1.7	5

#	ARTICLE	IF	CITATIONS
1512	High thrombotic risk increases adverse clinical events up to 5 years after acute myocardial infarction. A nationwide retrospective cohort study. <i>Monaldi Archives for Chest Disease</i> , 2019, 89, .	0.3	6
1513	Management of Lipid Abnormalities in Patients with Diabetes. <i>Current Cardiology Reports</i> , 2019, 21, 147.	1.3	15
1514	The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes. <i>Medicine (United States)</i> , 2019, 98, e18510.	0.4	4
1515	Maximizing the benefits of cholesterol-lowering drugs. <i>Current Opinion in Lipidology</i> , 2019, 30, 388-394.	1.2	9
1516	Association between Lipid Profiles and Renal Functions among Adults with Type 2 Diabetes. <i>International Journal of Diabetes and Metabolism</i> , 2019, 25, 134-138.	0.7	1
1517	Managing dyslipidemia for CVD prevention. <i>Nurse Practitioner</i> , 2019, 44, 8-16.	0.2	11
1518	Can atherosclerosis be cured?. <i>Current Opinion in Lipidology</i> , 2019, 30, 477-484.	1.2	12
1519	Diabetes and Cardiovascular Disease: an Update. <i>Current Diabetes Reports</i> , 2019, 19, 161.	1.7	53
1520	Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2019, 8, e013225.	1.6	114
1521	Management of Hyperlipidemia After Stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 93.	0.4	11
1522	Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting. <i>AIDS Patient Care and STDs</i> , 2019, 33, 500-506.	1.1	36
1523	Hyperlipidemia and cardiovascular disease: new insights on lipoprotein(a). <i>Current Opinion in Lipidology</i> , 2019, 30, 260-261.	1.2	16
1524	A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 265-271.	0.6	2
1525	Balanced Dysfunction in the Healthcare Ecosystem Harms Patients. <i>Circulation</i> , 2019, 140, 1860-1864.	1.6	1
1526	Influence of hypercholesterolemia and diabetes on long-term outcome in patients with stable coronary artery disease receiving percutaneous coronary intervention. <i>Medicine (United States)</i> , 2019, 98, e16927.	0.4	10
1527	Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2019, 30, 1-9.	1.2	51
1529	The need to improve cardiac care after acute coronary syndrome. <i>Hellenic Journal of Cardiology</i> , 2019, 60, 254-255.	0.4	2
1530	The Hypercholesterolemia Paradox in Percutaneous Coronary Intervention: An Analysis of a Multicenter PCI Registry. <i>Internal Medicine</i> , 2019, 58, 345-353.	0.3	6

#	ARTICLE	IF	CITATIONS
1531	Remnant lipoproteins and atherosclerotic cardiovascular disease. <i>Clinica Chimica Acta</i> , 2019, 490, 1-5.	0.5	23
1532	Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos. <i>Clínica E Investigación En Arteriosclerosis</i> , 2019, 31, 75-88.	0.4	6
1533	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
1534	Cholesterol Lowering and Prevention of Stroke. <i>Stroke</i> , 2019, 50, 537-541.	1.0	27
1535	Is very low LDL-C harmful?. <i>Current Pharmaceutical Design</i> , 2019, 24, 3658-3664.	0.9	16
1536	Cost-Effectiveness of Alirocumab. <i>Annals of Internal Medicine</i> , 2019, 170, 221.	2.0	57
1537	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 113-131.	1.0	4
1538	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1144-e1161.	1.6	87
1539	Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. <i>Circulation</i> , 2019, 139, 410-412.	1.6	12
1540	Health Issues and Care System for the Elderly. <i>Current Topics in Environmental Health and Preventive Medicine</i> , 2019, , .	0.1	0
1541	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, e285-e350.	1.2	1,550
1542	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019, 380, 11-22.	13.9	2,153
1543	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1046-e1081.	1.6	361
1544	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1082-e1143.	1.6	2,380
1546	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3168-3209.	1.2	1,128
1547	PCSK9 inhibitors: clinical evidence and implementation. <i>Nature Reviews Cardiology</i> , 2019, 16, 155-165.	6.1	195
1548	ApoB in clinical care: Pro and Con. <i>Atherosclerosis</i> , 2019, 282, 169-175.	0.4	27
1549	Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3210-3227.	1.2	124



#	ARTICLE	IF	CITATIONS
1550	Variations in the eicosapentaenoic acidâ€œarachidonic acid ratio associated with age in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. <i>Heart and Vessels</i> , 2019, 34, 755-762.	0.5	2
1551	Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. <i>Frontline Gastroenterology</i> , 2019, 10, 401-408.	0.9	14
1552	Future perspectives of the pharmacological management of diabetic dyslipidemia. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 129-143.	1.3	29
1553	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2019, , 117-138.e7.		2
1554	What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?. <i>Cardiovascular Research</i> , 2019, 115, e26-e31.	1.8	46
1555	Plaque characteristics and slow flow during percutaneous coronary intervention of irregular protrusion by optical coherence tomography. <i>Heart and Vessels</i> , 2019, 34, 1076-1085.	0.5	3
1556	Hypercholesterolaemia and coronary artery disease: A silent killer with several faces. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 75-78.	0.7	5
1557	Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 199.	1.1	47
1558	Drug Therapy of Dyslipidemia in the Elderly. <i>Drugs and Aging</i> , 2019, 36, 321-340.	1.3	22
1559	Determinantes de la inercia en el tratamiento hipolipemiente de pacientes con diabetes mellitus tipo 2. <i>Endocrinología, Diabetes Y NutriciÃ“n</i> , 2019, 66, 223-231.	0.1	4
1560	Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. <i>International Journal of Cardiology</i> , 2019, 286, 214-219.	0.8	30
1561	Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). <i>Pathology</i> , 2019, 51, 227-232.	0.3	30
1562	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	0.9	23
1563	Lipid paradox in patients with acute myocardial infarction: Potential impact of malnutrition. <i>Clinical Nutrition</i> , 2019, 38, 2311-2318.	2.3	18
1564	Review of the 2017 European Society of Cardiology's Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation and Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Developed in Collaboration with the European Association for Cardio-Thoracic Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2019, 33, 2334-2343.	0.6	13
1565	Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II <sub>CHD</sub>). <i>Acta Clinica Belgica</i> , 2019, 74, 399-404.	0.5	4
1566	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. <i>Annual Review of Medicine</i> , 2019, 70, 19-32.	5.0	6
1567	Imaging as a surrogate marker of drug efficacy in cardiovascular disease. <i>Heart</i> , 2019, 105, 567-578.	1.2	13

#	ARTICLE	IF	CITATIONS
1568	Evaluation and Treatment of Atherogenic Dyslipidemia. , 2019, , 211-234.		0
1569	Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor. <i>Cardiology in Review</i> , 2019, 27, 49-56.	0.6	26
1570	Management of Dyslipidemia. <i>Contemporary Cardiology</i> , 2019, , 39-69.	0.0	0
1572	Management of Diabetes Mellitus. <i>Contemporary Cardiology</i> , 2019, , 113-177.	0.0	0
1573	Lipoprotein Subfractions in Patients with Acute Coronary Syndromes: Should we Reach Beyond LDL-C?. <i>Current Vascular Pharmacology</i> , 2019, 17, 376-378.	0.8	2
1574	New Directions in Managing Dyslipidemia. <i>Journal for Nurse Practitioners</i> , 2019, 15, 73-79.e2.	0.4	2
1575	Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. <i>Clinical Research in Cardiology</i> , 2019, 108, 520-538.	1.5	39
1576	Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 69-74.	1.2	3
1577	Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. <i>Clinical Research in Cardiology</i> , 2019, 108, 487-509.	1.5	19
1578	Design and monitoring of survival trials in complex scenarios. <i>Statistics in Medicine</i> , 2019, 38, 192-209.	0.8	12
1579	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 47-54.	1.4	16
1580	Real-world use of PCSK9 inhibitors: A single-center experience. <i>Journal of International Medical Research</i> , 2019, 47, 265-270.	0.4	9
1581	World Heart Federation Cholesterol Roadmap. <i>Global Heart</i> , 2017, 12, 179.	0.9	30
1582	Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing. <i>Clinica Chimica Acta</i> , 2019, 489, 189-195.	0.5	4
1583	Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 745-754.	0.4	4
1584	Should we continue to consider serum cholesterol as an exogenous poisoning?. <i>British Journal of Sports Medicine</i> , 2019, 53, 1045.1-1045.	3.1	0
1585	Colesterol e ictus: papel de los inhibidores de la proproteína convertasa subtilisina/kexina tipo 9. <i>Neurología</i> , 2019, 34, 198-203.	0.3	3
1586	Modern Management of ST-Segment Elevation Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2020, 45, 100393.	1.1	26

#	ARTICLE	IF	CITATIONS
1587	Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine. <i>Acta Cardiologica</i> , 2020, 75, 10-19.	0.3	4
1588	Real-World Effectiveness of High- Versus Moderate-Intensity Statin Therapy in Thai Patients With Acute Coronary Syndrome and Who Had Undergone Primary Percutaneous Coronary Intervention. <i>Journal of Pharmacy Practice</i> , 2020, 33, 640-646.	0.5	2
1589	Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 151-157.	2.3	3
1590	Long-Term All-Cause and Cause-Specific Mortality in Asymptomatic Patients With CAC $\geq$ 1,000. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 83-93.	2.3	80
1591	A performance guide for major risk factors control in patients with atherosclerotic cardiovascular disease in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 674-684.	0.8	10
1592	Treatment practices and lipid profile of patients with acute coronary syndrome: results from a tertiary care hospital. <i>Acta Cardiologica</i> , 2020, 75, 527-534.	0.3	5
1593	Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II. <i>Heart Lung and Circulation</i> , 2020, 29, 405-413.	0.2	2
1594	Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 788-801.	0.4	7
1595	Dyslipidemia Management in Adults With Diabetes. <i>Canadian Journal of Diabetes</i> , 2020, 44, 53-60.	0.4	49
1596	High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 328-330.	1.4	3
1597	Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins – Confirmation from PCSK9 Inhibitor Studies. <i>American Journal of Medicine</i> , 2020, 133, 95-99.e6.	0.6	14
1598	Statin Intolerance Clinical Guide 2018. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 375-396.	0.9	17
1599	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	0.8	28
1600	Residual inflammatory risk after contemporary lipid lowering therapy. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 105-111.	1.8	6
1601	PCSK9 inhibitors and cardiovascular outcomes. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 35-47.	1.4	26
1602	The myth of “stable” coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 9-21.	6.1	89
1603	PCSK9: from molecular biology to clinical applications. <i>Annals of Clinical Biochemistry</i> , 2020, 57, 7-25.	0.8	7
1604	Three-year events and mortality in cardiovascular disease patients without lipid-lowering treatment. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2102-2104.	0.8	1

#	ARTICLE	IF	CITATIONS
1605	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 97-103.	1.4	14
1606	Efficacy of lipid-lowering therapy beyond statins to prevent cardiovascular events: a meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1675-1678.	0.8	4
1607	Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview. <i>International Journal of Stroke</i> , 2020, 15, 377-384.	2.9	29
1608	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	1.0	4,210
1609	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
1610	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
1611	Risk of Cardiovascular Events in Patients With Type 2 Diabetes and Metabolic Dyslipidemia Without Prevalent Atherosclerotic Cardiovascular Disease. <i>American Journal of Medicine</i> , 2020, 133, 200-206.	0.6	6
1612	Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1255-1268.	0.8	33
1613	High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 11-18.	1.0	0
1614	The Potential of Probiotics in the Prevention and Treatment of Atherosclerosis. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1900797.	1.5	39
1615	Combining Ubiquinol With a Statin May Benefit Hypercholesterolaemic Patients With Chronic Heart Failure. <i>Heart Lung and Circulation</i> , 2020, 29, 188-195.	0.2	10
1616	Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis. , 2020, 206, 107436.		17
1617	Genetics and Genomics of Atherosclerotic Cardiovascular Disease. , 2020, , 209-230.		0
1618	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. <i>American Heart Journal</i> , 2020, 219, 70-77.	1.2	18
1619	The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients. <i>Atherosclerosis</i> , 2020, 292, 231-233.	0.4	14
1620	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 325-332.	1.0	0
1621	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. <i>Revista Cl&amp;#x00ed;nica Espan&amp;#x00f5;la</i> , 2020, 220, 374-382.	0.3	0
1622	Non&#x00e0;High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History. <i>Laboratory Medicine</i> , 2020, 51, 14-23.	0.8	10

#	ARTICLE	IF	CITATIONS
1623	Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. <i>Lipids in Health and Disease</i> , 2020, 19, 3.	1.2	16
1624	Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention. <i>JAMA Cardiology</i> , 2020, 5, 209.	3.0	19
1625	An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 115-121.	1.4	46
1626	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. <i>European Heart Journal</i> , 2020, 41, 2304-2312.	1.0	54
1627	Mechanisms and regulation of cholesterol homeostasis. <i>Nature Reviews Molecular Cell Biology</i> , 2020, 21, 225-245.	16.1	899
1628	Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 239-248.	1.0	18
1629	Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. <i>Mayo Clinic Proceedings</i> , 2020, 95, 77-89.	1.4	97
1630	Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 107-120.	0.9	10
1631	Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application. <i>Heart Lung and Circulation</i> , 2020, 29, 619-633.	0.2	22
1632	Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study. <i>Diabetes Therapy</i> , 2020, 11, 453-465.	1.2	1
1633	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327,037 participants. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 36-49.	5.5	115
1634	Genetic disorders of lipoprotein metabolism. , 2020, , 245-265.		0
1635	Statins, LDL Cholesterol Control, Cardiovascular Disease Prevention, and Atherosclerosis Progression: A Clinical Perspective. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 405-412.	1.0	5
1636	Evolving concepts on the management of dyslipidaemia. <i>Acta Clinica Belgica</i> , 2020, 75, 80-90.	0.5	3
1637	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. <i>International Journal of Cardiology</i> , 2020, 303, 8-13.	0.8	5
1638	Have the Government's prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidemia influenced the management of dyslipidemia? The MEJORALO-CV Project. <i>Revista Científica Española de Cardiología</i> , 2020, 220, 282-289.	0.3	0
1639	Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. <i>Revista Española De Cardiología (English Ed)</i> , 2020, 73, 161-167.	0.4	10
1640	Impact of new lipid management guidelines on the treatment of extreme and very high-risk patients: AACE/ACE and AHA/ACC guidelines. <i>Journal of Diabetes</i> , 2020, 12, 105-109.	0.8	4

#	ARTICLE	IF	CITATIONS
1641	A practical algorithm for the management of patients with statin-associated muscle symptoms. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 137-140.	0.4	8
1642	What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104457.	0.7	3
1643	From hemorrhagic stroke to lipid paradox: a double-hit hypothesis underlying low low-density lipoprotein cholesterol related cardiovascular risk—a narrative review. <i>Journal of Bio-X Research</i> , 2020, 3, 97-103.	0.3	2
1644	Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 175-182.	0.1	4
1645	Role of Bempedoic Acid in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 376-388.	0.8	6
1646	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2020, 2020, CD011748.	1.5	42
1647	Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 31-38.	1.8	13
1648	Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). <i>Current Cardiology Reports</i> , 2020, 22, 176.	1.3	27
1649	LDL-C: lower is better for longer—even at low risk. <i>BMC Medicine</i> , 2020, 18, 320.	2.3	78
1650	Statins in primary prevention: is the enthusiasm justified?. <i>Indian Heart Journal</i> , 2020, 72, 221-224.	0.2	0
1651	Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 617-629.	0.7	3
1652	Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. <i>Atherosclerosis</i> , 2020, 313, 126-136.	0.4	52
1653	Early impact of the 2018 AHA/ACC/multisociety cholesterol guideline on lipid monitoring after statin initiation. <i>Journal of Clinical Lipidology</i> , 2020, 14, 784-790.	0.6	1
1654	Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 873-880.	0.6	1
1655	Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation. <i>PLoS ONE</i> , 2020, 15, e0239934.	1.1	26
1656	A Combination of Single Nucleotide Polymorphisms is Associated with the Interindividual Variability of Cholesterol Bioavailability in Healthy Adult Males. <i>Molecular Nutrition and Food Research</i> , 2020, 64, 2000480.	1.5	3
1657	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 435-450.	1.2	7
1658	Guidelines on multidisciplinary approaches for the prevention and management of diabetic foot disease (2020 edition). <i>Burns and Trauma</i> , 2020, 8, tkaa017.	2.3	47

#	ARTICLE	IF	CITATIONS
1659	Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-9.	0.5	14
1660	2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 324-333.	1.4	22
1661	Real-World Comparison of Ticagrelor and Clopidogrel: Rosetta Stone or Lost in Translation?. <i>Journal of the American Heart Association</i> , 2020, 9, e017888.	1.6	3
1662	Bias and Loss to Follow-Up in Cardiovascular Randomized Trials: A Systematic Review. <i>Journal of the American Heart Association</i> , 2020, 9, e015361.	1.6	7
1663	Efficacy of Statin/Ezetimibe for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Asian Populations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2020, 40, 809-826.	1.1	7
1664	The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes. <i>Diabetes Care</i> , 2020, 43, 1673-1678.	4.3	31
1665	Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2020, 17, e1003121.	3.9	64
1666	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1926-1936.	1.1	7
1667	Effect of Ezetimibe + Pitavastatin on Cardiovascular Outcomes in Patients with ST-Segment Elevation Myocardial Infarction (from the HIJ-PROPER Study). <i>American Journal of Cardiology</i> , 2020, 132, 15-21.	0.7	0
1668	In-hospital statin initiation characteristics and one-year statin adherence rates in patients hospitalised for acute coronary syndrome. <i>Acta Cardiologica</i> , 2020, 76, 1-7.	0.3	2
1670	Case Report: Cardiac Surgery and Combined Lipid-Lowering Drug Therapy for Homozygous Familial Hypercholesterolemia. <i>Frontiers in Pediatrics</i> , 2020, 8, 535949.	0.9	1
1671	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. <i>International Journal of Stroke</i> , 2021, 16, 738-750.	2.9	11
1672	Effect of Ezetimibe on Glucose Metabolism and Inflammatory Markers in Adipose Tissue. <i>Biomedicines</i> , 2020, 8, 512.	1.4	12
1673	Recurrent Atherosclerotic Cardiovascular Event Rates Differ Among Patients Meeting the Very High Risk Definition According to Age, Sex, Race/Ethnicity, and Socioeconomic Status. <i>Journal of the American Heart Association</i> , 2020, 9, e017310.	1.6	13
1674	The Impact of Information Technology on the Diffusion of New Pharmaceuticals. <i>American Economic Journal: Applied Economics</i> , 2020, 12, 1-39.	1.5	5
1675	In vivo imaging of vulnerable plaque with intravascular modalities: its advantages and limitations. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1461-1479.	0.7	12
1676	Low-dose colchicine after MI reduced a composite ischemic cardiovascular outcome vs placebo. <i>Annals of Internal Medicine</i> , 2020, 172, JC39.	2.0	0
1677	Low Levels of Low-Density Lipoprotein Cholesterol and Endothelial Function in Subjects without Lipid-Lowering Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3796.	1.0	4

#	ARTICLE	IF	CITATIONS
1679	Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 658-670.	0.8	9
1681	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm " 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 1196-1224.	1.1	117
1682	Hitos hist3ricos en el tratamiento hipolipemiante antes de la era de los inhibidores de la proproteína convertasa subtilisina/kexina tipo 9. <i>Revista Espanola De Cardiologia Suplementos</i> , 2020, 20, 8-14.	0.2	0
1683	Anticuerpos monoclonales inhibidores de la proproteína convertasa subtilisina/kexina tipo 9: nuevas evidencias. <i>Revista Espanola De Cardiologia Suplementos</i> , 2020, 20, 15-20.	0.2	1
1685	The Role of Statins in Current Guidelines. <i>Current Atherosclerosis Reports</i> , 2020, 22, 50.	2.0	17
1686	Targeting Inflammation After Myocardial Infarction. <i>Current Cardiology Reports</i> , 2020, 22, 110.	1.3	19
1687	Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. <i>Journal of the American College of Cardiology</i> , 2020, 76, 653-664.	1.2	39
1688	Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2137-2151.	0.9	7
1689	Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 837-851.	1.5	8
1690	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1020-1076.	1.1	159
1691	A Focus on Evaluating Major Study Limitations in Order to Apply Clinical Trials to Patient Care: Implications for the Healthcare Team. <i>Hospital Pharmacy</i> , 2020, 56, 001857872093175.	0.4	0
1694	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. <i>International Journal of Diabetes in Developing Countries</i> , 2020, 40, 1-122.	0.3	16
1695	Risk Differences in Secondary Prevention Patients Who Present With Acute Coronary Syndrome and Implications of Guideline-Directed Cholesterol Management. <i>American Journal of Cardiology</i> , 2020, 133, 1-6.	0.7	0
1696	"Fishing" for therapies to "net" cost-effective benefits. <i>European Journal of Preventive Cardiology</i> , 2020, 28, 893-896.	0.8	1
1697	Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1C in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular events: a cohort study from China. <i>Cardiovascular Diabetology</i> , 2020, 19, 116.	2.7	39
1698	Cardiovascular Risk and Statin Therapy Considerations in Women. <i>Diagnostics</i> , 2020, 10, 483.	1.3	45
1699	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e016506.	1.6	8
1700	Type 2 diabetes mellitus is a strong predictor of LDL cholesterol target achievement in patients with peripheral artery disease. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107692.	1.2	7



#	ARTICLE	IF	CITATIONS
1701	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Diabetology International</i> , 2020, 11, 165-223.	0.7	266
1702	Hit or miss: the new cholesterol targets. <i>BMJ Evidence-Based Medicine</i> , 2020, 26, bmjebm-2020-111413.	1.7	9
1703	Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status: an observational cohort study from China. <i>Lipids in Health and Disease</i> , 2020, 19, 179.	1.2	11
1704	Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial. <i>Current Therapeutic Research</i> , 2020, 93, 100595.	0.5	5
1705	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 4-33.	6.6	113
1706	Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. <i>Current Opinion in Cardiology</i> , 2020, 35, 517-523.	0.8	2
1707	Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2020, 38, 1007-1020.	1.7	20
1708	Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2252-2266.	1.2	52
1709	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2020. <i>Diabetes Care</i> , 2020, 43, S111-S134.	4.3	421
1710	Cholesteryl ester transfer protein inhibitors in precision medicine. <i>Clinica Chimica Acta</i> , 2020, 510, 733-740.	0.5	4
1711	The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 435-441.	1.4	6
1712	Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. <i>Vascular Health and Risk Management</i> , 2020, Volume 16, 403-418.	1.0	4
1713	Role of the Nuclear Receptor Corepressor 1 (NCOR1) in Atherosclerosis and Associated Immunometabolic Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 569358.	2.2	9
1714	Updates in Anti-anginal and Anti-ischemic Therapies for Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2020, 22, 126.	1.3	2
1715	Targeting Inflammation to Reduce Residual Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2020, 22, 66.	2.0	29
1716	LDL-cholesterol reduction in chronic kidney disease: options beyond statins. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 480-488.	1.0	3
1717	Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update. <i>Journal of Drug Assessment</i> , 2020, 9, 129-144.	1.1	17
1719	Survival analysis using a step stratified testing and amalgamation routine (STAR) in randomized clinical trials. <i>Statistics in Medicine</i> , 2020, 39, 4724-4744.	0.8	3

#	ARTICLE	IF	CITATIONS
1720	The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. <i>Current Atherosclerosis Reports</i> , 2020, 22, 67.	2.0	15
1721	Estimation of the major cardiovascular events prevention with Inclisiran. <i>Atherosclerosis</i> , 2020, 313, 76-80.	0.4	19
1722	Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. <i>Clinical Research in Cardiology</i> , 2022, 111, 243-252.	1.5	32
1723	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3613-3682.	1.8	63
1724	High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. <i>Lipids in Health and Disease</i> , 2020, 19, 194.	1.2	13
1725	Lipid-lowering Therapies in Myositis. <i>Current Rheumatology Reports</i> , 2020, 22, 70.	2.1	3
1726	Inclisiran, the billion-dollar drug, to lower LDL cholesterol “is it worth it?”. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1971-1974.	0.9	2
1727	Recent advances and emerging therapies in management of dyslipidemias. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 419-424.	2.3	3
1728	Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?. <i>Current Cardiology Reports</i> , 2020, 22, 146.	1.3	6
1730	Vertebral Artery Stenosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	0
1731	REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Tj ETQq0 0 0 rBT /Overlock 10 Tf	0.7	10
1732	Lowering Low-Density Lipoprotein Cholesterol Concentration with Plant Stanol Esters to Reduce the Risk of Atherosclerotic Cardiovascular Disease Events at a Population Level: A Critical Discussion. <i>Nutrients</i> , 2020, 12, 2346.	1.7	7
1733	Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1440-1450.	1.2	29
1735	Chronic kidney disease: a high-risk group that deserves intensive lipid lowering. <i>European Heart Journal</i> , 2020, 41, 4124-4126.	1.0	4
1736	<p></p>Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 835-845.	1.5	2
1737	Universal cholesterol screening of youth“Are pediatric lipidologists smarter than a fifth grader?. <i>Journal of Clinical Lipidology</i> , 2020, 14, 747-750.	0.6	0
1738	LDL cholesterol in one step. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 316-317.	0.1	0
1739	Editorial commentary: Advances in the management of dyslipidemia: The future is bright, but what we do today is what matters most. <i>Trends in Cardiovascular Medicine</i> , 2020, 31, 425-426.	2.3	0

#	ARTICLE	IF	CITATIONS
1740	Prevalence, treatment, and control of severe hyperlipidemia. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100079.	1.3	5
1742	Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100117.	1.3	2
1743	Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists. <i>CJC Open</i> , 2020, 2, 625-631.	0.7	1
1744	Improvement initiative in LDL-C management in Saudi Arabia: A call to action. <i>IJC Heart and Vasculature</i> , 2020, 31, 100667.	0.6	7
1746	Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care – Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108416.	1.1	0
1747	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. <i>Journal of the American Heart Association</i> , 2020, 9, e018897.	1.6	23
1749	Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 347-362.	1.3	23
1750	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo. <i>JACC: CardioOncology</i> , 2020, 2, 385-396.	1.7	7
1751	Bempedoic acid: A new player in lipid-lowering therapies. <i>Journal of Clinical Lipidology</i> , 2020, 14, 615-616.	0.6	0
1752	Colesterol LDL en un paso. <i>Medicina Clínica</i> , 2020, 155, 316-317.	0.3	5
1753	Higher baseline lipid levels amplify the benefit of secondary prevention therapy with statins in Chinese patients with acute coronary syndrome. <i>Journal of International Medical Research</i> , 2020, 48, 030006052096584.	0.4	0
1754	Novel emerging therapies in atherosclerosis targeting lipid metabolism. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 611-622.	1.9	36
1755	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction. <i>JAMA Cardiology</i> , 2020, 5, 787.	3.0	23
1757	An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 879-887.	0.4	17
1758	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 409-417.	1.0	15
1759	Cognition After Lowering LDL-Cholesterol With Evolocumab. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2283-2293.	1.2	62
1760	Meta-analysis of cardiovascular superiority trials published in the <i>New England Journal of Medicine</i> to elucidate the concept of superiority margin. <i>Postgraduate Medical Journal</i> , 2021, 97, 227-233.	0.9	0
1761	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2297-2308.	1.2	48

#	ARTICLE	IF	CITATIONS
1762	Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2602-2618.	1.2	175
1764	Insights into incretin-based therapies for treatment of diabetic dyslipidemia. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 34-53.	6.6	21
1765	Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome. <i>Atherosclerosis</i> , 2020, 303, 21-28.	0.4	9
1766	Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry. <i>Journal of Cardiology</i> , 2020, 76, 385-394.	0.8	3
1767	Lipid lowering therapy in cardiovascular disease: From myth to molecular reality. , 2020, 213, 107592.		35
1768	Treatment Patterns of Lipid-Lowering Therapy in Patients with Coronary Artery Disease Aged Above and Below 75 Years: A Retrospective Cross-Sectional Study of 1500 Patients in a Tertiary Care Referral Center in Germany. <i>Drugs and Aging</i> , 2020, 37, 521-527.	1.3	3
1769	Fibrosis and diabetes: Chronic hyperglycemia triggers organ-specific fibrotic mechanisms. , 2020, , 121-147.		0
1770	Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 361-379.	3.5	119
1771	Genomic Strategies Toward Identification of Novel Therapeutic Targets. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	0.9	3
1772	Is the novel LDL-cholesterol goal <math>< 1.4\text{ mmol/L}</math> achievable without a PCSK9 inhibitor in a chronic coronary population from clinical practice?. <i>European Journal of Preventive Cardiology</i> , 2020, , 2047487320923187.	0.8	7
1773	Goal achievement of <math>\text{HbA1c}</math> and <math>\text{LDL-C}</math> cholesterol in a randomized trial comparing colesevelam with ezetimibe: <math>\text{GOAL-RCT}</math>. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1722-1728.	2.2	6
1774	Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 1030-1039.e4.	0.4	4
1775	A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy. <i>American Journal of Medicine</i> , 2020, 133, 1322-1327.	0.6	16
1776	Prevalence of poor lipid control in patients with premature coronary artery disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1697-1705.	1.1	9
1777	Impact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids. <i>Journal of Clinical Medicine</i> , 2020, 9, 1596.	1.0	15
1778	A tale of two technologies: Can nuclear cardiology survive the emergence of cardiac CT the seventeenth annual Mario S. Verani lectureship. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 865-890.	1.4	0
1779	Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression. <i>Lipids in Health and Disease</i> , 2020, 19, 111.	1.2	20
1780	Bempedoic acid: a promising novel agent for LDL-C lowering. <i>Future Cardiology</i> , 2020, 16, 361-371.	0.5	14

#	ARTICLE	IF	CITATIONS
1781	Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey. <i>Lipids in Health and Disease</i> , 2020, 19, 131.	1.2	5
1782	Low Reporting of Cointerventions in Recent Cardiovascular Clinical Trials: A Systematic Review. <i>Journal of the American Heart Association</i> , 2020, 9, e014890.	1.6	5
1783	Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. <i>Cardiovascular Diabetology</i> , 2020, 19, 80.	2.7	161
1784	Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2020, 9, 1675.	1.0	1
1785	Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV. <i>Current HIV/AIDS Reports</i> , 2020, 17, 394-404.	1.1	11
1786	Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies. <i>European Heart Journal Supplements</i> , 2020, 22, E64-E67.	0.0	9
1787	Preventing myocardial infarction: use and limitation of non-invasive imaging modalities. <i>European Heart Journal Supplements</i> , 2020, 22, E110-E112.	0.0	2
1788	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 723-735.	1.3	11
1789	A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. <i>Cardiology and Therapy</i> , 2020, 9, 447-465.	1.1	6
1790	The LDL cholesterol in stroke limbo. <i>Current Opinion in Lipidology</i> , 2020, 31, 161-162.	1.2	1
1791	Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition. <i>Science Advances</i> , 2020, 6, eabb1989.	4.7	49
1792	Current Status of Dyslipidemia Treatment for Stroke Prevention. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 31.	2.0	11
1793	Small rodent models of atherosclerosis. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110426.	2.5	68
1794	Clinical Pharmacology of Statins: an Update. <i>Current Atherosclerosis Reports</i> , 2020, 22, 26.	2.0	31
1795	Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 759-765.	0.8	16
1796	Reorganizing the treatment of cardiovascular disease in response to coronavirus disease 2019; time for the polypill?. <i>Current Opinion in Cardiology</i> , 2020, 35, 428-433.	0.8	7
1797	Reducing residual cardiovascular risk with novel therapies. <i>Current Opinion in Lipidology</i> , 2020, 31, 108-110.	1.2	7
1798	Dyslipidaemias and their treatment in high complexity centres in Colombia. <i>Clínica E Investigación en Arteriosclerosis (English Edition)</i> , 2020, 32, 101-110.	0.1	2

#	ARTICLE	IF	CITATIONS
1799	Statins Alone or in Combination with Ezetimibe or PCSK9 Inhibitors in Atherosclerotic Cardiovascular Disease Protection. , 2020, , .		1
1800	Eligibility for PCSK-9 inhibitors treatment in acute coronary syndrome, chronic coronary artery disease and outpatient dyslipidemic patients. <i>Atherosclerosis</i> , 2020, 303, 29-35.	0.4	5
1801	Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?. <i>Scandinavian Cardiovascular Journal</i> , 2020, 54, 274-279.	0.4	9
1802	What is the Sweet Spot for Platelet Reactivity in Japanese Patients?. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 1-3.	0.9	1
1803	CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL-Cholesterol to ACC/AHA and ESC/EAS Targets. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1961-1972.	2.3	16
1804	New possible pharmacological targets for statins and ezetimibe. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110388.	2.5	35
1805	Cardiometabolic Medicine: Development of a New Subspecialty. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2095-2104.	1.8	15
1806	Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002–2016. <i>Journal of Clinical Lipidology</i> , 2020, 14, 305-314.	0.6	6
1807	In-depth Mendelian randomization analysis of causal factors for coronary artery disease. <i>Scientific Reports</i> , 2020, 10, 9208.	1.6	9
1808	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets. <i>Current Cardiology Reports</i> , 2020, 22, 66.	1.3	26
1809	Management of diabetic dyslipidemia: Navigating the new American and European Guidelines. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 877-879.	1.8	4
1810	Ezetimibe: An Unusual Suspect in Angioedema. <i>Case Reports in Medicine</i> , 2020, 2020, 1-3.	0.3	2
1811	Translating evidence from clinical trials of omega-3 fatty acids to clinical practice. <i>Future Cardiology</i> , 2020, 16, 343-350.	0.5	0
1812	GOAL Canada: Physician Education and Support Can Improve Patient Management. <i>CJC Open</i> , 2020, 2, 49-54.	0.7	4
1813	The association of repeatedly measured low-density lipoprotein cholesterol and all-cause mortality and cardiovascular disease in dyslipidemic patients: A longitudinal study. <i>International Journal of Cardiology</i> , 2020, 311, 97-103.	0.8	5
1814	Acute Coronary Syndromes and the Nontarget Lesion. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1107-1110.	1.2	1
1815	A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 535-548.	1.0	22
1816	Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 798.	1.0	4

#	ARTICLE	IF	CITATIONS
1817	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000943.	1.2	15
1818	Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review. <i>Advances in Therapy</i> , 2020, 37, 1724-1736.	1.3	32
1819	Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelines. <i>Acta Cardiologica</i> , 2021, 76, 375-383.	0.3	2
1820	Coronary Artery Disease: Therapeutics and Drug Discovery. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	4
1821	Triglycerides and Cardiovascular Outcomesâ€”Can We REDUCE-ITâ€™s?. <i>International Journal of Angiology</i> , 2020, 29, 002-011.	0.2	5
1822	Pharmacokinetics of current and emerging treatments for hypercholesterolemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 371-385.	1.5	9
1823	<p>Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 423-431.	1.1	4
1824	Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 122, 105735.	1.2	47
1825	Management of <sc>LDL</sc>â€™cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. <i>Clinical Cardiology</i> , 2020, 43, 684-690.	0.7	7
1826	Genetic drug target validation using Mendelian randomisation. <i>Nature Communications</i> , 2020, 11, 3255.	5.8	175
1827	Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 381-392.	1.0	29
1828	Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100013.	1.3	10
1829	Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. <i>Pharmacoeconomics</i> , 2020, 38, 1095-1113.	1.7	28
1830	The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232092456.	1.1	8
1831	New Recommendations and Revised Concepts in Recent Guidelines on the Management of Dyslipidemias to Prevent Cardiovascular Disease: the 2018 ACC/AHA and 2019 ESC/EAS Guidelines. <i>Current Cardiology Reports</i> , 2020, 22, 87.	1.3	17
1833	&lt;p&gt;Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 157-165.	2.0	14
1834	Triglycerides and residual risk. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 95-103.	1.2	42
1836	Ischemic Heart Disease: An Update. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 195-207.	2.5	40

#	ARTICLE	IF	CITATIONS
1837	Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study. <i>Diabetes Therapy</i> , 2020, 11, 859-871.	1.2	11
1838	Effect of Aggressive Lipid-Lowering Therapy in Single-Vessel vs. Multivessel Coronary Artery Disease Patients With Acute Coronary Syndrome—Heart Institute of Japan-Proper Level of Lipid Lowering With Pitavastatin and Ezetimibe in Acute Coronary Syndrome (HIJ-PROPER) Substudy. <i>Circulation Reports</i> , 2020, 2, 128-134.	0.4	4
1839	Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 744-757.	1.1	41
1840	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. <i>Journal of the American College of Cardiology</i> , 2020, 75, 835-837.	1.2	1
1841	Upholding trust in therapeutic trials and evidence-based medicine: need for full disclosure of data, crowdsourcing data analysis and independent review?. <i>BMJ Evidence-Based Medicine</i> , 2020, , bmjebm-2019-111242.	1.7	0
1842	Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience. <i>Journal of Clinical Lipidology</i> , 2020, 14, 231-240.	0.6	35
1843	What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. <i>Cardiology and Therapy</i> , 2020, 9, 59-73.	1.1	16
1844	An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 531-539.	0.9	17
1845	Lower diabetes rate in patients with familial hypercholesterolaemia: What is the link?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1647-1648.	0.8	1
1846	Statin-Associated Muscle Symptoms. <i>Contemporary Cardiology</i> , 2020, , .	0.0	0
1847	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. <i>Nature Reviews Cardiology</i> , 2020, 17, 360-377.	6.1	82
1848	Pemafibrate, a New Selective PPAR $\alpha$ Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. <i>Current Atherosclerosis Reports</i> , 2020, 22, 5.	2.0	106
1849	Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction. <i>Journal of Clinical Lipidology</i> , 2020, 14, 260-270.	0.6	11
1850	Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. <i>Current Cardiology Reports</i> , 2020, 22, 13.	1.3	1
1851	Outcomes of lipid control in secondary prevention of coronary artery disease in Finland: A 24-month follow-up after acute coronary syndrome. <i>Atherosclerosis</i> , 2020, 296, 4-10.	0.4	6
1852	Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step back. <i>European Heart Journal</i> , 2020, 41, 1650-1652.	1.0	3
1853	Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	14
1854	The Journal of Cardiovascular Computed Tomography year in review—2019. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, 107-117.	0.7	5



#	ARTICLE	IF	CITATIONS
1855	Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 307-315.	1.0	4
1856	Temporal Trends of the Management and Outcome of Patients With Myocardial Infarction According to the Risk for Recurrent Cardiovascular Events. <i>American Journal of Medicine</i> , 2020, 133, 839-847.e2.	0.6	6
1857	Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-8.	1.1	7
1858	Prevention of stroke in people living with HIV. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 160-169.	1.6	13
1859	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. <i>Current Vascular Pharmacology</i> , 2020, 18, 125-138.	0.8	9
1860	LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 805-812.	0.8	57
1861	Combining Nanomaterials and Developmental Pathways to Design New Treatments for Cardiac Regeneration: The Pulsing Heart of Advanced Therapies. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 323.	2.0	13
1862	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.	4.3	21
1863	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020, 2, 402-415.	0.7	6
1864	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	0.9	8
1865	Squalene monooxygenase: a journey to the heart of cholesterol synthesis. <i>Progress in Lipid Research</i> , 2020, 79, 101033.	5.3	47
1866	Impact of LR11 as Residual Risk on Long-Term Clinical Outcomes in Patients with Coronary Artery Disease Treated with Statins after First Percutaneous Coronary Intervention. <i>International Heart Journal</i> , 2020, 61, 470-475.	0.5	2
1867	Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 489-498.	0.9	14
1868	Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1945-1955.	1.2	47
1869	Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?. <i>European Heart Journal</i> , 2020, 41, 3910-3912.	1.0	4
1870	A Narrative Review and Expert Panel Recommendations on Dyslipidaemia Management After Acute Coronary Syndrome in Countries Outside Western Europe and North America. <i>Advances in Therapy</i> , 2020, 37, 1754-1777.	1.3	0
1871	Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2119-2121.	1.2	20
1872	A perspective on targeting inflammation and cytokine actions in atherosclerosis. <i>Future Medicinal Chemistry</i> , 2020, 12, 613-626.	1.1	15

#	ARTICLE	IF	CITATIONS
1873	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 107-139.	1.1	410
1874	Identification and Evaluation of Controlled Trials in Pediatric Cardiology: Crowdsourced Scoping Review and Creation of Accessible Searchable Database. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1795-1804.	0.8	11
1875	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. <i>American Heart Journal</i> , 2020, 225, 97-107.	1.2	5
1876	Statins and PCSK9 inhibitors: A new lipid-lowering therapy. <i>European Journal of Pharmacology</i> , 2020, 878, 173114.	1.7	54
1877	Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020. <i>Journal of Women's Health</i> , 2020, 29, 1091-1100.	1.5	9
1878	Emerging opportunities to harness real world data: An introduction to data sources, concepts, and applications. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 3-12.	2.2	30
1879	Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. <i>Stroke</i> , 2020, 51, 1546-1554.	1.0	102
1880	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e779-e806.	1.6	157
1881	Probuocol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE). <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 103-123.	0.9	26
1882	Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013–17. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 59-67.	1.8	10
1883	Biotechnology Approaches for the Treatment of Dyslipidemia. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 167-183.	1.3	4
1884	Prognostic significance of suboptimal secondary prevention pharmacotherapy after acute coronary syndromes. <i>Internal Medicine Journal</i> , 2021, 51, 366-374.	0.5	9
1885	Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 905-916.	0.8	13
1886	Mechanistic Insights to Target Atherosclerosis Residual Risk. <i>Current Problems in Cardiology</i> , 2021, 46, 100432.	1.1	21
1887	Verification of Low-Density Lipoprotein Cholesterol Levels Measured by Anion-Exchange High-Performance Liquid Chromatography in Comparison with Beta Quantification Reference Measurement Procedure. <i>Journal of Applied Laboratory Medicine</i> , The, 2021, 6, 654-667.	0.6	3
1888	Reduction in Revascularization With Icosapent Ethyl. <i>Circulation</i> , 2021, 143, 33-44.	1.6	46
1889	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 59-65.	0.8	30
1890	Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 153-166.	1.3	15

#	ARTICLE	IF	CITATIONS
1891	Personalized medicine for cardiovascular diseases. <i>Journal of Human Genetics</i> , 2021, 66, 67-74.	1.1	23
1892	Prevalence and Predictors of Out-of-Target LDL Cholesterol 1 to 3 Years After Myocardial Infarction. A Subanalysis From the EYESHOT Post-MI Registry. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 149-157.	1.0	9
1893	Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology. <i>Diabetes and Metabolism</i> , 2021, 47, 101185.	1.4	23
1894	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127.	1.2	60
1895	Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. <i>International Journal of Clinical Practice</i> , 2021, 75, e13861.	0.8	3
1896	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. <i>Annual Review of Medicine</i> , 2021, 72, 447-458.	5.0	12
1897	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. <i>Annual Review of Medicine</i> , 2021, 72, 431-446.	5.0	9
1898	The relationship between residual cholesterol risk and plaque characteristics in patients with acute coronary syndrome: Insights from an optical coherence tomography study. <i>Atherosclerosis</i> , 2021, 317, 10-15.	0.4	6
1899	Linear and Nonlinear Mendelian Randomization Analyses of the Association Between Diastolic Blood Pressure and Cardiovascular Events. <i>Circulation</i> , 2021, 143, 895-906.	1.6	73
1900	Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. <i>Clinical Chemistry</i> , 2021, 67, 143-153.	1.5	120
1901	Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 259-267.	1.2	24
1902	Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. <i>JAMA Cardiology</i> , 2021, 6, 582.	3.0	5
1903	Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 150-172.	0.7	6
1904	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€”2021</i>. <i>Diabetes Care</i> , 2021, 44, S125-S150.	4.3	359
1905	Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials. <i>Clinical Drug Investigation</i> , 2021, 41, 19-28.	1.1	13
1906	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. <i>Diabetology International</i> , 2021, 12, 1-51.	0.7	6
1907	Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. <i>American Heart Journal</i> , 2021, 235, 104-112.	1.2	82
1908	May need more comprehensive approach to residual risks in well controlled hypertensive patients. <i>Hypertension Research</i> , 2021, 44, 253-255.	1.5	0

#	ARTICLE	IF	CITATIONS
1909	Unique roles of rare variants in the genetics of complex diseases in humans. <i>Journal of Human Genetics</i> , 2021, 66, 11-23.	1.1	74
1910	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	1.0	3,048
1911	Impact of high-dose statin on cardiovascular outcomes in real-world patients with ST-elevation acute myocardial infarction. <i>Heart and Vessels</i> , 2021, 36, 297-307.	0.5	3
1912	Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges. <i>British Journal of Pharmacology</i> , 2021, 178, 2168-2185.	2.7	7
1913	Integrated Analysis of Two Probuocol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 850-865.	0.9	5
1914	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. <i>Contemporary Cardiology</i> , 2021, , 1-22.	0.0	0
1915	Precision Medicine and Informatics. , 2021, , 941-966.		0
1916	How low is safe? The frontier of very low (&lt;30 mg/dL) LDL cholesterol. <i>European Heart Journal</i> , 2021, 42, 2154-2169.	1.0	28
1917	Clinical characteristics, secondary prevention goal attainment, and outcomes of patients with recurrent acute coronary syndrome. <i>Journal of Nippon Medical School</i> , 2021, 88, 432-440.	0.3	0
1918	Benefits of LDL cholesterol reduction in the secondary prevention of ischemic stroke New evidence. <i>Cl�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2021, 33, 53-54.	0.1	0
1920	Lipid-Lowering Drugs. , 2021, , 1-8.		0
1921	The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104�mg/dL. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 41.	0.7	13
1922	How I treat statin-associated side effects in an outpatient setting. <i>Future Cardiology</i> , 2021, 17, 1249-1260.	0.5	6
1923	Combination of Statin and Ezetimibe versus Statin Monotherapy on Cardiovascular Disease and Type 2 Diabetes Incidence among Adults with Impaired Fasting Glucose: a Propensity-Matched Nationwide Cohort Study. <i>Journal of Lipid and Atherosclerosis</i> , 2021, 10, 303.	1.1	8
1924	Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 19.	0.7	9
1925	Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-Analysis. <i>Cardiology Research</i> , 2021, 12, 98-108.	0.5	8
1926	PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance. <i>In Vivo</i> , 2021, 35, 61-68.	0.6	5
1927	Understanding of Clinical Practice Guidelines for Dyslipidemia. <i>Stroke Revisited</i> , 2021, , 145-151.	0.2	0

#	ARTICLE	IF	CITATIONS
1928	Cholesterol metabolism in prostate cancer. , 2021, , 211-240.		1
1930	Neurological complications of cardiovascular drugs. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 177, 319-344.	1.0	1
1931	Dietary Approaches to Lowering LDL-C. Contemporary Cardiology, 2021, , 193-209.	0.0	0
1932	The Questions on Everyone's Mind: What is and Why Do We Need Preventive Cardiology?. Methodist DeBaake Cardiovascular Journal, 2021, 17, 8-14.	0.5	3
1933	Comparison of the Effects of High-intensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study. Journal of Lipid and Atherosclerosis, 2021, 10, 291.	1.1	7
1934	Ezetimibe. Stroke Revisited, 2021, , 91-101.	0.2	1
1935	Diabetes, Lipids, and CV Risk. Current Atherosclerosis Reports, 2021, 23, 8.	2.0	6
1937	Should We Target Global Risk or Risk Factors?. Current Atherosclerosis Reports, 2021, 23, 2.	2.0	2
1938	Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1307-1322.	0.9	5
1939	Racionalidad científica para la evolución de las metas de LDL-c. , 2021, 32, 182-191.		0
1940	Bempedoic acid: Review of a novel therapy in lipid management. American Journal of Health-System Pharmacy, 2021, 78, 95-104.	0.5	5
1941	Tratamiento hipolipemiente en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica. REC: CardioClinics, 2021, 56, 39-48.	0.1	5
1942	Shared Decision Making. , 2021, , 169-192.		0
1943	Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review. Therapeutic Advances in Drug Safety, 2021, 12, 204209862095927.	1.0	3
1944	Dyslipidemia and Cardiovascular Disease Prevention in South Asians: A Review and Discussion of Causes, Challenges and Management Strategies. Current Diabetes Reviews, 2021, 17, e011221190238.	0.6	6
1945	Medical and Revascularization Management of Stable Ischemic Heart Disease: An Overview. International Journal of Angiology, 2021, 30, 083-090.	0.2	0
1946	Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance. Cardiovascular Drugs and Therapy, 2021, 35, 841-852.	1.3	7
1947	Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care. European Heart Journal, 2021, 42, 253-256.	1.0	14

#	ARTICLE	IF	CITATIONS
1948	PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study. Archives of Medical Science, 2021, 17, 241-244.	0.4	12
1949	HDL-C and Cardiovascular Risk: You Don't Need to Worry about Extremely High HDL-C Levels. Journal of Lipid and Atherosclerosis, 2021, 10, 57.	1.1	7
1950	Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. European Journal of Preventive Cardiology, 2022, 29, e53-e64.	0.8	15
1951	Dyslipidemia Fact Sheets in Korea 2020: an Analysis of Nationwide Population-based Data. Journal of Lipid and Atherosclerosis, 2021, 10, 202.	1.1	61
1952	Recent Updates of Lipoprotein(a) and Cardiovascular Disease. Chonnam Medical Journal, 2021, 57, 36.	0.5	14
1953	Update on prevention of diabetic foot ulcer. Archives of Medical Sciences Atherosclerotic Diseases, 2021, 6, 123-131.	0.5	11
1955	Improved lipid target level attainment in patients with peripheral artery disease. Current Vascular Pharmacology, 2021, 19, 634-642.	0.8	0
1956	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. Current Pharmaceutical Design, 2021, 27, 263-275.	0.9	27
1957	Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents. Vascular Health and Risk Management, 2021, Volume 17, 59-67.	1.0	16
1958	The comparative impact among different intensive statins and combination therapies with niacin/ezetimibe on carotid intima-media thickness: a systematic review, traditional meta-analysis, and network meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2021, 77, 1133-1145.	0.8	8
1959	Novel Experimental Agents for the Treatment of Hypercholesterolemia. Journal of Experimental Pharmacology, 2021, Volume 13, 91-100.	1.5	14
1960	Effects of Huatan Jiangzhuo decoction on diet-induced hyperlipidemia and gene expressions in rats. Chinese Journal of Natural Medicines, 2021, 19, 100-111.	0.7	3
1961	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation, 2021, 143, 685-695.	1.6	22
1962	Effects of Statin Plus Ezetimibe on Coronary Plaques in Acute Coronary Syndrome Patients with Diabetes Mellitus: Sub-Analysis of PRECISE-IVUS Trial. Journal of Atherosclerosis and Thrombosis, 2021, 28, 181-193.	0.9	6
1963	2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTEMI-ACS guideline group. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 224-233.	0.4	54
1964	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. Atherosclerosis, 2021, 319, 51-61.	0.4	37
1965	Coronary artery disease: differential expression of ceRNAs and interaction analyses. Annals of Translational Medicine, 2021, 9, 229-229.	0.7	3
1966	A Synergistic Effect of Lp(a) and GRACE Score on Cardiovascular Risk in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study From China. Frontiers in Cardiovascular Medicine, 2021, 8, 637366.	1.1	2

#	ARTICLE	IF	CITATIONS
1967	Development and Validation of a Predictive Model for Coronary Artery Disease Using Machine Learning. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 614204.	1.1	9
1968	Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?. <i>Journal of Clinical Medicine</i> , 2021, 10, 886.	1.0	5
1969	Low dose of ROSuvastatin in combination with EZetimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study " preliminary results. <i>Cardiology Journal</i> , 2021, 28, 58-66.	0.5	2
1970	Effects and Issues of Diet Fat on Cardiovascular Metabolism. , 0, , .		0
1971	Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 962-975.	1.1	18
1972	Emerging views of statin pleiotropy and cholesterol lowering. <i>Cardiovascular Research</i> , 2022, 118, 413-423.	1.8	54
1973	Pharmacotherapy for acute myocardial infarction. <i>Journal of the Korean Medical Association</i> , 2021, 64, 139-151.	0.1	0
1974	Lipid Management in the Elderly Population. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 60-63.	0.1	0
1975	Lipid goal achievements after acute myocardial infarction: the gap between real-life and ESC 2019 guidelines. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e65-e67.	0.8	2
1976	Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 120-129.	0.7	41
1977	Lipid-lowering therapies: Better together. <i>Atherosclerosis</i> , 2021, 320, 86-88.	0.4	23
1978	Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13519.	1.7	32
1979	Use of ADAM and CHA2DS2-VASc scores to predict complex aortic atheroma after brain ischemia: A prospective observational study. <i>Echocardiography</i> , 2021, 38, 612-622.	0.3	0
1980	Residual recurrence risk of ischaemic cerebrovascular events: concept, classification and implications. <i>Stroke and Vascular Neurology</i> , 2021, 6, 155-157.	1.5	13
1981	Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2021, , .	0.8	11
1982	Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1290-1296.	0.8	3
1983	Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines. <i>Clínica e Investigación en Arteriosclerosis (English Edition)</i> , 2021, 33, 85-107.	0.1	4
1984	Influence of lipid-lowering drugs on inflammation: what is yet to be done?. <i>Archives of Medical Science</i> , 2021, , .	0.4	6

#	ARTICLE	IF	CITATIONS
1985	Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 677-690.	1.3	11
1986	Mechanisms and Treatment of Dyslipidemia in Diabetes. <i>Current Cardiology Reports</i> , 2021, 23, 26.	1.3	39
1987	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2021, 143, 1109-1122.	1.6	46
1988	High-density lipoprotein cholesterol levels are associated with major adverse cardiovascular events in male but not female patients with hypertension. <i>Clinical Cardiology</i> , 2021, 44, 723-730.	0.7	4
1989	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , 2021, 320, 1-9.	0.4	11
1990	Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks. <i>Scientific Reports</i> , 2021, 11, 6697.	1.6	2
1991	Personalized medicine in lipid-modifying therapy. <i>Personalized Medicine</i> , 2021, 18, 185-203.	0.8	2
1992	JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases. <i>Circulation Journal</i> , 2021, 85, 402-572.	0.7	52
1993	Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome. <i>Current Atherosclerosis Reports</i> , 2021, 23, 16.	2.0	6
1994	New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1564-1575.	1.2	49
1995	Comentario del CEIPV a la actualizaci3n de las Gu3as Europeas de Prevenci3n Vascul ar en la Pr3ctica Cl3nica. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2021, 33, 85-107.	0.4	1
1996	Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation. <i>Medicine (United States)</i> , 2021, 100, e25114.	0.4	7
1997	Uso de Estatinas e Hipercolesterolemia: Est3o sendo Seguidas as Recomenda3es das Diretrizes Atuais?. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 742-743.	0.3	0
1998	Recomendaciones para mejorar el control lip3dico en pacientes en prevenci3n primaria. Documento de consenso de la Sociedad Espa3ola de Cardiolog3a. <i>REC: CardioClinics</i> , 2021, 56, 118-128.	0.1	3
1999	Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. <i>Heart</i> , 2021, 107, 1369-1375.	1.2	53
2000	Stage A Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 167-177.	1.0	4
2002	Editorial commentary: A new era for preventive cardiology. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 195-197.	2.3	0
2003	LDL-C Levels Below 55 mg/dl and Risk of Hemorrhagic Stroke: A Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105655.	0.7	9



#	ARTICLE	IF	CITATIONS
2004	Update on cardiovascular risk in nonalcoholic fatty liver disease. <i>Current Opinion in Cardiology</i> , 2021, 36, 478-486.	0.8	5
2005	The changing landscape of atherosclerosis. <i>Nature</i> , 2021, 592, 524-533.	13.7	921
2006	Relationship between small dense low density lipoprotein and cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 169.	0.7	8
2007	Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence. <i>Atherosclerosis</i> , 2021, 323, 57-58.	0.4	1
2008	Escalation of lipid-lowering therapy in patients with vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study. <i>Scientific Reports</i> , 2021, 11, 8884.	1.6	1
2009	Mechanisms of Atherosclerosis Induced by Postprandial Lipemia. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 636947.	1.1	29
2010	Age is just a number: the concept of time to benefit in older adults. <i>European Journal of Hospital Pharmacy</i> , 2021, , ejhpharm-2020-002561.	0.5	0
2011	Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study. <i>BMJ Open</i> , 2021, 11, e037457.	0.8	4
2012	TRS2P and LDL-C alone or in combination for predicting absolute benefits from additional LDL-C lowering: Analysis from the TNT trial. <i>Atherosclerosis</i> , 2021, 322, 8-14.	0.4	2
2013	Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting. <i>Frontiers in Pharmacology</i> , 2021, 12, 648244.	1.6	5
2014	<sc>CARotid plaqUe StabilizatiOn</sc> and regression with evolocumab: Rationale and design of the <sc>CARUSO</sc> study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E115-E121.	0.7	5
2015	Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome. <i>Scientific Reports</i> , 2021, 11, 7480.	1.6	5
2016	Association of Treatment Intensity and Adherence to Lipid-Lowering Therapy with Major Adverse Cardiovascular Events Among Post-MI Patients in Germany. <i>Advances in Therapy</i> , 2021, 38, 2532-2541.	1.3	5
2017	Coronary heart disease risk: Low-density lipoprotein and beyond. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 181-194.	2.3	56
2018	Perfil de PrescriÃ§Ã£o de Estatinas e de NÃveis LipÃmicos em AmbulatÃrios de Hospital TerciÃrio PÃblico. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 736-741.	0.3	3
2019	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27,979 Patients With Incident Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006646.	0.9	13
2020	Lipid-lowering therapy and percutaneous coronary interventions. <i>EuroIntervention</i> , 2021, 16, 1389-1403.	1.4	12
2021	Lipid therapy: A new whiteboard video for patient education. <i>Canadian Pharmacists Journal</i> , 2021, 154, 175-178.	0.4	1

#	ARTICLE	IF	CITATIONS
2022	Implementación de las guías de práctica clínica: deseo o realidad. Algoritmo de decisión. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 33-39.	0.4	1
2023	2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. <i>Russian Journal of Cardiology</i> , 2021, 26, 4449.	0.4	63
2024	Nuevos tratamientos en la dislipemia. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 1-2.	0.4	0
2025	Colesterol LDL y aterosclerosis: evidencias. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 25-32.	0.4	13
2026	Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2021, 15, 402-422.	0.6	20
2027	Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents. <i>Current Atherosclerosis Reports</i> , 2021, 23, 30.	2.0	19
2028	Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 793-806.	1.3	8
2029	Dianas terapéuticas en el tratamiento de las dislipemias: de las estatinas a los inhibidores de PCSK9. Necesidades no cubiertas. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 46-52.	0.4	2
2030	Effects of Bilberry and Oat intake on lipids, inflammation and exercise capacity after Acute Myocardial Infarction (BIOAMI): study protocol for a randomized, double-blind, placebo-controlled trial. <i>Trials</i> , 2021, 22, 338.	0.7	5
2031	New Trends in Dyslipidemia Treatment. <i>Circulation Journal</i> , 2021, 85, 759-768.	0.7	16
2032	Lipid Optimization in Lower Extremity Peripheral Arterial Disease. <i>Annals of Vascular Surgery</i> , 2021, 76, 542-554.	0.4	3
2033	Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1955-1963.	2.0	15
2035	Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. <i>Clinical Cardiology</i> , 2021, 44, 863-870.	0.7	2
2036	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , 2021, , 6-61.	0.2	9
2037	Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 815-834.	0.6	11
2038	Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2021, 33, 117-126.	0.1	1
2039	Desarrollo clínico de Ácido bempedoico: estudios fase 2 y fase 3. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 58-64.	0.4	0
2040	Association between baseline LDL-C and prognosis among patients with coronary artery disease and advanced kidney disease. <i>BMC Nephrology</i> , 2021, 22, 168.	0.8	10

#	ARTICLE	IF	CITATIONS
2041	A lipid loverâ€™s guide to novel therapeutics for lipid and cardiovascular risk reduction. <i>Future Cardiology</i> , 2021, 17, 507-520.	0.5	2
2042	Effects of an Avocado-based Mediterranean Diet on Serum Lipids for Secondary Prevention after Ischemic Stroke Trial (ADD-SPISE). <i>Medicine (United States)</i> , 2021, 100, e26425.	0.4	0
2043	Peripheral Artery Disease and Abdominal Aortic Aneurysm: The Forgotten Diseases in COVID-19 Pandemic. Results from an Observational Study on Real-World Management. <i>Medicina (Lithuania)</i> , 2021, 57, 672.	0.8	1
2044	Optimal Medical Management of Asymptomatic Carotid Stenosis. <i>Stroke</i> , 2021, 52, 2191-2198.	1.0	17
2045	Novel biomarker panel measuring endothelial injury identifies patients at risk of coronary artery syndrome and discordance with low-density lipoprotein cholesterol. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, e51-e58.	0.3	0
2047	Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course study. <i>Atherosclerosis</i> , 2021, 327, 31-38.	0.4	15
2048	Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2237-2251.	1.1	16
2049	Potential Relation between Plasma BDNF Levels and Human Coronary Plaque Morphology. <i>Diagnostics</i> , 2021, 11, 1010.	1.3	6
2050	Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials. <i>Current Atherosclerosis Reports</i> , 2021, 23, 42.	2.0	2
2053	Thrombolysis In Myocardial Infarction (TIMI) Study Group. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2822-2845.	1.2	23
2054	The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 40.	2.0	15
2055	Statin Intolerance: Alternative Therapy for Lipid Management. <i>ADCES in Practice</i> , 2021, 9, 50-54.	0.2	0
2056	Drugs in secondary stroke prevention. <i>Australian Prescriber</i> , 2021, 44, 85-90.	0.5	6
2057	Bempedoic Acid: A New Avenue for the Treatment of Dyslipidemia. <i>Cardiology in Review</i> , 2021, 29, 274-280.	0.6	2
2058	Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologistâ€™s Perspective. <i>Medicina (Lithuania)</i> , 2021, 57, 616.	0.8	8
2059	Impact of a preventive cardiology clinic focusing on lifestyle and nutrition counseling: A pilot analysis. <i>American Heart Journal Plus</i> , 2021, 6, 100032.	0.3	0
2060	How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. <i>Panminerva Medica</i> , 2022, 64, .	0.2	4
2061	Pharmacological Management of Hyperlipidemia in Older Individuals. , 2021, 36, 284-303.		1

#	ARTICLE	IF	CITATIONS
2062	A Less than Provocative Approach for the Primary Prevention of CAD. Journal of Cardiovascular Translational Research, 2021, , 1.	1.1	1
2063	Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines.. American Journal of Preventive Cardiology, 2021, 6, 100186.	1.3	4
2064	Residual Recurrence Risk of Ischemic Cerebrovascular Events: Elements and Implications. Neuroscience Bulletin, 2021, 37, 1361-1364.	1.5	2
2065	Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias. Current Cardiology Reports, 2021, 23, 83.	1.3	6
2066	Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2021, 19, 575-580.	0.6	10
2067	Effect of More Intensive LDL-Cholesterol Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis. Clinical Therapeutics, 2021, 43, e217-e229.	1.1	1
2068	Secondary prevention after acute coronary syndrome: are dyslipidaemia guideline targets achieved?. European Journal of Preventive Cardiology, 2022, 29, e122-e124.	0.8	2
2069	Evaluaci3n del coste-efectividad de la utilizaci3n de los inhibidores de PCSK9. Endocrinologia, Diabetes Y Nutrici3n, 2021, 68, 369-371.	0.1	4
2070	The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes. Current Opinion in Lipidology, 2021, Publish Ahead of Print, 231-243.	1.2	2
2071	Contemporary Medical Management of Peripheral Artery Disease. Circulation Research, 2021, 128, 1868-1884.	2.0	53
2072	Management of Dyslipidemia in Women and Men with Coronary Heart Disease: Results from POLASPIRE Study. Journal of Clinical Medicine, 2021, 10, 2594.	1.0	4
2073	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	6
2074	Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients. International Journal of Cardiology, 2021, 332, 22-28.	0.8	16
2075	The TIMI Study Group's Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-. Journal of Atherosclerosis and Thrombosis, 2021, 28, 563-572.	0.9	1
2076	Managing dyslipidemia in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2221-2234.	0.9	14
2077	Dyslipidemia: Current Perspectives and Implications for Clinical Practice. , 0, , .		0
2078	Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 2021, 78, 384-407.	1.2	16
2079	Trends in lipid-modifying agent use in 83 countries. Atherosclerosis, 2021, 328, 44-51.	0.4	57

#	ARTICLE	IF	CITATIONS
2080	EAS Task Force gives practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients. <i>Atherosclerosis</i> , 2021, 329, 32-35.	0.4	1
2081	2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 461-481.	1.8	146
2082	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <i>Circulation</i> , 2021, 144, 74-84.	1.6	34
2083	The clinical role of combined serum C1q and hsCRP in predicting coronary artery disease. <i>Clinical Biochemistry</i> , 2021, 93, 50-58.	0.8	6
2084	An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 539-548.	1.4	8
2085	Roadmap Consensus on Carotid Artery Plaque Imaging and Impact on Therapy Strategies and Guidelines: An International, Multispecialty, Expert Review and Position Statement. <i>American Journal of Neuroradiology</i> , 2021, 42, 1566-1575.	1.2	25
2086	Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 266.	3.8	19
2087	Recommendations to improve lipid control in primary prevention patients. A consensus document of the Spanish Society of Cardiology. <i>REC: CardioClinics</i> , 2021, 56, 208-217.	0.1	4
2088	Working towards full eradication of lipid-driven cardiovascular risk?. <i>Netherlands Heart Journal</i> , 2022, 30, 15-24.	0.3	2
2089	Pharmacological secondary prevention of MI. <i>The Prescriber</i> , 2021, 32, 13-20.	0.1	0
2090	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). <i>Archivos De Cardiologia De Mexico</i> , 2021, 92, .	0.1	4
2091	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2117963.	2.8	5
2092	Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targetsâ€™ attainment in subjects with and without type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 144.	2.7	17
2093	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 181-264.	0.3	45
2094	Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2968.	1.0	15
2095	Treatment Inertia in Patients With Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2021, 10, e020126.	1.6	7
2096	The challenge of choosing in cardiovascular risk management. <i>Netherlands Heart Journal</i> , 2022, 30, 47-57.	0.3	5
2097	Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?. <i>Current Cardiology Reports</i> , 2021, 23, 116.	1.3	2

#	ARTICLE	IF	CITATIONS
2099	Statin intolerance and new lipid-lowering treatments. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 381-387.	0.6	3
2100	How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 65-74.	1.6	23
2101	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2021, 52, e364-e467.	1.0	1,123
2102	Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease. <i>Clinical Cardiology</i> , 2021, 44, 1457-1466.	0.7	3
2103	PCSK9 Inhibition could be Effective for Acute Myocardial Infarction. <i>Current Medicinal Chemistry</i> , 2022, 29, 1016-1026.	1.2	3
2105	Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa. <i>BMC Endocrine Disorders</i> , 2021, 21, 159.	0.9	10
2106	Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction. <i>Scientific Reports</i> , 2021, 11, 15973.	1.6	8
2107	Cholesterol: the race to the bottom. <i>European Heart Journal</i> , 2021, 42, 4612-4613.	1.0	10
2108	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
2109	Human Angiotensin-like Protein 3/ANGPTL3 Antibodies. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, e631-e640.	0.8	0
2110	Tolerability of statin-based management of patients with a history of statin-associated muscle symptoms: protocol for a systematic review. <i>BMJ Open</i> , 2021, 11, e052341.	0.8	0
2111	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1129-1150.	0.8	367
2112	A critical review of chronic kidney disease as a risk factor for coronary artery disease. <i>IJC Heart and Vasculature</i> , 2021, 35, 100822.	0.6	5
2113	Efficacy of Lipid-Lowering Therapy during Cardiac Rehabilitation in Patients with Diabetes Mellitus and Coronary Heart Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 105.	0.8	4
2114	Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis. <i>European Heart Journal Open</i> , 2021, 1, .	0.9	9
2115	Targeting residual inflammatory risk in coronary disease: to catch a "monkey by its tail. <i>Netherlands Heart Journal</i> , 2022, 30, 25-37.	0.3	3
2116	Risks of Recurrent Cardiovascular Events and Mortality in 1-Year Survivors of Acute Myocardial Infarction Implanted with Newer-Generation Drug-Eluting Stents. <i>Journal of Clinical Medicine</i> , 2021, 10, 3642.	1.0	5
2117	What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e020893.	1.6	9

#	ARTICLE	IF	CITATIONS
2118	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. <i>Nutrients</i> , 2021, 13, 2830.	1.7	27
2119	Communication approaches to enhance patient motivation and adherence in cardiovascular disease prevention. <i>Clinical Cardiology</i> , 2021, 44, 1199-1207.	0.7	13
2120	Diabetic dyslipidaemia. <i>Practical Laboratory Medicine</i> , 2021, 26, e00248.	0.6	14
2121	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	1.2	58
2122	Cardiovascular Disease in Patients with Diabetes: a Comparison of Professional Society Guidelines. <i>Current Diabetes Reviews</i> , 2021, 17, .	0.6	0
2123	Detección de hipercolesterolemia familiar a través de datos analíticos centralizados. Programa DETECTA HF HUELVA. <i>Endocrinología, Diabetes Y Nutrición</i> , 2021, 68, 450-457.	0.1	3
2124	Determination of Diabetes and Dyslipidemia Goals in the Management of Diabetes. , 2021, , 58-64.		0
2125	Temporal trends of lipid control in very high cardiovascular risk patients. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 641-648.	0.2	4
2126	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	0.8	220
2127	The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mediators of Inflammation</i> , 2021, 2021, 1-12.	1.4	11
2128	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. <i>JAMA Cardiology</i> , 2021, 6, 1060.	3.0	86
2129	Is it Time for Single-Pill Combinations in Dyslipidemia?. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 239-249.	1.0	4
2130	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes) <i>Tj ETQq000 rgBT3/Overlock</i>		
2131	The power of lipid registries for cardiovascular disease prevention. <i>Current Opinion in Lipidology</i> , 2021, Publish Ahead of Print, 342-348.	1.2	4
2132	Rationale and pathways forward in the implementation of coronary artery calcium-based enrichment of randomized trials. <i>American Heart Journal</i> , 2022, 243, 54-65.	1.2	3
2133	Belgian data of ODYSSEY APPRISE: stringent LDLâ€ targets are in reach when using all available tools. <i>International Journal of Clinical Practice</i> , 2021, 75, e14916.	0.8	3
2134	Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. <i>Pharmacoeconomics - Open</i> , 2022, 6, 277-291.	0.9	3
2135	Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e022069.	1.6	15

#	ARTICLE	IF	CITATIONS
2136	Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis. <i>American Journal of Cardiology</i> , 2021, 154, 22-28.	0.7	4
2137	Effects of lipid-lowering therapy on major adverse limb events in patients with peripheral arterial disease: A meta-analysis of randomized clinical trials. <i>Vascular</i> , 2022, 30, 1134-1141.	0.4	4
2138	Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiologica cEnTer (TERCET) registry. <i>Atherosclerosis</i> , 2021, 333, 16-23.	0.4	19
2139	Metabolic signatures of cholesterol biosynthesis and absorption in patients with coronary artery disease. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 212, 105940.	1.2	2
2140	Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies. <i>Vascular Health and Risk Management</i> , 2021, Volume 17, 527-542.	1.0	15
2141	RNA Silencing in the Management of Dyslipidemias. <i>Current Atherosclerosis Reports</i> , 2021, 23, 69.	2.0	19
2142	AtualizaÃ§Ã£o da Diretriz Brasileira de Hipercolesterolemia Familiar â€“ 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 782-844.	0.3	10
2143	Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 141-150.	1.3	4
2144	Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. <i>American Heart Journal</i> , 2022, 243, 15-27.	1.2	8
2145	CauchyCP: A powerful test under non-proportional hazards using Cauchy combination of change-point Cox regressions. <i>Statistical Methods in Medical Research</i> , 2021, 30, 096228022110370.	0.7	1
2147	Resolving the Egg and Cholesterol Intake Controversy: New Clinical Insights Into Cholesterol Regulation by the Liver and Intestine. <i>Endocrine Practice</i> , 2022, 28, 102-109.	1.1	10
2148	Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol. <i>World Journal of Cardiology</i> , 2021, 13, 472-482.	0.5	0
2149	Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 141-155.	1.0	10
2150	Temporal trends of lipid control in very high cardiovascular risk patients. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 641-648.	0.2	0
2151	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. <i>International Journal of Women's Dermatology</i> , 2021, 7, 560-575.	1.1	7
2152	Unique Challenges of Randomised Controlled Trials in Pediatric Cardiology. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1394-1403.	0.8	11
2153	Management and outcome across the spectrum of high-risk patients with myocardial infarction according to the thrombolysis in myocardial infarction (TIMI) risk score for secondary prevention. <i>Clinical Cardiology</i> , 2021, 44, 1535-1542.	0.7	5
2154	Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. <i>European Heart Journal</i> , 2021, 42, 4821-4829.	1.0	23



#	ARTICLE	IF	CITATIONS
2155	When is it Appropriate to Lower Low Density Lipoprotein-Cholesterol Levels to <30 mg/dL?. American Journal of Cardiology, 2021, 157, 142-144.	0.7	1
2156	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clinic Proceedings, 2021, 96, 2660-2670.	1.4	7
2157	Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106057.	0.7	8
2158	Dyslipidemia. , 2022, , 387-393.		0
2159	Non-ST-Elevation Acute Coronary Syndromes. , 2022, , 413-428.		0
2160	Preventive Cardiology. , 2022, , 341-375.		0
2161	It's never too early to beat your low-density lipoprotein cholesterol. Archives of Cardiovascular Diseases, 2021, 114, 1-3.	0.7	1
2162	The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target?. Current Cardiology Reports, 2021, 23, 13.	1.3	4
2163	Optimum lipid testing for diabetic patients to enhance clinical care. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 461-464.	1.8	2
2164	Cross-Sectional Study of Plant Sterols Intake as a Basis for Designing Appropriate Plant Sterol-Enriched Food in Indonesia. Nutrients, 2021, 13, 452.	1.7	11
2165	Beneficios de la reducci3n del colesterol LDL en la prevenci3n secundaria del ictus isqu3mico. Nuevas evidencias. Cl3nica E Investigaci3n En Arteriosclerosis, 2021, 33, 53-54.	0.4	1
2168	Association Between BMI and Cardiovascular Benefits After More Intensive LDL-C Lowering Strategy: A Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	0
2170	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JAMA Cardiology, 2020, 5, 952.	3.0	56
2173	Lipid-Modifying Drugs: Pharmacology and Perspectives. Advances in Experimental Medicine and Biology, 2020, 1177, 133-148.	0.8	6
2174	Case Histories: Anacetrapib. , 2017, , 284-307.		1
2175	PCSK9 inhibitors in the current management of atherosclerosis. Archivos De Cardiologia De Mexico, 2017, 87, 43-48.	0.1	8
2176	Actualizaci3n de las tablas de planificaci3n terap3utica hipocolesterolemia orientadas a la obtenci3n de los objetivos terap3uticos. Cl3nica E Investigaci3n En Arteriosclerosis, 2019, 31, 271-277.	0.4	13
2177	Colesterol LDL, cuanto m3s bajo mejor. Cl3nica E Investigaci3n En Arteriosclerosis, 2019, 31, 16-27.	0.4	16

#	ARTICLE	IF	CITATIONS
2178	Las dislipidemias y su tratamiento en centros de alta complejidad en Colombia. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 32, 101-110.	0.4	3
2179	Tratamiento hipolipemiante en la prevenci3n secundaria de la enfermedad cerebrovascular isqu3mica. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 32, 175-182.	0.4	7
2180	Management of patients with statin intolerance. <i>Atherosclerosis Supplements</i> , 2017, 30, 33-37.	1.2	11
2181	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020, 42, e30-e34.	1.2	6
2182	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020, 42, e49-e58.	1.2	23
2183	A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. <i>Journal of Cardiology</i> , 2017, 70, 537-544.	0.8	134
2184	Comparison of Transatlantic Approaches to Lipid Management: The AHA/ACC/Multisociety Guidelines vs the ESC/EAS Guidelines. <i>Mayo Clinic Proceedings</i> , 2020, 95, 998-1014.	1.4	13
2185	Clinical approach to the inflammatory etiology of cardiovascular diseases. <i>Pharmacological Research</i> , 2020, 159, 104916.	3.1	56
2186	Individual trends in LDL-C control in patients with previous myocardial infarction. <i>REC: CardioClinics</i> , 2020, 55, 23-29.	0.1	3
2187	Inhibidores de PCSK9: ratificaci3n del papel del colesterol LDL en prevenci3n cardiovascular. ¿Hacia la convergencia en las guías de prevenci3n europeas y norteamericanas?. <i>Revista Clinica Espanola</i> , 2020, 220, 374-382.	0.2	5
2188	¿Han influido el algoritmo de prescripci3n de la Administraci3n y las guías de manejo de la dislipemia de la ACC/AHA 2013 en el manejo de la dislipemia? Proyecto MEJORA-LO CV. <i>Revista Clínica Espanola</i> , 2020, 220, 282-289.	0.2	1
2190	Una historia resumida. Impacto de los avances en cardiopatía isqu3mica. <i>Revista Espanola De Cardiologia Suplementos</i> , 2017, 17, 2-6.	0.2	1
2192	ESVM Guideline on peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 1-79.	0.6	110
2193	5 Conservative treatment for PAD â€“ Risk factor management. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 1-12.	0.6	15
2194	Regulation of plasma glycerol-lysophospholipid levels by lipoprotein metabolism. <i>Biochemical Journal</i> , 2019, 476, 3565-3581.	1.7	8
2196	Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 605-613.	1.3	5
2197	Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. <i>European Heart Journal</i> , 2021, 42, 243-252.	1.0	84
2199	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMII/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnosticâ€“therapeutic pathway in Italy. <i>European Heart Journal Supplements</i> , 2017, 19, D3-D54.	0.0	19

#	ARTICLE	IF	CITATIONS
2200	Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 2001-2009.	0.8	10
2201	Novel lipid modifying drugs to lower LDL cholesterol. <i>Current Opinion in Lipidology</i> , 2017, 28, 367-373.	1.2	22
2202	Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?. <i>Current Opinion in Lipidology</i> , 2020, 31, 125-131.	1.2	15
2211	Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective. <i>Singapore Medical Journal</i> , 2016, 57, 360-367.	0.3	6
2212	The application of big data to cardiovascular disease: paths to precision medicine. <i>Journal of Clinical Investigation</i> , 2020, 130, 29-38.	3.9	74
2213	Sex differences in systemic metabolites at four life stages: cohort study with repeated metabolomics. <i>BMC Medicine</i> , 2021, 19, 58.	2.3	32
2214	Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. <i>Egyptian Heart Journal</i> , 2020, 72, 23.	0.4	4
2215	2016 Chinese guidelines for the management of dyslipidemia in adults. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 1-29.	0.2	226
2216	The rate of patients at high risk for cardiovascular disease with an optimal low-density cholesterol level: a multicenter study from Thailand. <i>Journal of Geriatric Cardiology</i> , 2019, 16, 344-353.	0.2	2
2217	Associations between Lifestyle-Related Diseases and Transporters Involved in Intestinal Absorption and Biliary Excretion of Cholesterol. <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 1-10.	0.6	7
2218	JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. <i>Circulation Journal</i> , 2019, 83, 1085-1196.	0.7	324
2219	Increased Serum Malondialdehyde-Modified Low-Density Lipoprotein and Coronary Angiographic Progression After Drug-Eluting Stent Implantation in Patients With Stable Angina. <i>Circulation Journal</i> , 2020, 84, 1837-1845.	0.7	3
2220	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes. A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society. <i>Circulation Journal</i> , 2020, 85, 82-125.	0.7	16
2221	Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. <i>F1000Research</i> , 2017, 6, 134.	0.8	63
2222	The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 173.	1.1	19
2223	Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 183.	1.1	16
2224	Statin Intensity or Achieved LDL? Practice-based Evidence for the Evaluation of New Cholesterol Treatment Guidelines. <i>PLoS ONE</i> , 2016, 11, e0154952.	1.1	11
2225	Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol. <i>PLoS ONE</i> , 2016, 11, e0166246.	1.1	9

#	ARTICLE	IF	CITATIONS
2226	Low cholesterol level associated with severity and outcome of spontaneous intracerebral hemorrhage: Results from Taiwan Stroke Registry. PLoS ONE, 2017, 12, e0171379.	1.1	25
2227	Increased cardiovascular risk associated to hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities. Anatolian Journal of Cardiology, 2019, 23, 60-69.	0.5	4
2228	Statins: Then and Now. Methodist DeBakey Cardiovascular Journal, 2021, 15, 23.	0.5	54
2229	Poststatin Lipid Therapeutics: A Review. Methodist DeBakey Cardiovascular Journal, 2021, 15, 32.	0.5	8
2230	Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids. Methodist DeBakey Cardiovascular Journal, 2021, 15, 171.	0.5	39
2231	Management of lipids in adults with diabetes mellitus and nephropathy and/or chronic kidney disease: summary of joint guidance from the Association of British Clinical Diabetologists (ABCD) and the Renal Association (RA). British Journal of Diabetes, 2017, 17, 64.	0.1	17
2232	Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes. British Journal of Diabetes, 2018, 18, 101-105.	0.1	4
2233	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. European Cardiology Review, 2020, 15, 1-9.	0.7	38
2234	Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion. Russian Journal of Cardiology, 2019, , 44-51.	0.4	10
2235	2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology, 2020, 25, 4103.	0.4	132
2236	Management of Hypertension and Dyslipidemia for Primary Prevention of Cardiovascular Disease. , 2017, , 389-404.		9
2237	Statin-Associated Muscle Adverse Events: Update for clinicians. Sultan Qaboos University Medical Journal, 2016, 16, e406-415.	0.3	10
2238	Experimental and clinical pharmacology: PCSK9 inhibitors - clinical applications. Australian Prescriber, 2016, 39, 168-170.	0.5	9
2239	Clinical outcomes of PCSK9Is: a meta-analysis of randomized clinical trials. Cardiovascular Diagnosis and Therapy, 2017, 7, 598-606.	0.7	3
2240	Molecular Insights into the Mechanisms Underlying the Cholesterol- Lowering Effects of Phytosterols. Current Medicinal Chemistry, 2019, 26, 6704-6723.	1.2	40
2241	Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications. Current Medicinal Chemistry, 2020, 27, 1021-1040.	1.2	21
2242	Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. Current Pharmaceutical Design, 2019, 25, 85-95.	0.9	11
2243	Diabetes and Vascular Disease: Is It All About Glycemia?. Current Pharmaceutical Design, 2019, 25, 3112-3127.	0.9	14

#	ARTICLE	IF	CITATIONS
2244	A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. <i>Current Pharmaceutical Design</i> , 2019, 25, 4063-4084.	0.9	200
2245	Pro-inflammatory Cytokines in Acute Coronary Syndromes. <i>Current Pharmaceutical Design</i> , 2020, 26, 4624-4647.	0.9	23
2246	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. <i>Current Drug Metabolism</i> , 2019, 20, 72-82.	0.7	12
2247	Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects. <i>Current Vascular Pharmacology</i> , 2019, 17, 332-340.	0.8	6
2248	The Pleiotropic Effects of Statins – From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. <i>Current Vascular Pharmacology</i> , 2019, 17, 222-232.	0.8	54
2249	Pharmacological Management of Diabetic Nephropathy. <i>Current Vascular Pharmacology</i> , 2020, 18, 139-147.	0.8	5
2250	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. <i>Current Vascular Pharmacology</i> , 2019, 17, 498-514.	0.8	38
2251	Hypertriglyceridemia - Common Causes, Prevention and treatment Strategies. <i>Current Cardiology Reviews</i> , 2018, 14, 67-76.	0.6	33
2252	Medical therapy does not confer stroke prevention for all patients: identification of high-risk patients with asymptomatic carotid stenosis is still needed. <i>International Angiology</i> , 2019, 38, 372-380.	0.4	9
2253	Recent updates in dyslipidemia management: perspectives in stroke-specific situation. <i>Precision and Future Medicine</i> , 2020, 4, 9-20.	0.5	3
2254	Current Guidelines on the Management of Dyslipidemia. <i>Korean Journal of Clinical Pharmacy</i> , 2017, 27, 276-283.	0.0	4
2255	Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 162-171.	0.6	10
2256	The Treatment of Disorders of Lipid Metabolism. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2016, 113, 261-8.	0.6	55
2257	The Diagnosis and Treatment of Hypertriglyceridemia. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2019, 116, 825-832.	0.6	50
2258	Treatment of Hypertriglyceridemia: a Review of Current Options. <i>Physiological Research</i> , 2015, 64, S331-S340.	0.4	22
2259	Success and Failure of Cardiovascular Disease Prevention in Czech Republic Over the Past 30 Years. Czech Part of the EUROASPIRE I-IV Surveys. <i>Physiological Research</i> , 2017, 66, S77-S84.	0.4	7
2260	Hypolipidemic treatment and target values of lipids. <i>Interni Medicina Pro Praxi</i> , 2018, 20, 82-84.	0.0	1
2261	The current state of lipid modifying therapy in the Czech population. <i>Intervencni A Akutni Kardiologie</i> , 2016, 15, 81-84.	0.0	1

#	ARTICLE	IF	CITATIONS
2262	CURRENT ASPECTS OF CORONARY HEART DISEASE DIAGNOSIS AND TREATMENT. International Medical Journal, 2020, , 5-10.	0.1	2
2263	EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF ACUTE CORONARY SYNDROME WITH ST SEGMENT ELEVATION (STEMI). Eurasian Heart Journal, 2020, , 4-77.	0.2	17
2264	Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry. Korean Journal of Internal Medicine, 2020, 35, 342-350.	0.7	2
2265	9. Statins in the treatment and prevention of cardiovascular diseases. Human Health Handbooks, 2016, , 155-178.	0.1	3
2266	15. Phytosterol consumption and coronary artery disease. Human Health Handbooks, 2017, , 303-320.	0.1	2
2267	PCSK9 inhibition: A promise fulfilled?. Cleveland Clinic Journal of Medicine, 2016, 83, S36-S44.	0.6	2
2268	Advances in the treatment of dyslipidemia. Cleveland Clinic Journal of Medicine, 2016, 83, 181-186.	0.6	12
2269	Severely frail elderly patients do not need lipid-lowering drugs. Cleveland Clinic Journal of Medicine, 2017, 84, 131-142.	0.6	14
2270	Familial hypercholesterolemia: Detect, treat, and ask about family. Cleveland Clinic Journal of Medicine, 2020, 87, 109-120.	0.6	12
2271	ACC/AHA lipid guidelines: Personalized care to prevent cardiovascular disease. Cleveland Clinic Journal of Medicine, 2020, 87, 231-239.	0.6	48
2272	Evaluation of the physical-mechanical properties of cement-lime based masonry mortars produced with mixed recycled aggregates. Materiales De Construccion, 2020, 70, 210.	0.2	15
2273	Anbefalt nordisk kosthold og risikomarkÅrer for hjerte- og karsykdom. Tidsskrift for Den Norske Laegeforening, 2017, 137, 721-726.	0.2	13
2274	2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction. Korean Circulation Journal, 2020, 50, 845.	0.7	16
2275	Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2019, 43, 582.	1.8	14
2276	Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians. Journal of Anaesthesiology Clinical Pharmacology, 2016, 32, 440.	0.2	8
2277	Triglyceride and cardiovascular risk: A critical appraisal. Indian Journal of Endocrinology and Metabolism, 2016, 20, 418.	0.2	29
2278	Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable and acute coronary heart disease in the United Arab Emirates. Heart Views, 2019, 20, 37.	0.1	5
2279	RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism, 2020, 24, 1.	0.2	85

#	ARTICLE	IF	CITATIONS
2280	Evolving Concepts in LDL-Lowering Strategies: Are We There?. Journal of Clinical & Experimental Cardiology, 2016, 7, .	0.0	2
2281	The Application of the LDL Principle. World Journal of Cardiovascular Diseases, 2016, 06, 109-125.	0.0	12
2282	Residual Cardiovascular Riskâ€™s Inflammation the Primary Cause?. World Journal of Cardiovascular Diseases, 2018, 08, 59-69.	0.0	4
2283	Clinical, angiographic, IVUS, and OCT predictors for irregular protrusion after coronary stenting. EuroIntervention, 2017, 12, e2204-e2211.	1.4	23
2284	FOURIER to ODYSSEY: the end of the journey for lipid-lowering therapy trials? Lessons from recent clinical trials with anti-PCSK9 antibodies. EuroIntervention, 2018, 14, 144-146.	1.4	1
2285	Comparison of Novel Equations for Estimating Low-Density Lipoprotein Cholesterol in Patients Undergoing Coronary Angiography. Journal of Atherosclerosis and Thrombosis, 2020, 27, 1359-1373.	0.9	15
2286	Similarities and differences between European and United States guidelines for the management of dyslipidaemias. Kardiologia Polska, 2015, 73, 471-477.	0.3	4
2287	Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy. Journal of Stroke, 2017, 19, 109-110.	1.4	4
2288	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. Arquivos Brasileiros De Cardiologia, 2019, 113, 787-891.	0.3	102
2289	Bempedoic acid for the treatment of dyslipidemia. Drugs in Context, 2020, 9, 1-9.	1.0	21
2290	Repeated In-Stent Restenosis Despite Aggressive Lipid Loweringby PCSK-9 Inhibitor Treatment: A Case Report. Tohoku Journal of Experimental Medicine, 2021, 255, 123-126.	0.5	4
2291	Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nature Communications, 2021, 12, 5640.	5.8	57
2292	Metaâ€analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. Pharmacotherapy, 2021, 41, 1009-1023.	1.2	26
2293	Diabetes, Vascular Aging and Stroke: Old Dogs, New Tricks?. Journal of Clinical Medicine, 2021, 10, 4620.	1.0	13
2294	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Journal of the American College of Cardiology, 2021, 78, 1499-1507.	1.2	22
2295	Human Genomics and Drug Development. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a039230.	2.9	16
2296	Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. Nature Communications, 2021, 12, 6120.	5.8	13
2297	Proprotein convertase subtilisin/kexin type 9 inhibitors treatment in dyslipidemic patients. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, .	0.6	3

#	ARTICLE	IF	CITATIONS
2298	Lipid lowering in patients 75 years and older. <i>World Journal of Cardiology</i> , 2021, 13, 526-532.	0.5	2
2299	Residual Cardiovascular Risk Factors in Dyslipidemia. , 0, , .		0
2300	Low density lipoprotein cholesterol is associated with increased risk of cardiovascular disease in participants over 70 years old: A prospective cohort study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 447-455.	1.1	1
2301	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1575.	2.6	28
2302	Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. <i>The IRIS-PCSK9I study. Atherosclerosis Plus</i> , 2021, 45, 32-38.	0.3	2
2303	Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 713007.	1.6	6
2304	Pro a pÅ™edem prohranÃ½ souboj proti PCSK9 inhibitorÅ™m. <i>Vnitřni Lekarstvi</i> , 2021, 67, 3-8.	0.1	0
2305	Effectiveness of hospital lipid-lowering protocol of intensive lipid-lowering therapy for patients with acute coronary syndrome. <i>Journal of Cardiology</i> , 2022, 79, 391-399.	0.8	1
2306	Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 74.	2.0	0
2307	Molecular mechanisms of antiatherogenic drugs action. <i>Reviews on Clinical Pharmacology and Drug Therapy</i> , 2021, 19, 291-301.	0.2	1
2308	A Modern Approach to Dyslipidemia. <i>Endocrine Reviews</i> , 2022, 43, 611-653.	8.9	110
2309	Cost-effectiveness evaluation of the use of PCSK9 inhibitors. <i>EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed )</i> , 2021, 68, 369-371.	0.1	1
2310	Lipid goal attainment in postâ€acute coronary syndrome patients in China: Results from the 6â€month realâ€world dyslipidemia international study <scp>ll</scp>. <i>Clinical Cardiology</i> , 2021, 44, 1575-1585.	0.7	9
2311	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. <i>Heart Failure Clinics</i> , 2021, 18, 177-188.	1.0	14
2312	Primeros datos clÃnicos y de eficacia de evolocumab en prÃctica clÃnica habitual en servicios de endocrinologÃa y nutriciÃ³n en EspaÃ±a: un estudio observacional retrospectivo (RETOSS-ENDO). <i>EndocrinologÃa, Diabetes Y NutriciÃ³n</i> , 2021, , .	0.1	0
2313	The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	1.3	2
2314	Medical Management of Peripheral Artery Disease. <i>Cardiology Clinics</i> , 2021, 39, 471-482.	0.9	3
2316	Update on the Pharmacologic Agents for Dyslipidemia. <i>Journal of Korean Diabetes</i> , 2015, 16, 269.	0.1	0



#	ARTICLE	IF	CITATIONS
2318	Management of Dyslipidemia according to the 2015 Treatment Guideline for Diabetes: Controversies and Issues to Resolve. <i>Journal of Korean Diabetes</i> , 2016, 17, 96.	0.1	0
2319	25+ Observations Over 25+ Years for Surviving and Thriving in the Dietary Supplement Quality Control and/or Perception Versus Reality World. , 2016, , 5-67.		0
2322	Coronary Artery Disease and Cardiomyopathy. , 2016, , 1-21.		0
2323	Update on PCSK9 Inhibitors and New Therapies. <i>US Endocrinology</i> , 2016, 12, 18.	0.3	1
2325	S.A.M. and Breast Cancerâ€™Focus on Statins, Red Yeast Rice, Sterols, and Other Integrative Cholesterol Medicines: The Real â€™Naturalâ€™Options. , 2016, , 141-171.		0
2326	Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study. <i>Arquivos Brasileiros De Cardiologia</i> , 2016, 106, 247-9.	0.3	1
2327	New options in the treatment of hypercholesterolaemia. <i>Interni Medicina Pro Praxi</i> , 2016, 18, 6-8.	0.0	0
2328	12. Some chronobiological investigations relevant to cholesterol. <i>Human Health Handbooks</i> , 2016, , 203-234.	0.1	1
2330	More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Hormones</i> , 2016, 15, 5-7.	0.9	0
2331	Are Sex Differences in Outcomes of Patients with ACS from Observational Registries Similar to the Findings from Randomized Clinical Trials?. <i>Current Pharmaceutical Design</i> , 2016, 22, 3779-3789.	0.9	0
2332	Statins, Targets and Chronic Kidney Disease. <i>Journal of Cardiology &amp; Current Research</i> , 2016, 6, .	0.1	0
2335	En veltrent kvinne i 30-Ã¥rene med anstrengelsesdyspnÃ©. <i>Tidsskrift for Den Norske Laegeforening</i> , 2017, 137, 456-458.	0.2	1
2336	Coronary Artery Disease and Cardiomyopathy. , 2017, , 1-21.		0
2337	VII. Triglyceride and HDL Cholesterol as Risk Factors and the Treatment Targets for Atherosclerosis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 725-734.	0.0	0
2338	VI. Update on Lipid-lowering Therapies. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 718-724.	0.0	0
2339	OUP accepted manuscript. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 23-24.	1.4	3
2340	Evidence that Low Density Lipoprotein Is the Primary Cause of Atherosclerotic Cardiovascular Disease: A Bradford-Hill Approach. <i>World Journal of Cardiovascular Diseases</i> , 2017, 07, 271-284.	0.0	1
2341	Coronary Artery Disease and Cardiomyopathy. , 2017, , 637-657.		0

#	ARTICLE	IF	CITATIONS
2342	Paradigm Shift of the Treatment of Dyslipidemia for Prevention of Atherosclerotic Cardiovascular Diseases. Nihon Ika Daigaku Igakkai Zasshi, 2017, 13, 199-204.	0.0	0
2343	Optimal medical therapy to improve saphenous vein graft patency. Journal of the Japanese Coronary Association, 2017, 23, 196-203.	0.0	0
2345	The target level and the difference of pathway on lipid lowering therapy. Journal of the Japanese Coronary Association, 2017, 23, 165-169.	0.0	0
2347	Sitosterol Blood Levels are Elevated in Diabetics and may be the Cause of Coronary Artery Disease and Stroke. The Journal of Medical Sciences, 2017, 3, 89-94.	0.0	0
2348	Kardiologie. , 2017, , 61-143.		0
2349	Hilfen durch Medikamente. , 2017, , 139-155.		0
2350	2. Up to Date Lipid Lowering Treatment. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 208-215.	0.0	0
2352	V. Lipid Managements from the Point of View of Human Genetics. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 711-717.	0.0	0
2353	The topics of treatment for dyslipidemia. Journal of the Japanese Coronary Association, 2017, 23, 108-112.	0.0	0
2354	Management of Acute Coronary Syndrome. , 2017, , 111-120.		0
2355	Lipidsenkende Mittel. , 2017, , 529-538.		0
2356	VIII. Development of New Strategy and Modality of Lipid Management. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 735-741.	0.0	0
2357	No Clinical Relevance. Deutsches A&#x0308;rztblatt International, 2017, 114, 70.	0.6	0
2358	No Indication for Routine Administration. Deutsches A&#x0308;rztblatt International, 2017, 114, 70.	0.6	2
2359	In Reply. Deutsches A&#x0308;rztblatt International, 2017, 114, 71.	0.6	0
2360	Hyperlipidemia. , 2017, , .		0
2361	Dyslipidemia. , 2017, , .		0
2362	Some comments on the 2016 ESC/EAS guidelines for diagnosing and treating dyslipidaemias. MedicÃna Pro Praxi, 2017, 14, 58-60.	0.0	0

#	ARTICLE	IF	CITATIONS
2363	Clinical study FOURIER. Vnitřní Lekarství, 2017, 63, 411-414.	0.1	2
2364	What has changed in treatment of patients with dyslipidemia?. Interni Medicina Pro Praxi, 2017, 19, 106-108.	0.0	0
2368	Lipidhypercholesterolemie familiale. Bulletin De L'Academie Nationale De Medecine, 2017, 201, 1323-1334.	0.0	1
2369	Modern opportunities for lifestyle changes and statin therapy in the prevention of cardiovascular diseases. Cardiosomatics, 2017, 8, 39-4.	0.2	0
2370	Do we have reserves in treatment after myocardial infarction?. Medicina Pro Praxi, 2017, 14, 224-229.	0.0	0
2371	Lipidsenkende Mittel. , 2018, , 577-586.		0
2372	Epidemiology of hypercholesterolemia. Vnitřní Lekarství, 2018, 64, 30-37.	0.1	1
2373	Treatment for major high-risk condition in patients with coronary heart disease. Journal of the Japanese Coronary Association, 2018, 24, 38-41.	0.0	0
2374	治療の進歩. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 73-74.		0
2375	Traitement de l'angor stable et des syndromes coronariens aigus sans sus-décalage du segment ST. , 2018, , 75-98.e1.		0
2376	Diabetes and Dislipidemia. Endocrinology, 2018, , 51-70.	0.1	0
2377	What Do We Get from Recent Statin and CETP Inhibitors Trials?. Journal of Lipid and Atherosclerosis, 2018, 7, 12.	1.1	1
2378	OBSOLETE: Non-ST-Elevation Myocardial Infarction: Management. , 2018, , .		0
2379	Familial combined hyperlipidemia - the most common genetic dyslipidemia in population and in patients with premature atherothrombotic cardiovascular disease. Vnitřní Lekarství, 2018, 64, 25-29.	0.1	0
2380	Examination methods for coronary atherosclerosis regression with special focus on GLAGOV trial. Vnitřní Lekarství, 2018, 64, 61-64.	0.1	0
2381	Obstacles to Optimal Lipid-Lowering Therapy - Any Solution?. Circulation Journal, 2018, 82, 948-950.	0.7	0
2383	Fall 59: Spätschaden bei 51 Jahre, DM Typ 2, Herzinfarkt- und Schlaganfallrisiko. , 2018, , 237-240.		0
2384	Störungen von Ernährung und Stoffwechsel. , 2018, , 695-704.		0

#	ARTICLE	IF	CITATIONS
2386	Lack of accurate evidence on non-statin medication in patients receiving highintensity statin therapy: Re-evaluation of recommendations is needed. <i>Anatolian Journal of Cardiology</i> , 2018, 19, 230.	0.5	0
2387	Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?. <i>Annals of Translational Medicine</i> , 2018, 6, 60-60.	0.7	0
2388	The year in cardiology 2017: prevention. <i>Cardiologia Croatica</i> , 2018, 13, 79-98.	0.0	0
2389	Are there caveats in a treatment of CAD?. <i>Interni Medicina Pro Praxi</i> , 2018, 20, 127-130.	0.0	0
2390	HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW. <i>Russian Journal of Cardiology</i> , 2018, , 191-201.	0.4	0
2391	New options in diagnostics and treatment of familial hypercholesterolemia. <i>MedicĀna Pro Praxi</i> , 2018, 15, 122-126.	0.0	0
2392	Diabetes mellitus and cerebral stroke: a modern look at the problem. <i>MĀ-Ā¼narodnij EndokrinologĀ-Ānij Ā¼urnal</i> , 2018, 14, 298-309.	0.1	1
2393	RAISED LEVEL OF LIPOPROTEIDE(A) AS A PREDICTOR OF CARDIOVASCULAR COMPLICATION POST REVASCULARIZATION OF THE LOWER EXTREMITIES ARTERIES. <i>Russian Journal of Cardiology</i> , 2018, , 7-12.	0.4	0
2394	New clinical and pharmacological aspects of the use of atorvastatin for primary and secondary prevention of complications of cardiovascular diseases. <i>Meditinskiy Sovet</i> , 2018, , 110-117.	0.1	0
2396	Coronary heart disease: how to improve the effectiveness of treatment?. <i>Meditinskiy Sovet</i> , 2018, , 46-52.	0.1	0
2397	Why do we fail when treating dyslipidemia?. <i>Interni Medicina Pro Praxi</i> , 2018, 20, 171-176.	0.0	0
2399	Stroke in theĀElderly Population. <i>Current Topics in Environmental Health and Preventive Medicine</i> , 2019, , 121-135.	0.1	0
2400	PCSK9 inhibitors and diabetes mellitus. <i>Vnitri Lekarstvi</i> , 2018, 64, 1186-1189.	0.1	4
2401	Combined lipid-lowering therapy. <i>Vnitri Lekarstvi</i> , 2018, 64, 1177-1184.	0.1	0
2402	Treating hypercholesterolaemia with evolocumab. <i>Intervencni A Akutni Kardiologie</i> , 2018, 17, 212-217.	0.0	0
2403	Diabetes and Dyslipidemia. <i>Endocrinology</i> , 2019, , 1-20.	0.1	0
2404	Should We Intensify Statin Management in ACS Patients with Very Low LDL Cholesterol Levels?. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 204.	1.1	0
2405	Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabĀ©tique. , 2019, , 377-390.		0

#	ARTICLE	IF	CITATIONS
2407	Clasificaci3n de los desenlaces en los ensayos cl3nicos. Medicina UPB, 2019, 38, 147-157.	0.1	2
2408	How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines. Methodist DeBakey Cardiovascular Journal, 2021, 15, 16.	0.5	1
2409	Diabetes and Dyslipidemia. Endocrinology, 2019, , 1-20.	0.1	0
2410	Management of Coronary Artery Disease & Dyslipidemia and Pharmacist's Role. , 2019, , 169-187.		0
2411	Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol. Journal of Lipid and Atherosclerosis, 2019, 8, 208.	1.1	2
2412	In Defense of the LDL Hypothesis. World Journal of Cardiovascular Diseases, 2019, 09, 245-252.	0.0	0
2413	Encouragement of Super-aggressive LDL-lowering Therapies. Journal of Coronary Artery Disease, 2019, 25, 84-89.	0.1	0
2414	Introduction to translational research in vascular surgery/medicine. Indian Journal of Vascular and Endovascular Surgery, 2019, 6, 162.	0.0	0
2415	Familial Hypercholesterolemia. , 2019, , 43-56.		0
2416	Lipidsenkende Mittel. , 2019, , 749-760.		0
2417	2. Pathophysiology of Atherosclerosis and Its Prevention and Treatment. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 96a-103a.	0.0	0
2418	Principles of optimal antisclerotic nutrition. Hygiena, 2019, 64, 10-15.	0.1	0
2419	The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease. Cor Et Vasa, 2019, 61, 20-27.	0.1	1
2420	RISK FACTORS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RISK STRATIFICATION AND TREATMENT TACTICS. Science and Innovations in Medicine, 2019, 4, 20-25.	0.2	0
2421	Selecci3n de lo mejor del a3o 2018 en riesgo vascular y rehabilitaci3n cardiaca. REC: CardioClinics, 2019, 54, 44-50.	0.1	0
2422	PCSK9 Inhibition with Evolocumab Reaching Physiologic LDL-C Levels for Reducing Atherosclerotic Burden and Cardiovascular Disease-The Full Landscape. Frontiers in Cardiovascular Drug Discovery, 2019, , 148-185.	0.0	0
2424	Regression of coronary atherosclerosis in light of recent studies. Intervencni A Akutni Kardiologie, 2019, 18, 81-85.	0.0	0
2425	Ezetimibe in the treatment of hypercholesterolaemia. Interni Medicina Pro Praxi, 2019, 21, 112-116.	0.0	0

#	ARTICLE	IF	CITATIONS
2426	Tratar la dislipemia, algo más que dar estatinas. Clínica E Investigaci3n En Arteriosclerosis, 2019, 31, 119-120.	0.4	1
2429	Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II. Singapore Medical Journal, 2019, 60, 454-462.	0.3	4
2430	Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of Contemporary Pharmacy Practice, 2019, 66, 54-63.	0.2	1
2431	2. Pathophysiology of Atherosclerosis and Its Prevention and Treatment. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1685-1699.	0.0	0
2432	Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy. Meditsinskiy Sovet, 2019, , 21-26.	0.1	2
2433	Diagnosis and treatment of stable coronary heart disease in the practice of a family doctor. Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini, 2019, 2019, 63-68.	0.0	0
2434	Novel Therapies for Dyslipidemia. , 0, , .		0
2435	Stanovisko v1/2boru ACEsk© spoleAnosti pro ateroskler3zu k doporuAnAm ESC/EAS pro diagnostiku a lA©Abu,1 dyslipidemiA-z roku 2019. Vnitri Lekarstvi, 2019, 65, 743-754.	0.1	6
2436	Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects. International Journal of Clinical Pharmacology and Therapeutics, 2019, 57, 575-589.	0.3	5
2437	Drug Discovery for Coronary Artery Disease. Advances in Experimental Medicine and Biology, 2020, 1177, 297-339.	0.8	6
2438	PCSK9 monoclonal antibodies: An overview. Heart Views, 2020, 21, 97.	0.1	4
2439	Cholesterol Levels. , 2020, , 1-7.		0
2440	Low-Density Lipoprotein Cholesterol Targets in Patients With Coronary Heart Disease in Extremadura (Spain): LYNX Registry. Cardiology Research, 2020, 11, 311-318.	0.5	1
2441	Bayesian Flexible Hierarchical Skew Heavy-Tailed Multivariate Meta Regression Models for Individual Patient Data with Applications. Statistics and Its Interface, 2020, 13, 485-500.	0.2	1
2442	Lipidsenkende Mittel. , 2020, , 601-614.		0
2445	2019 clinical trials in lipid lowering. Current Opinion in Cardiology, 2020, 35, 319-324.	0.8	2
2446	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS,) Tj ETQq0 0 0 rgBT /Overloc TREATMENT OF ATHEROSCLEROSIS (2020). Eurasian Heart Journal, 2020, , 6-29.	0.2	28
2447	Comparison of Archival Angiographic Findings in Patients Later Developing Acute Coronary Syndrome or Stable Angina. International Heart Journal, 2020, 61, 454-462.	0.5	0

#	ARTICLE	IF	CITATIONS
2448	Stanovisko vÁ½boru ĀEeskĀ© spoleĀnosti pro aterosklerĀzu k doporuĀenĀm ESC/EAS pro diagnostiku a lĀ©Ābu dyslipidemiĀ-z roku 2019. Cor Et Vasa, 2020, 62, 185-197.	0.1	6
2450	New approaches to managing patients with high total risk (review of year 2019 recommendations). Medical Alphabet, 2020, , 24-28.	0.0	0
2451	Secondary prevention after acute coronary syndrome. Vnitřni Lekarstvi, 2020, 66, 236-241.	0.1	1
2452	Fixed combination of atorvastatin and ezetimibe in the dyslipidemia treatment. Intervencni A Akutni Kardiologie, 2020, 19, 122-124.	0.0	0
2453	Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials. Iranian Journal of Public Health, 0, , .	0.3	0
2454	Statin Intolerance and Noncompliance: An Empiric Approach. American Journal of Medicine, 2022, 135, 318-323.	0.6	5
2455	Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. International Journal of Molecular Sciences, 2021, 22, 11687.	1.8	44
2456	High-Intensity Statin vs. Low-Density Lipoprotein Cholesterol Target for Patients Undergoing Percutaneous Coronary Intervention: Insights From a Territory-Wide Cohort Study in Hong Kong. Frontiers in Cardiovascular Medicine, 2021, 8, 760926.	1.1	3
2457	Statin-Related New-Onset Diabetes Appears Driven by Increased Insulin Resistance: Are There Clinical Implications?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2798-2801.	1.1	7
2458	Cardiorenal outcomes in eligible patients referred for bariatric surgery. Obesity, 2021, 29, 2035-2043.	1.5	4
2459	The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: A Personalized Approach to Risk Reduction. Contemporary Cardiology, 2021, , 179-200.	0.0	0
2461	Management of Hypertriglyceridemia (Including Fibrates and n-3 FattyĀcids). Contemporary Cardiology, 2021, , 295-306.	0.0	1
2462	The effect of switching from statin-monotherapy to statin/ezetimibe combination therapy on lipid profiles in patients with type 2 diabetes and dyslipidemia: a multicenter open-label study (EUCLID). Vascular Failure, 2020, 4, 22-31.	0.2	1
2463	Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 104-113.	1.2	2
2464	European Society of Cardiology / European Atherosclerosis Society 2019 Dyslipidemia Treatment Guideline: What Has Changed?. Eurasian Journal of Family Medicine Avrasya Aile HekimliĀyi Dergisi, 2020, 9, 187-198.	0.0	0
2465	Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols. Contemporary Cardiology, 2021, , 219-268.	0.0	0
2466	Prevention of Ischemic Stroke. Contemporary Cardiology, 2021, , 581-609.	0.0	0
2467	Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis. ClĀnica E InvestigaciĀn En Arteriosclerosis, 2020, 33, 117-126.	0.4	4

#	ARTICLE	IF	CITATIONS
2468	Genetic Disorders of Lipoprotein Metabolism. Contemporary Cardiology, 2021, , 35-80.	0.0	0
2469	Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. Atherosclerosis Supplements, 2020, 42, e59-e64.	1.2	8
2470	Management of Statin Intolerance. Contemporary Cardiology, 2021, , 207-218.	0.0	0
2471	The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. Contemporary Cardiology, 2021, , 121-138.	0.0	0
2472	Comparison of 2018 AHA-ACC Multi-Society Cholesterol Guidelines with 2013 ACC-AHA Cholesterol Guidelines. Contemporary Cardiology, 2021, , 107-120.	0.0	0
2473	Cardiometabolism: Reducing Risks to Optimize Cardiovascular Disease Outcomes. Contemporary Cardiology, 2021, , 227-248.	0.0	0
2474	Cardiology clinic visit increases likelihood of evidence-based cholesterol prescribing in severe hypercholesterolemia. Clinical Cardiology, 2021, 44, 186-192.	0.7	4
2475	Cardiovascular Disease in Women: Focus on Lipid Management. Contemporary Cardiology, 2021, , 467-487.	0.0	0
2476	Primary Prevention of Cardiovascular Disease Guidelines. Contemporary Cardiology, 2021, , 653-672.	0.0	0
2477	Fixed-dose combination of rosuvastatin and ezetimibe. Vnitri Lekarstvi, 2020, 66, 513-517.	0.1	0
2478	Diabetes and cardiovascular disease: inter-relation of risk factors and treatment. Future Journal of Pharmaceutical Sciences, 2020, 6, .	1.1	23
2479	Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. Global Cardiology Science & Practice, 2020, 2020, e202039.	0.3	2
2480	Management of Dyslipidaemia in the Elderly. Contemporary Cardiology, 2021, , 489-505.	0.0	0
2481	Focus on Cardiovascular Health Promotion and Disease Prevention: Opportunities for Improvement. Contemporary Cardiology, 2021, , 1-16.	0.0	0
2482	Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 114-121.	1.2	1
2483	Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy. Atherosclerosis Supplements, 2020, 42, e25-e29.	1.2	1
2484	Biomarkers in drug development. , 2022, , 323-342.		3
2485	ERKRANKUNGEN DER ENDOKRINEN ORGANE UND DES STOFFWECHSELS. , 2020, , H-1-H9-9.		0



#	ARTICLE	IF	CITATIONS
2486	Diabetes and Dyslipidemia. <i>Endocrinology</i> , 2020, , 51-70.	0.1	0
2487	The Canadian Consensus Working Group's Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. <i>Contemporary Cardiology</i> , 2020, , 137-150.	0.0	1
2488	Management of Hyperlipidemia in Very High and Extreme Risk Patients in Croatia: an Observational Study of Treatment Patterns and Lipid Control. <i>Acta Clinica Croatica</i> , 2020, 59, 641-649.	0.1	1
2489	Statin therapy and low-density lipoprotein cholesterol reduction after acute coronary syndrome: Insights from the United Arab Emirates. <i>Heart Views</i> , 2020, 21, 80.	0.1	0
2490	Current and Emerging Therapies for Atherosclerosis. , 2020, , 71-88.		0
2491	Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management. , 2020, , 387-411.		0
2492	Treatment of Diabetes and Heart Failure. , 2020, , 719-733.		0
2493	Atherogenic dyslipidemia typical for metabolic syndrome. <i>Vnitri Lekarstvi</i> , 2020, 66, 15-20.	0.1	0
2494	Recent Guideline for the Management of Dyslipidemia in Patients with Diabetes. <i>Journal of Korean Diabetes</i> , 2020, 21, 11-20.	0.1	1
2496	Lipid Lowering Treatment and Follow Up in Recent Post Acute Coronary Syndrome Patients: Real-World Evidence from the Multicenter Observational Prospective - Post Acute Coronary Syndrome Italian Study (PACSI). <i>International Cardiovascular Forum Journal</i> , 0, 19, .	1.1	1
2497	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Atherosclerosis</i> , 2021, 338, 55-63.	0.4	8
2499	Suboptimal control of cardiovascular risk factors in myocardial infarction survivors in a cardiac rehabilitation program. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 911-911.	0.2	5
2501	Cost-utility analysis of evolocumab in patients with ASCVD in Italy. <i>Global &amp; Regional Health Technology Assessment</i> , 0, 8, 155-167.	0.2	0
2502	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2021, 50, 401-411.	0.6	18
2503	The Ratio of Triglyceride to High-density Lipoprotein Cholesterol as an Indicator of Risk Stratification for Atherosclerotic Cardiovascular Disease in a Clinical Setting. <i>Internal Medicine</i> , 2020, 59, 2639-2640.	0.3	3
2504	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. <i>PLoS ONE</i> , 2020, 15, e0240166.	1.1	2
2507	Acute Coronary Syndrome. , 2021, , 59-80.		0
2508	Primary Prevention of Coronary Artery Disease. , 2021, , 81-123.		0

#	ARTICLE	IF	CITATIONS
2509	Stable Ischemic Heart Disease. , 2021, , 125-154.		0
2510	Statin therapy in patients with high and very high cardiovascular risk: an optimal approach. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2696.	0.4	0
2512	Modern principles of atherogenic dyslipidemia management in special groups of patients. Cardiosomatics, 2020, 11, 6-15.	0.2	2
2513	Variability in lipid measurements can have major impact on treatment during secondary prevention. European Journal of Preventive Cardiology, 2022, 28, e4-e5.	0.8	0
2514	A Comparative Overview of Prescription Omega-3 Fatty Acid Products. P and T, 2015, 40, 826-57.	1.0	23
2515	The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice. American Health and Drug Benefits, 2015, 8, 483-9.	0.5	16
2516	Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. Canadian Family Physician, 2016, 62, 32-7.	0.1	36
2517	Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia. American Health and Drug Benefits, 2016, 9, 123-6.	0.5	9
2518	Determinants of Treatment Modification in Hypercholesterolemic Patients. Acta Cardiologica Sinica, 2017, 33, 156-164.	0.1	7
2519	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. European Heart Journal Supplements, 2017, 19, D163-D189.	0.0	0
2520	Lipid metabolism and carcinogenesis, cancer development. American Journal of Cancer Research, 2018, 8, 778-791.	1.4	102
2521	Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?. Topics in Antiviral Medicine, 2016, 23, 169-73.	0.1	4
2522	Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. Acta Cardiologica Sinica, 2018, 34, 371-378.	0.1	12
2524	Impediments to clinical application of exercise interventions in the treatment of cardiometabolic disease. Canadian Family Physician, 2019, 65, 164-170.	0.1	2
2525	Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. American Journal of Translational Research (discontinued), 2020, 12, 463-477.	0.0	6
2526	Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials. Iranian Journal of Public Health, 2019, 48, 1405-1417.	0.3	0
2527	Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. BMJ Open, 2020, 10, e036769.	0.8	1
2528	Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK) Tj ETQq1 1 0.784324 rgBT fOverloc		

#	ARTICLE	IF	CITATIONS
2529	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. <i>Nutrients</i> , 2021, 13, .	1.7	1
2530	Risk factors and pharmacological therapy in patients with vascular disease. , 2022, , 11-24.		0
2531	Detection of Familial Hypercholesterolemia through centralized analytical data. HF HUELVA DETECTA Program. <i>Endocrinología y Nutrición (English Ed)</i> , 2021, 68, 450-457.	0.1	1
2532	Liver Fibrosis Scoring Systems as Novel Tools for Predicting Recurrent Cardiovascular Events in Patients with a Prior Cardiovascular Event. <i>Cardiology Discovery</i> , 2021, 1, 214-222.	0.6	2
2533	The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus. <i>Metabolites</i> , 2021, 11, 807.	1.3	17
2534	Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 789931.	1.1	32
2535	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. <i>Diagnostyka Laboratoryjna i Wiadomości PTDL</i> , 2021, 57, 1-99.	0.0	0
2536	An update on emerging drugs for the treatment of hypercholesterolemia. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 363-369.	1.0	4
2537	Peligro: se ha detectado un cortocircuito en la prescripción de los inhibidores de PCSK9. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 306-307.	0.4	0
2538	Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 684-691.	1.1	8
2539	Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. <i>Cell Reports Medicine</i> , 2021, 2, 100446.	3.3	16
2540	Association of Apolipoprotein Bâ€‘Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. <i>JAMA Cardiology</i> , 2022, 7, 250.	3.0	108
2542	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS). <i>Eurasian Heart Journal</i> , 2021, , 6-59.	0.2	4
2543	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. <i>Archives of Medical Science</i> , 2021, 17, 1447-1547.	0.4	78
2544	Effect of Omega-3 Fatty Acids on Coronary Plaque Morphologyâ€‘â€‘ A Serial Computed Tomography Angiography Study â€‘. <i>Circulation Journal</i> , 2022, 86, 831-842.	0.7	7
2545	Cerebrovascular Disease and Statins. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 778740.	1.1	8
2546	ABCA1 and ABCG1 as potential therapeutic targets for the prevention of atherosclerosis. <i>Journal of Pharmacological Sciences</i> , 2022, 148, 197-203.	1.1	63
2547	Aplicaci3n de los objetivos individualizados definidos por la gu3a europea 2019 de l3pidos en pacientes con diabetes tipo 2. <i>Cl3nica E Investigaci3n En Arteriosclerosis</i> , 2022, 34, 19-26.	0.4	0

#	ARTICLE	IF	CITATIONS
2550	Cholesterol Levels. , 2021, , 970-976.		0
2551	Lipidsenkende Mittel. , 2021, , 509-521.		0
2552	The dawn of a new era of targeted lipid-lowering therapies. European Heart Journal, 2022, 43, 3198-3208.	1.0	48
2554	Novel therapeutic targets and agents for pediatric dyslipidemia. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110583.	1.4	4
2555	Lipid-Lowering Drugs. , 2021, , 929-936.		0
2556	Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention. 2022. 29. 105-113.	1.0	3
2557	Kardiovaskuläre Prophylaxe: Wenn man Surrogatmarker "therapiert". , 0, , .		0
2558	Akutes Koronarsyndrom: Wie geht es nach der Akutphase weiter?. , 0, , .		0
2559	Stellenwert der Statine: Nach wie vor die erste Wahl. , 0, , .		0
2560	Herzinfarkt: Was kommt in den Jahren danach?. , 0, , .		0
2561	Dyslipidämien: Aktuelles Lipid-Management. , 0, , .		0
2563	Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study. BMJ Open, 2020, 10, e036769.	0.8	3
2564	Cholesterol-Lowering Drugs. , 2020, , 233-248.		0
2565	The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. , 2021, 12, 1857.		2
2566	Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly. Minerva Medica, 2022, 112, .	0.3	7
2567	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. Nutrients, 2021, 13, 2957.	1.7	9
2568	Diabetes mellitus: an overview of the types, symptoms, complications and management. Nursing Standard (Royal College of Nursing (Great Britain): 1987), 2022, 37, 61-66.	0.1	76
2569	Real-world utilization of bempedoic acid in an academic preventive cardiology practice. Journal of Clinical Lipidology, 2022, 16, 94-103.	0.6	16

#	ARTICLE	IF	CITATIONS
2570	Is there a role of lipid-lowering therapies in the management of fatty liver disease?. World Journal of Hepatology, 2022, 14, 119-139.	0.8	13
2571	Asymptomatic carotid stenosis: Several guidelines with unclear answers. Annals of Indian Academy of Neurology, 2022, 25, 171.	0.2	3
2572	Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany. Cardiovascular Drugs and Therapy, 2023, 37, 683-694.	1.3	8
2573	Addressing dyslipidemic risk beyond LDL-cholesterol. Journal of Clinical Investigation, 2022, 132, .	3.9	51
2574	Ezetimibe Prevents IL-1 $\beta$ -induced Inflammatory Reaction in Mouse Chondrocytes via Modulating NF- $\kappa$ B and Nrf2/HO-1 Signaling Crosstalk. Current Pharmaceutical Biotechnology, 2022, 23, 1772-1780.	0.9	3
2575	Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer. Pharmaceuticals, 2022, 15, 151.	1.7	34
2576	Relationship between Low-Density Lipoprotein Cholesterol, Lipid Lowering Agents and the Risk of Stroke: A meta-analysis of Observational studies (n=355,591) and Randomized Controlled Trials (n=165,988).. Archives of Medical Science, 2022, , .	0.4	2
2577	JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. Circulation Journal, 2022, 86, 477-588.	0.7	38
2578	Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease. American Journal of the Medical Sciences, 2022, , .	0.4	1
2579	Daeshiho-tang Attenuates Atherosclerosis by Regulating Cholesterol Metabolism and Inducing M2 Macrophage Polarization. Life, 2022, 12, 197.	1.1	2
2580	Where the Action Isâ€”Leukocyte Recruitment in Atherosclerosis. Frontiers in Cardiovascular Medicine, 2021, 8, 813984.	1.1	24
2581	OUP accepted manuscript. Protein Engineering, Design and Selection, 2022, 35, .	1.0	4
2582	The Association between Low Levels of Low Density Lipoprotein Cholesterol and Intracerebral Hemorrhage: Cause for Concern?. Journal of Clinical Medicine, 2022, 11, 536.	1.0	7
2584	An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. Expert Opinion on Drug Metabolism and Toxicology, 2022, , 1-9.	1.5	7
2585	Exploring the Role of Nutraceuticals (Red Yeast Rice) in Secondary Prevention: A New Pathway Can Be Opened. World Journal of Cardiovascular Diseases, 2022, 12, 24-29.	0.0	0
2587	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 91-102.	1.0	17
2588	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation, 2022, 145, CIR0000000000001040.	1.6	193
2589	Personalizing cholesterol treatment recommendations for primary cardiovascular disease prevention. Scientific Reports, 2022, 12, 23.	1.6	5

#	ARTICLE	IF	CITATIONS
2590	Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology. <i>Neurología (English Edition)</i> , 2022, 37, 61-72.	0.2	2
2591	Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 585-598.	1.3	6
2592	Application of the very high risk criterion and evaluation of cholesterol guideline adherence in acute myocardial infarction patients at an urban academic medical center. <i>American Heart Journal Plus</i> , 2022, 13, 100082.	0.3	0
2593	Impact of Lipoprotein(a) as a Residual Risk Factor in Long-Term Cardiovascular Outcomes in Patients With Acute Coronary Syndrome Treated With Statins. <i>American Journal of Cardiology</i> , 2022, 168, 11-16.	0.7	10
2594	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. <i>Atherosclerosis</i> , 2022, 343, 28-50.	0.4	12
2595	Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. <i>Journal of the American Heart Association</i> , 2022, 11, e022733.	1.6	4
2596	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
2597	Application of the individualized objectives defined by the European 2019 lipid guidelines in patients with type 2 diabetes. <i>Clínica e Investigación En Arteriosclerosis (English Edition)</i> , 2022, 34, 19-19.	0.1	0
2598	What is the Optimal Low-Density Lipoprotein Cholesterol?. <i>Medical Clinics of North America</i> , 2022, 106, 285-298.	1.1	2
2599	The design and rationale of the Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypercholesterolemia (ACCURATE) study. <i>American Heart Journal Plus</i> , 2022, 13, 100097.	0.3	0
2600	Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2022, 16, 104-111.	0.6	4
2601	Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea. <i>BMC Cancer</i> , 2022, 22, 156.	1.1	1
2602	Barriers to prescribing proprotein convertase subtilisin/kexin type 9 inhibitors after coronary revascularisation. <i>Internal Medicine Journal</i> , 2022, , .	0.5	2
2603	Clonal hematopoiesis in cardiovascular disease and therapeutic implications. , 2022, 1, 116-124.		32
2604	Long-term clinical impact of low-density lipoprotein cholesterol target attainment according to lesion complexity after percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2022, Publish Ahead of Print, .	0.3	0
2605	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetesâ€”2022</i>. <i>Diabetes Care</i> , 2022, 45, S144-S174.	4.3	282
2607	1. Frontiers of Laboratory Examination and Treatment of Dyslipidemia. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 546-555.	0.0	0
2608	Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007903.	0.9	5

#	ARTICLE	IF	CITATIONS
2609	Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. <i>American Heart Journal Plus</i> , 2022, 13, 100127.	0.3	7
2610	Estimated Aggregate Treatment Benefit With Addition of Multiple Novel Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842210847.	1.0	1
2611	Safety issues associated with the clinical application of PCSK9 inhibitors. <i>Cardiology in Review</i> , 2022, Publish Ahead of Print, .	0.6	1
2612	Key Roles of Inflammation in Atherosclerosis: Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation. <i>Methods in Molecular Biology</i> , 2022, 2419, 21-37.	0.4	6
2613	Diagnosis and Treatment of Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 662.	3.8	219
2614	Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes. <i>Clinical Therapeutics</i> , 2022, 44, 331-348.	1.1	4
2615	Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis. <i>PharmacoEconomics - Open</i> , 2022, 6, 799-809.	0.9	2
2617	Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention. <i>JAMA Neurology</i> , 2022, 79, 349.	4.5	39
2618	Association of Prior Statin Therapy With Cardiovascular Outcomes in Patients With Initial Diagnosis of OCAD and LDL-C Below 1.8Åmmol/L. <i>Angiology</i> , 2022, , 000331972210758.	0.8	0
2619	Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e048893.	0.8	20
2621	Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. <i>PLoS Biology</i> , 2022, 20, e3001547.	2.6	69
2622	Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study. <i>Cardiovascular Diabetology</i> , 2022, 21, 28.	2.7	5
2623	Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). <i>BMC Medicine</i> , 2022, 20, 93.	2.3	30
2624	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	4.9	14
2625	Causal relationship of excess body weight on cardiovascular events through risk factors. <i>Scientific Reports</i> , 2022, 12, 5269.	1.6	3
2626	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCEâ€™ PCI. <i>Journal of the American Heart Association</i> , 2022, 11, e022937.	1.6	26
2627	Coronary plaque vulnerability in statin-treated patients with elevated LDL-C and hs-CRP: optical coherence tomography study. <i>International Journal of Cardiovascular Imaging</i> , 0, , 1.	0.2	0
2628	Statin intolerance: how common is it and how do we work with patients to overcome it?. <i>European Heart Journal</i> , 2022, 43, 3224-3226.	1.0	7

#	ARTICLE	IF	CITATIONS
2629	The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial. <i>Frontiers in Pharmacology</i> , 2022, 13, 755469.	1.6	5
2630	Aggressive lipid-lowering therapy after percutaneous coronary intervention &ndash; for whom and how?. <i>Asialntervention</i> , 2022, 8, 24-31.	0.1	0
2631	Achieving lipid targets within 12 months of an acute coronary syndrome: an observational analysis. <i>Medical Journal of Australia</i> , 2022, , .	0.8	3
2632	Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review. <i>Geriatrics (Switzerland)</i> , 2022, 7, 38.	0.6	0
2633	Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1308-1321.	2.3	137
2635	Reducing the Damage of Ox-LDL/LOX-1 Pathway to Vascular Endothelial Barrier Can Inhibit Atherosclerosis. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-16.	1.9	7
2636	Optimal low-density lipoprotein cholesterol target level in Korean acute myocardial infarction patients (<math>70\text{mg/dL}</math> vs. <math>55\text{mg/dL}</math>): Based on Korea acute myocardial infarction registry-National Institute of Health. <i>International Journal of Cardiology</i> , 2022, 351, 15-22.	0.8	3
2637	Impacts of ezetimibe on risks of various types of cancers: a meta-analysis and systematic review. <i>European Journal of Cancer Prevention</i> , 2023, 32, 89-97.	0.6	4
2638	Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies. <i>PLoS ONE</i> , 2022, 17, e0264437.	1.1	5
2639	The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2022, 24, 379-389.	2.0	5
2640	Effects of the Current Japanese Guideline for Dedicated, Intensive Lipid-lowering Therapy on Lipid Profile and Coronary Events in Patients After Acute Coronary Syndrome. , 0, 1, .		0
2641	Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 111.	0.7	5
2642	Stepâ€byâ€step diagnosis and management of the nocebo/drucebo effect in statinâ€associated muscle symptoms patients: a position paper from<i>the International Lipid Expert Panel</i>(ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	2.9	35
2643	Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India. <i>Journal of Clinical Lipidology</i> , 2022, 16, 261-271.	0.6	8
2644	LDL como objetivo terapÃ©utico. <i>ClÃnica E InvestigaciÃ³n En Arteriosclerosis</i> , 2022, , .	0.4	0
2645	Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance. <i>NeurologÃa (English Edition)</i> , 2022, 37, 136-150.	0.2	3
2646	Effect of Vupanorsen on Nonâ€High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. <i>Circulation</i> , 2022, 145, 1377-1386.	1.6	81
2647	Statinâ€associated muscle symptomsâ€A review: Individualizing the approach to optimize care. <i>Pharmacotherapy</i> , 2022, 42, 428-438.	1.2	10



#	ARTICLE	IF	CITATIONS
2648	Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019. <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 189-203.	0.7	11
2649	Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications. <i>Cardiovascular Research</i> , 2023, 119, 121-135.	1.8	7
2650	Acute coronary syndromes. <i>Lancet, The</i> , 2022, 399, 1347-1358.	6.3	122
2652	A Paradigm Shift in Dyslipidemia Management in Primary Care: A 12-Month Cohort Study. <i>Clinical Therapeutics</i> , 2022, , .	1.1	0
2653	Evaluation and management of blood lipids through a woman's life cycle. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100333.	1.3	8
2654	Case presentation and panel discussion: Cardiometabolic risk mitigation. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, 45, 93-99.	1.3	0
2655	Warning: a short circuit has been detected in the prescription of PCSK9 inhibitors. <i>Clínica e Investigaci3n En Arteriosclerosis (English Edition)</i> , 2021, 33, 306-307.	0.1	0
2656	Bempedoic acid. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2021, 34, 8-10.	0.1	0
2657	VCSEL: Prioritizing SNP-set by penalized variance component selection. <i>Annals of Applied Statistics</i> , 2021, 15, 1652-1672.	0.5	2
2659	Consideration regarding the Analysis of Randomized Controlled Trials in the era of Evidence-Based Medicine. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, .	0.8	2
2660	The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke. <i>Diseases (Basel)</i> , 2021, 10, 103.	1.0	3
2661	Suboptimal control of cardiovascular risk factors in myocardial infarction survivors in a cardiac rehabilitation program. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 911-920.	0.2	1
2662	Comparison of Efficacy and Safety of Statin+Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 395-406.	1.0	6
2663	The role of bempedoic acid in the management of dyslipidaemia. <i>Journal of Prescribing Practice</i> , 2021, 3, 484-488.	0.1	0
2664	Guideline based eligibility for primary prevention statin therapy – Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI). <i>Journal of Clinical Lipidology</i> , 2021, , .	0.6	4
2665	Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 383-392.	0.9	6
2666	Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 170-179.	2.3	2
2668	Treatment goals in familial hypercholesterolaemia – time to consider low-density lipoprotein-cholesterol burden. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 2278-2280.	0.8	5

#	ARTICLE	IF	CITATIONS
2669	High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1731-1739.	0.8	3
2670	Topical issues concerning modern lipid-lowering therapy. <i>Consilium Medicum</i> , 2022, 24, 20-27.	0.1	1
2671	Residual Risk of Coronary Atherosclerotic Heart Disease and Severity of Coronary Atherosclerosis Assessed by ApoB and LDL-C in Participants With Statin Treatment: A Retrospective Cohort Study. <i>Frontiers in Endocrinology</i> , 2022, 13, 865863.	1.5	6
2672	Approach to patients with elevated low-density lipoprotein cholesterol levels. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101658.	2.2	2
2673	Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. <i>Acta Cardiologica</i> , 2024, 79, 20-29.	0.3	8
2674	Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Española De Cardiología</i> , 2022, 75, 429.e1-429.e104.	0.6	27
2676	Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention. <i>JACC Asia</i> , 2022, 2, 323-337.	0.5	5
2677	Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, 101161CIRCOUTCOMES121008552.	0.9	21
2678	A Systematic Review of Cost-Effectiveness of Non-Statins Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. <i>Current Problems in Cardiology</i> , 2023, 48, 101211.	1.1	5
2682	Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 905-916.	1.3	4
2683	Achieving coronary plaque regression: a decades-long battle against coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2022, , 1-15.	0.6	1
2688	Clinical strategies for reducing cholesterol levels. , 2022, , 853-901.		0
2689	Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement. <i>Cardiology Research and Practice</i> , 2022, 2022, 1-7.	0.5	1
2690	New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease. <i>Biomedicines</i> , 2022, 10, 970.	1.4	8
2691	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2022, 21, 3235.	0.4	37
2692	Macrovascular Complications. <i>Primary Care - Clinics in Office Practice</i> , 2022, 49, 255-273.	0.7	2
2693	Undertreatment or Overtreatment With Statins: Where Are We?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 808712.	1.1	9
2694	Hypertension and dyslipidemia treatment in stroke. <i>Vnitřní Lekarství</i> , 2022, 68, 172-177.	0.1	1

#	ARTICLE	IF	CITATIONS
2695	Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK. <i>BMJ Open</i> , 2022, 12, e055015.	0.8	0
2697	European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. <i>European Stroke Journal</i> , 2022, 7, I-XLI.	2.7	51
2698	Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. <i>Lancet</i> , The, 2022, 399, 1876-1885.	6.3	169
2699	Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: A retrospective cohort study in primary care. <i>Journal of Clinical Lipidology</i> , 2022, 16, 498-507.	0.6	4
2700	PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. <i>BMJ</i> , The, 2022, 377, e069116.	3.0	32
2701	Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 153.	0.8	2
2703	Effectiveness of Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy on Lipid Levels in Type 2 Diabetes: a Meta-analysis. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1575-1584.	0.9	3
2704	Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239,234 Patients During 2005 to 2018 in the United States. <i>Journal of the American Heart Association</i> , 2022, 11, e022198.	1.6	26
2705	review on epidemiology, biochemical characteristics, treatment suggestions, and continued studies on diabetes and cardiovascular disease. <i>International Journal of Health Sciences</i> , 0, , 5288-5311.	0.0	1
2706	Unstable Angina as a Component of Primary Composite Endpoints in Clinical Cardiovascular Trials: Pros and Cons. <i>Cardiology</i> , 2022, , .	0.6	5
2707	Application of a risk-guided strategy to secondary prevention of coronary heart disease: analysis from a state-wide data linkage in Queensland, Australia. <i>BMJ Open</i> , 2022, 12, e057856.	0.8	1
2708	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1660-1671.	1.2	36
2709	Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis. <i>Annals of Medicine</i> , 2022, 54, 1287-1296.	1.5	16
2710	Lipid-Modifying Therapies and Stroke Prevention. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 375-382.	2.0	7
2711	Aggressive treatment of LDL-cholesterol and patients undergoing CABG: news from IMPROVE-IT. <i>Clinical Lipidology</i> , 2016, 11, 26-27.	0.4	0
2712	Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. , 2022, 1, e000134.		13
2713	The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice. <i>Acta Cardiologica</i> , 2023, 78, 552-564.	0.3	2
2714	Clinical analysis of a case of recurrent myocardial infarction treated with combined therapy of Rivaroxaban and evolocumab. <i>Minerva Medica</i> , 2022, , .	0.3	0

#	ARTICLE	IF	CITATIONS
2718	Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 7.	0.1	3
2719	Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis, 2022, 349, 110-122.	0.4	36
2720	Longitudinal effects of lipid indices on incident cardiovascular diseases adjusting for time-varying confounding using marginal structural models: 25 years follow-up of two US cohort studies. Global Epidemiology, 2022, 4, 100075.	0.6	2
2721	Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient. Global & Regional Health Technology Assessment, 2022, 9, 17-26.	0.2	0
2722	LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?. Current Atherosclerosis Reports, 2022, 24, 635-642.	2.0	7
2723	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. Canadian Journal of Cardiology, 2022, 38, 1542-1549.	0.8	4
2724	Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper.. Archives of Medical Science, 0, , .	0.4	5
2725	A Comparison of Rehospitalization Risks on Diabetic and Non-Diabetic Patients after Recovery from Acute Coronary Syndrome. Healthcare (Switzerland), 2022, 10, 1003.	1.0	0
2726	Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome. Journal of Translational Medicine, 2022, 20, .	1.8	10
2727	Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008-2019. Clinical Epidemiology, 0, Volume 14, 737-748.	1.5	2
2728	Towards more personalized low-density lipoprotein-cholesterol lowering strategies in patients with atherosclerotic cardiovascular disease. European Journal of Preventive Cardiology, 0, , .	0.8	0
2731	Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211027.	1.1	11
2732	Managing residual inflammatory risk in atherosclerotic cardiovascular disease: another piece of the puzzle?. Cardiology Plus, 2022, 7, 1-2.	0.2	1
2733	Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia. Cardiology in Review, 2022, 30, 214-219.	0.6	1
2734	A statistical perspective on baseline adjustment in pharmacogenomic genome-wide association studies of quantitative change. Npj Genomic Medicine, 2022, 7, .	1.7	3
2735	A new and automated risk prediction of coronary artery disease using clinical endpoints and medical imaging-derived patient-specific insights: protocol for the retrospective GeoCAD cohort study. BMJ Open, 2022, 12, e054881.	0.8	2
2736	High-Risk Coronary Plaque Features: A Narrative Review. Cardiology and Therapy, 2022, 11, 319-335.	1.1	5
2737	Association of Common and Rare Genetic Variation in the 3- $\alpha$ -Hydroxy-3-Methylglutaryl Coenzyme A Reductase Gene and Cataract Risk. Journal of the American Heart Association, 2022, 11, .	1.6	4

#	ARTICLE	IF	CITATIONS
2738	Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1103-1114.	0.8	8
2739	Rationale, Criteria, and Impact of Identifying Extreme Risk in Patients with Atherosclerotic Cardiovascular Disease. <i>Cardiology Discovery</i> , 2022, 2, 114-123.	0.6	0
2740	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1842-1851.	0.8	7
2741	Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies. <i>PLoS ONE</i> , 2022, 17, e0264563.	1.1	4
2742	NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. <i>Journal of Clinical Lipidology</i> , 2022, 16, 361-375.	0.6	56
2743	Optimal cardiovascular medical therapy: current guidelines and new developments. <i>Baylor University Medical Center Proceedings</i> , 0, , 1-7.	0.2	3
2744	Would You Recommend a Statin to This Patient for Primary Prevention of Cardiovascular Disease?. <i>Annals of Internal Medicine</i> , 2022, 175, 862-872.	2.0	1
2745	Chasing LDL cholesterol to the bottom – PCSK9 in perspective. , 2022, 1, 554-561.		13
2746	Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
2747	Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. <i>Current Opinion in Lipidology</i> , 2022, 33, 147-159.	1.2	7
2748	Effects of blood lipids and lipid-modifying drugs on intracranial aneurysms. <i>European Journal of Neurology</i> , 2022, 29, 2967-2975.	1.7	6
2749	2022 Taiwan lipid guidelines for primary prevention. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 2393-2407.	0.8	10
2750	<i>Vasculome.</i> , 2022, , 441-451.		0
2751	Guidelines for the Prevention of Symptomatic Cardiovascular Disease, Based upon the Presence of Coronary Artery Calcified Plaque—Provided by the Society for the Prevention of Symptomatic Heart Disease. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 320-341.	0.0	6
2752	SAMSON and the Nocebo Effect: Management of Statin Intolerance. <i>Current Cardiology Reports</i> , 2022, 24, 1101-1108.	1.3	9
2753	Cardiometabolism: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks. <i>Canadian Journal of Physiology and Pharmacology</i> , 0, , .	0.7	0
2755	Achieving Lower LDL-C Levels After a Recent Myocardial Infarction Might Be Associated with Lower Healthcare Resource Use and Costs in Spain. <i>Advances in Therapy</i> , 2022, 39, 3578-3588.	1.3	1
2756	Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 327-336.	1.0	2

#	ARTICLE	IF	CITATIONS
2757	New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention. <i>Current Cardiovascular Risk Reports</i> , 2022, 16, 69-78.	0.8	5
2758	Lipid Management. , 2022, , 407-417.		0
2759	Best Practices in Pharmacotherapy for Acute Coronary Syndromes. <i>US Cardiology Review</i> , 0, 16, .	0.5	0
2760	Lipid-lowering therapy in patients with peripheral artery disease â€“ a call for action. <i>Vasa - European Journal of Vascular Medicine</i> , 2022, 51, 193-195.	0.6	1
2761	Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 5317-5325.	1.1	10
2762	The absolute cardiovascular benefits of PCSK9 inhibitors and ezetimibe added to maximally tolerated statin therapy depend on individual baseline cardiovascular risk. <i>European Heart Journal</i> , 2022, 43, 3016-3017.	1.0	3
2763	Critical Limb Ischemia: Update for the Cardiovascular Anesthesiologist. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 3939-3944.	0.6	1
2764	Safety of Statins and Nonstatins for Treatment of Dyslipidemia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 655-679.	1.2	7
2766	Directly Measured vs. Calculated Low-Density Lipoprotein Cholesterol Does Not Identify Additional Individuals With Coronary Artery Disease and Diabetes at Higher Risk of Adverse Events: Insight From a Large Percutaneous Coronary Intervention Cohort in Asia. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
2767	Evaluation of Subclinical Vascular Disease in Diabetic Kidney Disease: A Tool for Personalization of Management of a High-Risk Population. <i>Journal of Personalized Medicine</i> , 2022, 12, 1139.	1.1	5
2768	New Therapeutic Approaches in Treatment of Dyslipidaemiaâ€”A Narrative Review. <i>Pharmaceuticals</i> , 2022, 15, 839.	1.7	15
2769	Relationship between PCSK9 and endothelial function in patients with acute myocardial infarction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 2105-2111.	1.1	3
2770	Intensity of and Adherence to Lipidâ€“Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	13
2771	Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. <i>Clinical Drug Investigation</i> , 2022, 42, 643-656.	1.1	5
2772	The DA VINCI study: is Ireland achieving ESC/EAS guidelineâ€“directed LDL-C goals?. <i>Irish Journal of Medical Science</i> , 2023, 192, 1077-1084.	0.8	3
2773	Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. <i>Journal of Clinical Medicine</i> , 2022, 11, 3884.	1.0	22
2774	Using deep learning-based natural language processing to identify reasons for statin nonuse in patients with atherosclerotic cardiovascular disease. <i>Communications Medicine</i> , 2022, 2, .	1.9	8
2775	Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). <i>American Heart Journal</i> , 2022, 253, 76-85.	1.2	7

#	ARTICLE	IF	CITATIONS
2776	Dyslipidemia in Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 603-624.	1.2	13
2777	Decoding microRNA drivers in atherosclerosis. <i>Bioscience Reports</i> , 2022, 42, .	1.1	11
2778	Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2022, 400, 380-390.	6.3	100
2779	Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 190, 109980.	1.1	20
2780	Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging. <i>American Journal of Preventive Cardiology</i> , 2022, 11, 100366.	1.3	12
2781	Inter-Individual Variability in Lipid Response: A Narrative Review. <i>American Journal of Medicine</i> , 2022, 135, 1427-1433.e7.	0.6	2
2782	Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review. <i>Journal of Clinical Lipidology</i> , 2022, 16, 562-573.	0.6	4
2783	Effect of Novel Stratified Lipid Risk by "LDL-Window" and Flow-Mediated Dilatation on the Prognosis of Coronary Artery Disease Using the FMD-J Study A Data. <i>Circulation Journal</i> , 2022, 86, 1444-1454.	0.7	4
2784	Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 4344.	1.0	1
2785	Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 1111-1129.	2.5	2
2786	1/4Inclisiran: more hope less hype. <i>Drug and Therapeutics Bulletin</i> , 2022, 60, 102-107.	0.3	5
2787	Combination therapy in the guidelines: from high-intensity statins to high-intensity lipid-lowering therapies: Combination therapy in the guideline. , 2022, 1, 25-29.		2
2788	Lipid-lowering for the prevention of cardiovascular disease in the new era: A practical approach to combination therapy: Lipid-lowering and combination therapy. , 2022, 1, 30-36.		2
2790	The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs. , 2022, 1, 2-13.		0
2791	Cholesterol-lowering drugs: Focus on Ezetimibe: Cholesterol-lowering drugs: Focus on ezetimibe. , 2022, 1, 14-24.		0
2792	Atherosclerosis risk factor management - what's new for the neurologist?. <i>Arquivos De Neuro-Psiquiatria</i> , 2022, 80, 88-93.	0.3	0
2793	Cholesterol-Lowering Effects of Asperidine B, a Pyrrolidine Derivative from the Soil-Derived Fungus <i>Aspergillus sclerotiorum</i> PSU-RSPG178: A Potential Cholesterol Absorption Inhibitor. <i>Pharmaceuticals</i> , 2022, 15, 955.	1.7	2
2794	Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach. <i>Current Cardiology Reports</i> , 2022, 24, 1373-1385.	1.3	1

#	ARTICLE	IF	CITATIONS
2795	Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond. <i>Journal of Cardiology</i> , 2023, 81, 168-178.	0.8	17
2797	Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 2177-2186.	2.0	8
2798	2022 Consensus statement on the management of familial hypercholesterolemia in Korea. <i>Korean Journal of Internal Medicine</i> , 0, , .	0.7	3
2799	The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. <i>Kardiologiya</i> , 2022, 62, 12-22.	0.3	2
2800	Management of Dyslipidemia after Stroke. <i>Journal of the Korean Neurological Association</i> , 2022, 40, 217-227.	0.0	1
2801	Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome. <i>Journal of Clinical Lipidology</i> , 2022, 16, 635-642.	0.6	5
2802	Lipid Lowering Therapy: An Era Beyond Statins. <i>Current Problems in Cardiology</i> , 2022, 47, 101342.	1.1	24
2803	Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk. <i>Journal of Clinical Medicine</i> , 2022, 11, 4611.	1.0	5
2804	Global research trends in atherosclerosis: A bibliometric and visualized study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
2805	The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials. <i>Inflammopharmacology</i> , 2022, 30, 1597-1615.	1.9	5
2806	2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1366-1418.	1.2	147
2807	Management of Dyslipidemia in Secondary Prevention of Cardiovascular Disease: The Gap between Theory and Practice. <i>Journal of Clinical Medicine</i> , 2022, 11, 4608.	1.0	3
2808	Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9417.	1.8	17
2810	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€”2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
2812	Colesevelam â€” a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1363-1370.	0.9	2
2813	Coronary Artery Calcium-Based Approach to Lipid Management. <i>Current Cardiovascular Risk Reports</i> , 0, , .	0.8	0
2814	Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2023, 81, 35-44.	0.8	2
2815	Association of Lowâ€”Density Lipoprotein Cholesterol Levels with More than 20â€”Year Risk of Cardiovascular and Allâ€”Cause Mortality in the General Population. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	22



#	ARTICLE	IF	CITATIONS
2816	First clinical and efficacy data on evolocumab in routine clinical practice in endocrinology and nutrition services in Spain: A retrospective observational study (RETOSS-ENDO). <i>Endocrinología y Nutrición</i> (English Ed), 2022, , .	0.1	0
2817	Trends in treatment and outcomes of patients with diabetes and acute myocardial infarction: Insights from the nationwide AMIS plus registry. <i>International Journal of Cardiology</i> , 2022, , .	0.8	0
2818	LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. <i>Postgraduate Medicine</i> , 2022, 134, 752-762.	0.9	9
2819	Comorbidities Associated With Residual Cardiovascular Risk in Patients With Chronic Coronary Syndrome Receiving Statin Therapy—Subanalysis of the REAL-CAD Trial. <i>Circulation Reports</i> , 2022, 4, 422-428.	0.4	3
2820	Effect of 1PC111, a Fixed-dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase III Study. <i>Clinical Therapeutics</i> , 2022, 44, 1272-1281.	1.1	3
2821	Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment. <i>Current Cardiology Reports</i> , 2022, 24, 1647-1655.	1.3	1
2822	Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. <i>Circulation</i> , 2022, 146, 657-672.	1.6	32
2823	Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2023, 17, 19-39.	0.6	24
2824	Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods. <i>Nature Communications</i> , 2022, 13, .	5.8	20
2825	Risk stratification and lipid evaluation in mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The mexican registry of cardiovascular diseases (REMECAR group). <i>Atherosclerosis Plus</i> , 2022, 50, 32-39.	0.3	0
2826	Combining LC-MS/MS profiles with network pharmacology to predict molecular mechanisms of the hyperlipidemic activity of <i>Lagenaria siceraria</i> stand. <i>Journal of Ethnopharmacology</i> , 2023, 300, 115633.	2.0	4
2827	2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea. <i>Journal of Lipid and Atherosclerosis</i> , 2022, 11, 213.	1.1	2
2828	Association Between Intermediate-Density Lipoprotein Particles and the Progression of Carotid Atherosclerosis: A Community-Based Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2829	Low-density lipoprotein particles in atherosclerosis. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	33
2830	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2022, 16, e77-e95.	0.6	16
2831	Ezetimibe and diabetes mellitus: a new strategy for lowering cholesterol. <i>Mã-Å¼narodnj Endokrinologã-Å½urnal</i> , 2022, 18, 302-314.	0.1	2
2832	Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2022, 146, 1109-1119.	1.6	123
2833	Is It About the Destination or About the Journey?. <i>Stroke</i> , 2022, 53, 3268-3269.	1.0	1

#	ARTICLE	IF	CITATIONS
2834	Alirocumab Added to High-Intensity Statin Therapy and Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 891.	3.8	0
2835	Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. <i>Nature Reviews Cardiology</i> , 2023, 20, 181-196.	6.1	28
2836	Low-Density Lipoprotein Cholesterol Levels on Statins and Cardiovascular Event Risk in Stable Coronary Artery Disease—An Observation From the REAL-CAD Study. <i>Circulation Journal</i> , 2022, , .	0.7	0
2837	Combination Therapy with Ezetimibe: An Alternative Strategy to Statin Monotherapy in the Management of Patients with Non-cardiac Vascular Disease. <i>Current Vascular Pharmacology</i> , 2022, 20, 457-459.	0.8	1
2838	Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape. <i>European Heart Journal</i> , 2022, 43, 4227-4228.	1.0	1
2839	The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran. <i>Cardiology and Therapy</i> , 2022, 11, 461-471.	1.1	1
2840	Primary and secondary prevention of atherosclerotic cardiovascular disease: A case-based approach. <i>Cleveland Clinic Journal of Medicine</i> , 2022, 89, 513-522.	0.6	1
2841	Recent Advances on the Roles of PCSK-9 Inhibitors in the Management of Acute Ischemic Stroke Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10221.	1.8	2
2842	Low LDL-C level and intracranial haemorrhage risk after ischaemic stroke: a prospective cohort study. <i>Stroke and Vascular Neurology</i> , 2023, 8, 127-133.	1.5	1
2843	Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 2264-2271.	0.8	6
2844	Consider old and new approaches when treating dyslipidaemia. <i>Drugs and Therapy Perspectives</i> , 0, , .	0.3	0
2845	Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA). <i>Journal of Clinical Lipidology</i> , 2022, 16, 870-877.	0.6	9
2846	Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	12
2847	Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials. <i>Medicine (United States)</i> , 2022, 101, e30563.	0.4	4
2848	Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients. <i>Cardiology Research and Practice</i> , 2022, 2022, 1-9.	0.5	0
2849	Dietary 7-ketocholesterol exacerbates myocardial ischemia—reperfusion injury in mice through monocyte/macrophage-mediated inflammation. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
2850	Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline. <i>American Heart Journal Plus</i> , 2022, 21, 100201.	0.3	0
2851	Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations. <i>Molecular Therapy</i> , 2022, 30, 3106-3117.	3.7	23

#	ARTICLE	IF	CITATIONS
2852	Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events. <i>Heart Failure Clinics</i> , 2022, 18, 597-607.	1.0	2
2853	New algorithms for treating homozygous familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2022, 33, 326-335.	1.2	9
2854	Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009â€“2017. <i>Heart</i> , 0, , heartjnl-2022-321452.	1.2	6
2855	Impact of psychological status on cardiovascular diseases: Is it time for upgrading risk score charts?. <i>Atherosclerosis</i> , 2022, 359, 42-43.	0.4	0
2856	Cholesterol: how to measure and how to treat. <i>Practice Nursing</i> , 2022, 33, 402-410.	0.1	0
2857	Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels. <i>Metabolism: Clinical and Experimental</i> , 2022, 137, 155327.	1.5	4
2859	Peripheral Arterial Atherogenesis. <i>Contemporary Cardiology</i> , 2022, , 1-48.	0.0	0
2860	Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk. <i>PLoS ONE</i> , 2022, 17, e0276898.	1.1	6
2861	Global Trends in the Epidemiology and Management of Dyslipidemia. <i>Journal of Clinical Medicine</i> , 2022, 11, 6377.	1.0	5
2862	Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2022, 7, 1199.	3.0	7
2863	A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia. <i>Clinical Therapeutics</i> , 2022, 44, 1310-1325.	1.1	5
2864	Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	0.9	7
2865	Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
2866	Patterns of Lipid Lowering Therapy Use Among Older Adults in a Managed Care Advantage Plan in the United States. <i>Journal of Pharmacy Practice</i> , 2024, 37, 123-131.	0.5	0
2867	Comparison of Estimated LDL Cholesterol Equations with Direct Measurement in Patients with Angiographically Confirmed Coronary Artery Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 342.	0.8	1
2868	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. , 2022, 1, 100513.		3
2869	Familial Hypercholesterolemia Among Young Adults With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2023, 186, 189-195.	0.7	4
2870	Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e31199.	0.4	4

#	ARTICLE	IF	CITATIONS
2871	Management of patients with statin intolerance. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101714.	2.2	5
2872	The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	1
2873	Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	1
2874	Association of haemoglobin glycation index with outcomes in patients with acute coronary syndrome: results from an observational cohort study in China. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	4
2875	A stepwise approach to prescribing novel lipid-lowering medications. <i>Journal of Clinical Lipidology</i> , 2022, 16, 822-832.	0.6	1
2876	Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review. <i>Cureus</i> , 2022, , .	0.2	1
2877	Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. <i>European Heart Journal</i> , 2023, 44, 129-138.	1.0	74
2878	Effect of Atorvastatin on Serial Changes in Coronary Physiology and Plaque Parameters. <i>JACC Asia</i> , 2022, , .	0.5	0
2879	Lipoprotein(a) and the risk of recurrent events in patient with acute myocardial infarction treated by percutaneous coronary intervention. <i>Minerva Cardiology and Angiology</i> , 0, , .	0.4	1
2880	Long-term Management of Patients with Myocardial Infarction: An Updated Review. , 0, Publish Ahead of Print, .		1
2881	Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients. <i>American Journal of Cardiology</i> , 2023, 186, 91-99.	0.7	5
2882	Session Three: Innovating Beyond Glucose Control in Diabetes Care. <i>European Medical Journal Diabetes</i> , 0, , 56-69.	4.0	0
2883	Thoughts on secondary prevention after percutaneous coronary intervention in Japan. <i>AsiaIntervention</i> , 2018, 4, 67-70.	0.1	0
2884	Guidelines, Clinical Evidence, and Real-Life Practice: How to Find Your Way in Managing Hypercholesterolaemia. <i>EMJ Cardiology</i> , 0, , 38-46.	0.0	0
2885	Update on the Management of Diabetic Dyslipidaemia. <i>European Medical Journal Diabetes</i> , 0, , 53-61.	4.0	1
2886	Association between cholesterol levels and dementia risk according to the presence of diabetes and statin use: a nationwide cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
2887	Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH. <i>Circulation: Cardiovascular Imaging</i> , 2022, 15, .	1.3	3
2889	Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100432.	1.3	10

#	ARTICLE	IF	CITATIONS
2890	National Institute for Health and Care Excellence guidelines for lipid management. <i>Heart</i> , 2023, 109, 661-667.	1.2	5
2891	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Espa�ola de Cardiolog�a [Spanish Society of Cardiology] and the Sociedad Espa�ola de Diabetes [Spanish Diabetes Society]. <i>Endocrinolog�a Diabetes Y Nutrici�n (English Ed.)</i> , 2023, 70, 51-62.	0.1	0
2892	Guidelines for the management of hyperlipidemia: How can clinicians effectively implement them?. <i>Progress in Cardiovascular Diseases</i> , 2022, 75, 4-11.	1.6	7
2893	Initial statin dose after myocardial infarction and long-term cardiovascular outcomes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 156-164.	1.4	2
2894	Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. <i>BMC Medicine</i> , 2022, 20, .	2.3	6
2895	Robust Genetic Model-Based SNP-set Association Test Using CauchyGM. <i>Bioinformatics</i> , 0, , .	1.8	1
2896	Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
2897	Statin associated muscle symptoms: An update and review. <i>Progress in Cardiovascular Diseases</i> , 2022, 75, 40-48.	1.6	10
2898	Endothelium-Derived Relaxing Factors and Endothelial Function: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 2884.	1.4	11
2899	Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, , .	1.2	3
2901	Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis. <i>Medicina (Lithuania)</i> , 2022, 58, 1665.	0.8	8
2903	The effect of combination therapy with statins and ezetimibe on proinflammatory cytokines: A systematic review and meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2022, 113, 109477.	1.7	2
2905	Association between Serum Oxysterols and Coronary Plaque Regression during Lipid-Lowering Therapy with Statin and Ezetimibe: Insights from the CuVIC Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, , .	0.9	4
2906	A Phase 3 Randomized Controlled Trial to Evaluate Efficacy and Safety of New-Formulation Zenon (Rosuvastatin/Ezetimibe Fixed-Dose Combination) in Primary Hypercholesterolemia Inadequately Controlled by Statins. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842211382.	1.0	1
2907	Sex disparities and dyslipidemic control in a coronary rehabilitation program. <i>International Journal of Cardiology</i> , 2023, 370, 72-74.	0.8	0
2909	Hypolipidemic agents in the secondary prevention of the stroke. , 2022, 1, 96-102.		0
2910	Intestinal Cholesterol Absorption in Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, , .	0.9	0
2911	Statin-related Muscle Toxicity: An Evidence-based Review. <i>European Endocrinology</i> , 2022, 18, 89.	0.8	1

#	ARTICLE	IF	CITATIONS
2912	Le patient atteint de maladies cardiovasculaires. , 2022, , 99-122.		0
2914	Lipid lowering therapy in 2022 and beyond - How far we have come. Progress in Cardiovascular Diseases, 2022, 75, 1-3.	1.6	5
2915	Angina in 2022: Current Perspectives. Journal of Clinical Medicine, 2022, 11, 6891.	1.0	3
2916	Effects of rosuvastatin/ezetimibe on senescence of CD8+ T-cell in type 2 diabetic patients with hypercholesterolemia: A study protocol. Medicine (United States), 2022, 101, e31691.	0.4	1
2917	Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
2918	Achievement of Low-Density Lipoprotein Cholesterol Targets in Cardiac Rehabilitation: Impact of the 2019 ESC/EAS Dyslipidaemia Guidelines. Journal of Clinical Medicine, 2022, 11, 7057.	1.0	2
2919	Lipid-lowering therapies and cardiovascular risk-stratification strategies in adults with type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 0, Publish Ahead of Print, .	1.2	2
2920	Association of low-density lipoprotein cholesterol levels with the risk of mortality and cardiovascular events: A meta-analysis of cohort studies with 1,232,694 participants. Medicine (United) Tj ETQq1 104784314rgBT /O		
2921	Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience. Journal of Clinical Lipidology, 2023, 17, 142-149.	0.6	7
2922	Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria. Journal of the American Heart Association, 2023, 12, .	1.6	11
2923	Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy. International Journal of Environmental Research and Public Health, 2022, 19, 16899.	1.2	1
2924	Use of statins and other lipid-modifying agents across pregnancy: A nationwide drug utilization study in Norway in 2005-2018. Atherosclerosis, 2023, 368, 25-34.	0.4	2
2925	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes 2023. Diabetes Care, 2023, 46, S158-S190.	4.3	156
2926	Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. European Heart Journal, 2023, 44, 972-983.	1.0	17
2927	The University of Santo Tomas Hospital (USTH) 2022 Institutional Chest Pain Pathway: Approach to Diagnosis, Risk Stratification, and Management. Journal of Medicine University of Santo Tomas, 2022, 6, S11-S24.	0.0	0
2928	2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea. Korean Journal of Medicine, 2022, 97, 339-352.	0.1	0
2929	Trends in Lipid-Lowering Prescriptions: Increasing Use of Guideline-Concordant Pharmacotherapies, U.S., 2017-2022. American Journal of Preventive Medicine, 2023, 64, 561-566.	1.6	3
2930	Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2

#	ARTICLE	IF	CITATIONS
2932	Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	1.8	2
2934	Current Understanding of Diabetic Dyslipidemia: A Review. <i>Journal of the Indian Institute of Science</i> , 0, , .	0.9	0
2935	High prevalence of dyslipidaemia among persons with diabetes mellitus and hypertension at a tertiary hospital in Blantyre, Malawi. <i>BMC Cardiovascular Disorders</i> , 2022, 22, .	0.7	5
2938	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. <i>Contemporary Cardiology</i> , 2023, , 67-138.	0.0	0
2939	RACING to judgement: weighing the value of pre-specified subgroup analyses. <i>European Heart Journal</i> , 2023, 44, 984-985.	1.0	1
2940	Could Lowering Phytosterol Absorption as Part of Lipid-Lowering Therapy Have a Beneficial Effect on Residual Risk?. <i>Metabolites</i> , 2023, 13, 145.	1.3	0
2941	Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (â€œJena auf Zielâ€œ). <i>Clinical Research in Cardiology</i> , 2023, 112, 1212-1219.	1.5	8
2942	Value of expert opinion in recommending early intensive lipid lowering in patients with ACS. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 936-938.	0.4	1
2943	Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 939-949.	0.4	21
2944	New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3. <i>Journal of Lipid and Atherosclerosis</i> , 2023, 12, 23.	1.1	6
2945	Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statinâ€œTherapy: A 6-Year Retrospective Study. <i>Diagnostics</i> , 2023, 13, 503.	1.3	2
2946	Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. <i>Journal of Lipid and Atherosclerosis</i> , 2023, 12, 12.	1.1	6
2947	Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study. <i>Journal of Inflammation Research</i> , 0, Volume 16, 269-282.	1.6	0
2948	Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 59-71.	1.8	2
2949	Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i. <i>Cardiology and Therapy</i> , 2023, 12, 327-338.	1.1	1
2950	Effect of Early Use of Enwolocumab on Cardiovascular Events in Patients with Extremely-High-Risk Atherosclerotic Cardiovascular Disease after Percutaneous coronary Intervention. <i>Advances in Clinical Medicine</i> , 2023, 13, 1346-1355.	0.0	0
2951	Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 1-9.	1.8	9
2952	Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 45-58.	1.8	7

#	ARTICLE	IF	CITATIONS
2953	Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 42-44.	1.8	0
2954	What is the Role of Cholesterol Absorption and Synthesis Biomarkers in Humans?. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, , .	0.9	0
2955	Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	10
2956	Advanced therapeutics for targeting atherosclerosis. , 2023, , 93-105.		0
2957	Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 1580-1600.	0.9	2
2958	Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	4
2959	Residual risks and evolving atherosclerotic plaques. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 2629-2643.	1.4	6
2960	Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1339-1349.	1.2	8
2962	Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease. <i>American Journal of Preventive Cardiology</i> , 2023, 14, 100491.	1.3	0
2963	Disparities in statin prescription among patients with severe hypercholesterolemia in an integrated healthcare system. <i>American Journal of Preventive Cardiology</i> , 2023, 14, 100492.	1.3	1
2964	How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention. <i>Circulation</i> , 2023, 147, 1204-1207.	1.6	0
2965	Impact of lipid lowering on coronary atherosclerosis moving from the lumen to the artery wall. <i>Atherosclerosis</i> , 2023, 367, 8-14.	0.4	5
2966	Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 453-471.	0.9	5
2967	New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a). <i>Journal of Lipid and Atherosclerosis</i> , 2023, 12, 37.	1.1	8
2968	The Clock Is Ticking: The Imminent Need to Re-evaluate the Standard of Care in the 90-Day High-Risk Post-Acute Myocardial Infarction Period. <i>EMJ Cardiology</i> , 0, , 2-6.	0.0	0
2969	Lowering of Blood Lipid Levels with a Combination of Pitavastatin and Ezetimibe in Patients with Coronary Heart Disease: A Meta-Analysis. <i>Cardiovascular Innovations and Applications</i> , 2023, 7, .	0.1	1
2970	Using genetic association data to guide drug discovery and development: Review of methods and applications. <i>American Journal of Human Genetics</i> , 2023, 110, 195-214.	2.6	35
2971	Risk Factors Control After an Acute Coronary Syndrome and Association with Major Adverse Cardiovascular Events: A Single Center Experience in Latin-America. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2023, 30, 183-189.	1.0	0



#	ARTICLE	IF	CITATIONS
2972	Phytosterols and Cardiovascular Risk Evaluated against the Background of Phytosterolemia Cases—A German Expert Panel Statement. <i>Nutrients</i> , 2023, 15, 828.	1.7	6
2973	Remnant cholesterol, low-density lipoprotein cholesterol, and incident cardiovascular disease among Koreans: a national population-based study. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 1142-1150.	0.8	11
2974	Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 601-610.	0.8	7
2975	Subclinical atherosclerosis burden in non-diabetic hypertensives treated in primary care center: the IMTABI study. , 2023, 24, .		1
2976	Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients. <i>CJC Open</i> , 2023, 5, 357-363.	0.7	1
2977	Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. <i>Circulation</i> , 2023, 147, 1192-1203.	1.6	41
2978	Trends in LDL-C following coronary angiography involving assessment by fractional flow reserve in obstructive vs non-obstructive coronary artery disease. <i>American Journal of Preventive Cardiology</i> , 2023, 13, 100473.	1.3	0
2979	Exploring the Active Compounds of Traditional Mongolian Medicine Baolier Capsule (BLEC) in Patients with Coronary Artery Disease (CAD) Based on Network Pharmacology Analysis, Molecular Docking and Experimental Validation. <i>Drug Design, Development and Therapy</i> , 0, Volume 17, 459-476.	2.0	0
2980	Transcription factor c-Maf deletion improves streptozotocin-induced diabetic nephropathy by directly regulating Sglt2 and Glut2. <i>JCI Insight</i> , 2023, 8, .	2.3	1
2981	Therapeutic Strategies and Future Directions of Management for Patients with a History of Coronary Artery Bypass Grafting Who Require Secondary Coronary Revascularization. <i>Journal of Coronary Artery Disease</i> , 2023, 29, 1-7.	0.1	0
2982	High triglyceride- $\alpha$ -glucose index is associated with poor cardiovascular outcomes in Chinese acute coronary syndrome patients without diabetes mellitus who underwent emergency percutaneous coronary intervention with drug-eluting stents. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	3
2984	PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration. , 2023, 9, 100035.		1
2985	Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4268.	1.8	7
2986	The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2023, 13, 100472.	1.3	6
2987	Systolic blood pressure, low-density lipoprotein cholesterol levels, and adverse kidney outcome: results from KNOW-CKD. <i>Hypertension Research</i> , 2023, 46, 1395-1406.	1.5	2
2988	The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. <i>Journal of Clinical Lipidology</i> , 2023, 17, 208-218.	0.6	7
2991	A Review of Low-Density Lipoprotein-Lowering Diets in the Age of Anti-Sense Technology. <i>Nutrients</i> , 2023, 15, 1249.	1.7	3
2992	Vulnerable Plaque Characteristics at Coronary Computed Tomography Angiography. <i>Cardiologia Croatica</i> , 2023, 18, 7-21.	0.0	1

#	ARTICLE	IF	CITATIONS
2993	Benefits of Bempedoic Acid â€” Clearer Now. <i>New England Journal of Medicine</i> , 2023, 388, 1425-1426.	13.9	7
2994	Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. <i>New England Journal of Medicine</i> , 2023, 388, 1353-1364.	13.9	231
2995	PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients. <i>Progress in Cardiovascular Diseases</i> , 2023, 79, 12-18.	1.6	9
2998	Lipid-lowering Efficacy and Safety of High Doses of Atorvastatin and Rosuvastatin. <i>Kardiologiya</i> , 2023, 63, 59-67.	0.3	1
2999	Intracoronary Imaging of Coronary Atherosclerotic Plaque: From Assessment of Pathophysiological Mechanisms to Therapeutic Implication. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5155.	1.8	5
3000	Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets. <i>Journal of Clinical Medicine</i> , 2023, 12, 2161.	1.0	6
3001	Statin Treatment and the Alterations in the Platelet Lipidome: What Is the Impact of Lipid Profile on Thrombosis?. <i>Thrombosis and Haemostasis</i> , 2023, 123, 573-575.	1.8	2
3002	Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 1622-1634.	0.9	4
3003	A Risk Model to Predict Statin Non-Adherence Following an Acute Coronary Syndrome. <i>Heart Lung and Circulation</i> , 2023, , .	0.2	1
3004	Achievement of long-term lipid targets in a cohort of patients with acute coronary syndrome in real-world clinical practice. <i>Revista Cl&amp;#x00ed;nica Espan&amp;#x00f5;la</i> , 2023, 223, 223-230.	0.3	0
3005	Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 2424-2434.	1.8	6
3006	Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial. <i>American Heart Journal</i> , 2023, 261, 45-50.	1.2	5
3007	Role of plaque imaging for identification of vulnerable patients beyond the stage of myocardial ischemia. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
3008	Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. <i>Pharmacological Research</i> , 2023, 190, 106738.	3.1	1
3009	Efficacy and Safety of Coadministered Ezetimibeâ€”Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial. <i>Journal of Clinical Medicine</i> , 2023, 12, 2377.	1.0	1
3010	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. <i>Frontiers in Clinical Drug Research Diabetes and Obesity</i> , 2023, , 117-167.	0.1	0
3011	Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice. <i>Journal of Clinical Lipidology</i> , 2023, 17, 412-414.	0.6	2
3012	Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice. <i>Journal of Clinical Medicine</i> , 2023, 12, 2444.	1.0	5

#	ARTICLE	IF	CITATIONS
3013	Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 311-321.	1.0	1
3014	Meta-analysis and trial sequential analysis of ezetimibe for coronary atherosclerotic plaque compositions. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
3015	Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management. <i>PLoS ONE</i> , 2023, 18, e0283369.	1.1	0
3016	Association between lipid levels and all-cause and cause-specific mortality in critically ill patients. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
3017	Proprotein convertase subtilisin kexin type 9 inhibitors and other novel lipid-modifying drugs: broadening the perspective of cardiovascular disease prevention. , 2023, , 427-440.		0
3018	Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics. , 2023, , 97-135.		0
3019	Comparison of the effect of 40 and 80 mg/day doses of atorvastatin on changes in lipid profiles among acute coronary syndrome patients: A randomized clinical trial study. <i>Journal of Research in Medical Sciences</i> , 2023, 28, 24.	0.4	0
3020	French expert group proposal for lipid-lowering therapy in the first 3 months after acute myocardial infarction. <i>Panminerva Medica</i> , 0, , .	0.2	0
3021	Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial. <i>EClinicalMedicine</i> , 2023, 58, 101933.	3.2	2
3022	Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review. <i>Cardiosomatics</i> , 2023, 13, 168-175.	0.2	0
3023	Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial. <i>Journal of Stroke</i> , 0, , .	1.4	0
3024	Bempedoic acid: a CLEAR therapeutic option for statin-intolerant patients?. <i>European Heart Journal</i> , 0, , .	1.0	0
3025	Association between Intermediate-Density Lipoprotein Particles and the Progression of Carotid Atherosclerosis: A Community-Based Cohort Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, , .	0.9	0
3026	Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2023, 20, 600-616.	6.1	22
3027	Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	1
3028	Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology. <i>Journal of Cardiovascular Medicine</i> , 2023, 24, e86-e94.	0.6	1
3029	PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2023, 29, 1802-1824.	0.9	4
3030	Prevention of Coronary Atherosclerosis. , 2023, , 39-57.		0

#	ARTICLE	IF	CITATIONS
3031	Geographic and ethnic variations in response to lipid-lowering therapies: why do they matter?. European Journal of Preventive Cardiology, 0, , .	0.8	0
3032	Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. Medicina (Lithuania), 2023, 59, 776.	0.8	3
3033	Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia. Cardiology in Review, 2024, 32, 180-185.	0.6	0
3034	A bibliometric analysis and visualization of literature on non-fasting lipid research from 2012 to 2022. Frontiers in Endocrinology, 0, 14, .	1.5	1
3035	Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. Canadian Pharmacists Journal, 2023, 156, 117-127.	0.4	2
3036	Understanding the molecular mechanisms of statin pleiotropic effects. Archives of Toxicology, 2023, 97, 1529-1545.	1.9	9
3037	Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid. European Heart Journal Supplements, 2023, 25, B55-B59.	0.0	1
3038	Lipid treatment status and goal attainment among patients with premature acute coronary syndrome in Israel. Journal of Clinical Lipidology, 2023, , .	0.6	0
3047	Treatment Guidelines Overview. , 2024, , 113-121.e2.		0
3054	Lipidmanagement bei Älteren CKD-Patienten. , 2023, , 205-212.		0
3056	Diabetes and Atherogenic Dyslipidemia. , 2023, , 645-656.		0
3057	Diabetes and Dyslipidemia. Contemporary Cardiology, 2023, , 425-472.	0.0	3
3070	Epidemiology, Control, and Cardiovascular Outcomes of Dyslipidemia in Diabetes. Contemporary Diabetes, 2023, , 891-913.	0.0	0
3071	Clinical Care of Lipids in People with Type 1 Diabetes. Contemporary Diabetes, 2023, , 755-778.	0.0	0
3074	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. Contemporary Diabetes, 2023, , 821-878.	0.0	0
3075	Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes. Contemporary Diabetes, 2023, , 579-595.	0.0	0
3088	Special Patient Populations. , 2024, , 298-306.e2.		0
3089	Treatment Guidelines Overview. , 2024, , 101-112.e1.		0

#	ARTICLE	IF	CITATIONS
3090	Special Patient Populations. , 2024, , 375-382.e2.		0
3091	Cholesterol Absorption Inhibitors. , 2024, , 161-168.e1.		0
3092	Special Patient Populations. , 2024, , 287-297.e2.		0
3093	Special Patient Populations. , 2024, , 345-357.e3.		0
3098	Adding Niacin to Statin Therapy in CAD (AIM-HIGH)-2011. , 2023, , 157-159.		0
3100	The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials. Cardiovascular Drugs and Therapy, 0, ,	1.3	4
3166	Stoffwechselerkrankungen. , 2023, , 297-350.		0
3175	Dyslipidemia in Metabolic Syndrome. , 2023, , 1-18.		0
3181	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 1-25.		0
3188	Dyslipidemia. , 2024, , 476-488.		0
3203	Hypertension and Dyslipidemia in Pediatric Obesity. , 2023, , 343-376.		0
3204	Recent advances in anti-inflammatory active components and action mechanisms of natural medicines. Inflammopharmacology, 2023, 31, 2901-2937.	1.9	0
3219	HDL as a Treatment Target: Should We Abandon This Idea?. Current Atherosclerosis Reports, 0, ,	2.0	1
3231	Obesity and Dyslipidemia. Current Atherosclerosis Reports, 0, ,	2.0	0
3235	Lipid-lowering drugs and cancer: an updated perspective. Pharmacological Reports, 2024, 76, 1-24.	1.5	0
3236	Lipid Lowering Drugs in Acute Coronary Syndromes (ACS). Current Atherosclerosis Reports, 0, ,	2.0	0
3240	Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms. Bone Research, 2023, 11, .	5.4	2
3258	Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Current Atherosclerosis Reports, 2024, 26, 35-44.	2.0	2

#	ARTICLE	IF	CITATIONS
3262	Kardiovaskulärer Risikofaktor Dyslipidämie. Springer Reference Medizin, 2023, , 161-174.	0.0	0
3267	Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nature Reviews Cardiology, 0, , .	6.1	1
3289	Dyslipidemia in Metabolic Syndrome. , 2023, , 529-546.		0
3290	How Will Our Practice Change After the CLEAR Outcomes Trial?. Current Atherosclerosis Reports, 2024, 26, 83-89.	2.0	0
3291	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 713-737.		0
3322	Advances in familial hypercholesterolemia. Advances in Clinical Chemistry, 2024, , 167-201.	1.8	0
3333	Multimodale kardiovaskuläre Prävention. Springer Reference Medizin, 2023, , 1-13.	0.0	0